[
    {
        "ticker": "vrtx",
        "sector": "Healthcare",
        "data": [
            {
                "index": 1,
                "date": "2023-06-23",
                "press_title": "Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-presents-positive-vx-880-results-ongoing-phase-12-study",
                "content": "  –   All six patients treated with VX-880 engrafted islet cells, produced endogenous insulin (C-peptide) and had improved glycemic control while reducing or eliminating insulin use – –   The two patients with at least one year of follow-up met the criteria for the primary endpoint of elimination of  ",
                "1d_change": 0.1957182816,
                "index_price": -0.585612215,
                "norm_price": 0.7813304966
            },
            {
                "index": 2,
                "date": "2023-06-09",
                "press_title": "Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-presents-data-demonstrating-significant-benefits-long",
                "content": "  -Interim results of largest real-world study of TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) showed sustained improvement in lung function, reduction in pulmonary exacerbations frequency and lower rates of lung transplant and death for people with cystic fibrosis- - Twelve  ",
                "1d_change": 2.0786896544,
                "index_price": 0.7847624089,
                "norm_price": 1.2939272455
            },
            {
                "index": 3,
                "date": "2023-06-09",
                "press_title": "Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/positive-results-pivotal-trials-exa-cel-transfusion-dependent",
                "content": "  - Both trials met the primary and key secondary endpoints at the pre-specified interim analysis - - Data continue to demonstrate transformative and durable benefit - - Safety profile consistent with busulfan conditioning and   autologous hematopoietic stem cell transplant - BOSTON &amp; ZUG,  ",
                "1d_change": 2.0786896544,
                "index_price": 0.7847624089,
                "norm_price": 1.2939272455
            },
            {
                "index": 4,
                "date": "2023-06-08",
                "press_title": "FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/fda-accepts-biologics-license-applications-exagamglogene",
                "content": "  - First CRISPR gene-editing filings to be accepted for review by FDA - - FDA grants Priority Review for severe sickle cell disease (SCD) and Standard Review for transfusion-dependent beta thalassemia (TDT) – - PDUFA target action date of December 8, 2023 , for SCD and March 30, 2024 , for TDT –  ",
                "1d_change": 3.0259452859,
                "index_price": 0.7018121743,
                "norm_price": 2.3241331117
            },
            {
                "index": 5,
                "date": "2023-05-30",
                "press_title": "Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-participate-goldman-sachs-44th-annual-global-healthcare",
                "content": "  BOSTON --(BUSINESS WIRE)--May 30, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the Goldman Sachs 44 th Annual Global Healthcare Conference. Dr. Reshma Kewalramani , Chief Executive Officer and President, and Stuart A.  ",
                "1d_change": -1.9315758131,
                "index_price": -1.1215738902,
                "norm_price": -0.8100019229
            },
            {
                "index": 6,
                "date": "2023-05-03",
                "press_title": "Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-kalydecor-ivacaftor-treat",
                "content": "  -First and only CFTR modulator approved for this age group- BOSTON --(BUSINESS WIRE)--May 3, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO ® (ivacaftor) for use in children with cystic fibrosis (CF) ages 1  ",
                "1d_change": -0.7761338959,
                "index_price": -1.5027511373,
                "norm_price": 0.7266172414
            },
            {
                "index": 7,
                "date": "2023-05-01",
                "press_title": "Vertex Reports First Quarter 2023 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-first-quarter-2023-financial-results",
                "content": "  — Product revenue of $2.37 billion , a 13% increase compared to Q1 2022 — — Company reiterates full year 2023 financial guidance, including product revenue guidance of $9.55 to $9.7 billion — — TRIKAFTA approved in U.S. for children with cystic fibrosis 2 to 5 years of age — — Pipeline advancement  ",
                "1d_change": 1.6790444699,
                "index_price": -1.1459896407,
                "norm_price": 2.8250341106
            },
            {
                "index": 8,
                "date": "2023-04-27",
                "press_title": "Vertex Receives CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis  Ages 1 to <2 Years Old",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-chmp-positive-opinion-orkambir-0",
                "content": "  - If approved by the European Commission, nearly 300 children with cystic fibrosis and two copies of the F508del mutation would be eligible for the first time for a medicine&nbsp;that can treat the underlying cause of their disease - LONDON – 26/27/28 April 2023 – Vertex Pharmaceuticals (Nasdaq: VRTX)  ",
                "1d_change": 4.7633053923,
                "index_price": 2.2590333051,
                "norm_price": 2.5042720872
            },
            {
                "index": 9,
                "date": "2023-04-26",
                "press_title": "Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-trikaftar-0",
                "content": "  -About 900 children with cystic fibrosis will now have a medicine to treat the underlying cause of their disease for the first time- BOSTON --(BUSINESS WIRE)--Apr. 26, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved the  ",
                "1d_change": 3.7923196813,
                "index_price": 1.150327475,
                "norm_price": 2.6419922063
            },
            {
                "index": 10,
                "date": "2023-04-25",
                "press_title": "Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-bank-america-securities-2023-health-care",
                "content": "  BOSTON --(BUSINESS WIRE)--Apr. 25, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Bank of America Securities 2023 Health Care Conference on Tuesday, May 9, 2023 at 9:20 a.m. PT / 12:20 p.m. ET .  ",
                "1d_change": -3.4642785741,
                "index_price": -1.7366952511,
                "norm_price": -1.7275833229
            },
            {
                "index": 11,
                "date": "2023-04-10",
                "press_title": "Vertex to Announce First Quarter 2023 Financial Results on May 1",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-first-quarter-2023-financial-results-may-1",
                "content": "  BOSTON --(BUSINESS WIRE)--Apr. 10, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2023 financial results on Monday, May 1, 2023 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  ",
                "1d_change": 1.3391545626,
                "index_price": 0.5777643522,
                "norm_price": 0.7613902104
            },
            {
                "index": 12,
                "date": "2023-04-03",
                "press_title": "Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-complete-submission-rolling",
                "content": "  -EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023 - BOSTON &amp; ZUG, Switzerland --(BUSINESS WIRE)--Apr. 3, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced  ",
                "1d_change": -0.1844623585,
                "index_price": -0.0390210608,
                "norm_price": -0.1454412977
            },
            {
                "index": 13,
                "date": "2023-03-27",
                "press_title": "Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-licensing-agreement",
                "content": "  - Vertex to receive non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- - CRISPR Therapeutics to receive $100M upfront payment plus milestone and royalty payments on potential future gene-edited hypoimmune T1D products-  ",
                "1d_change": -0.4565020513,
                "index_price": -0.2936066309,
                "norm_price": -0.1628954204
            },
            {
                "index": 14,
                "date": "2023-03-16",
                "press_title": "Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-publication-new-england-journal-medicine",
                "content": "  BOSTON --(BUSINESS WIRE)--Mar. 16, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced publication in the New England Journal of Medicine   (NEJM)   of results from preclinical studies and a Phase 2 study evaluating the efficacy and safety of inaxaplin (VX-147) on top of  ",
                "1d_change": 1.4910247239,
                "index_price": 0.962814095,
                "norm_price": 0.5282106289
            },
            {
                "index": 15,
                "date": "2023-03-09",
                "press_title": "Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-fda-clearance-investigational-new-drug",
                "content": "    – Vertex to initiate a Phase 1/2 clinical trial in the coming months – – VX-264 is the second investigational program in Vertex’s pipeline containing stem cell-derived, fully differentiated pancreatic islet cells for the treatment of type 1 diabetes – – VX-264 program does not require  ",
                "1d_change": -0.3690285457,
                "index_price": -3.5495695063,
                "norm_price": 3.1805409606
            },
            {
                "index": 16,
                "date": "2023-02-21",
                "press_title": "Vertex to Present at Cowen’s 43rd Annual Health Care Conference on March 7",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-cowens-43rd-annual-health-care-conference-march-7",
                "content": "  BOSTON --(BUSINESS WIRE)--Feb. 21, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at Cowen’s 43 rd Annual Health Care Conference on Tuesday, March 7, 2023 at 2:50 p.m. ET . A live webcast of management's remarks will be available through the  ",
                "1d_change": 1.2229840213,
                "index_price": -1.5359378629,
                "norm_price": 2.7589218842
            },
            {
                "index": 17,
                "date": "2023-02-07",
                "press_title": "Vertex Reports Fourth Quarter and Full Year Financial 2022 Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-fourth-quarter-and-full-year-financial-2022",
                "content": "  — Full year product revenue of $8.93 billion , an 18% increase compared to full year 2021 — — Full year GAAP and non-GAAP net income increased 42% and 53%, respectively, versus 2021— — Company provides full year 2023 product revenue guidance of $9.55 to $9.7 billion — — Exa-cel regulatory  ",
                "1d_change": -3.4977705094,
                "index_price": 0.3037928934,
                "norm_price": -3.8015634028
            },
            {
                "index": 18,
                "date": "2023-01-17",
                "press_title": "Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-fourth-quarter-and-full-year-2022-financial",
                "content": "  BOSTON --(BUSINESS WIRE)--Jan. 17, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2022 financial results on Tuesday, February 7, 2023 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  ",
                "1d_change": 2.055765642,
                "index_price": -1.7923753951,
                "norm_price": 3.8481410372
            },
            {
                "index": 19,
                "date": "2023-01-04",
                "press_title": "Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-41st-annual-jp-morgan-healthcare-conference",
                "content": "  BOSTON --(BUSINESS WIRE)--Jan. 4, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. ET / 8:15 a.m. PT .  ",
                "1d_change": -0.1424061703,
                "index_price": -0.8471418539,
                "norm_price": 0.7047356836
            },
            {
                "index": 20,
                "date": "2022-12-12",
                "press_title": "Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-investigational-new-drug-ind-application-vx-522",
                "content": "  - Novel, inhaled mRNA therapy intended for the ~5,000 people with CF who cannot benefit from CFTR modulators - - VX-522 clinical trial in people with CF to initiate in coming weeks - BOSTON --(BUSINESS WIRE)--Dec. 12, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that  ",
                "1d_change": -2.6474339704,
                "index_price": 1.9991756803,
                "norm_price": -4.6466096507
            },
            {
                "index": 21,
                "date": "2022-12-10",
                "press_title": "Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-present-american-society",
                "content": "  - Oral presentation of encore clinical data from Phase 3 clinical trials of exa-cel - - Oral and poster presentations on quality-of-life impacts of sickle cell disease or transfusion-dependent beta-thalassemia and burden of hematopoietic stem cell transplant - BOSTON and ZUG, Switzerland  ",
                "1d_change": -2.6474339704,
                "index_price": 1.9991756803,
                "norm_price": -4.6466096507
            },
            {
                "index": 22,
                "date": "2022-12-08",
                "press_title": "Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-entrada-therapeutics-establish-collaboration-discover",
                "content": "  - Entrada to receive $224 million upfront payment and $26 million equity investment, as well as potential milestone payments and royalties - - Global collaboration includes ENTR-701, Entrada’s EEV-investigational candidate for the treatment of DM1 - BOSTON --(BUSINESS WIRE)--Dec.  ",
                "1d_change": -1.7071252807,
                "index_price": -0.3408454864,
                "norm_price": -1.3662797943
            },
            {
                "index": 23,
                "date": "2022-11-09",
                "press_title": "Vertex to Participate in Upcoming Investor Conferences",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-participate-upcoming-investor-conferences",
                "content": "  BOSTON --(BUSINESS WIRE)--Nov. 9, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced its participation in the following upcoming investor conferences: Jefferies London Healthcare Conference on Wednesday, November 16, 2022 , at 9:10 a.m. GMT ( 4:10 a.m.  ",
                "1d_change": 1.4564507594,
                "index_price": 3.6758486055,
                "norm_price": -2.2193978461
            },
            {
                "index": 24,
                "date": "2022-11-04",
                "press_title": "Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-partnership-basketball-hall-famer-alonzo",
                "content": "  BOSTON --(BUSINESS WIRE)--Nov. 4, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with basketball Hall-of-Famer Alonzo Mourning to launch “Power Forward” ( www.PowerForwardTogether.com ), an educational initiative aimed at raising awareness  ",
                "1d_change": -2.7701723418,
                "index_price": 1.0460246887,
                "norm_price": -3.8161970305
            },
            {
                "index": 25,
                "date": "2022-11-03",
                "press_title": "Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-new-data-its-portfolio-cystic-fibrosis-medicines",
                "content": "  - New clinical data show TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) continues to deliver significant benefit across a variety of outcomes and over the long term in people with CF - BOSTON --(BUSINESS WIRE)--Nov. 3, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today  ",
                "1d_change": 0.459819116,
                "index_price": 0.989246883,
                "norm_price": -0.5294277669
            },
            {
                "index": 26,
                "date": "2022-10-27",
                "press_title": "Vertex Reports Third Quarter 2022 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-third-quarter-2022-financial-results",
                "content": "  — Product revenue of $2.33 billion , an 18% increase compared to Q3 2021 — — Company increases full year 2022 product revenue guidance to $8.8 billion to $8.9 billion — — Significant progress in mid- and late-stage pipeline, with near-term commercialization opportunities: Initiating global exa-cel  ",
                "1d_change": 1.0131011007,
                "index_price": 1.7013354368,
                "norm_price": -0.6882343361
            },
            {
                "index": 27,
                "date": "2022-10-13",
                "press_title": "Vertex to Announce Third Quarter 2022 Financial Results on October 27",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-third-quarter-2022-financial-results-october-27",
                "content": "  BOSTON --(BUSINESS WIRE)--Oct. 13, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2022 financial results on Thursday, October 27, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  ",
                "1d_change": 2.8375488725,
                "index_price": 1.7498946427,
                "norm_price": 1.0876542298
            },
            {
                "index": 28,
                "date": "2022-10-11",
                "press_title": "Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-advances-program-targeting-alpha-1-antitrypsin-deficiency",
                "content": "   - Initiates first-in-human trial of next-wave AAT corrector, VX-634 - - Phase 2 study evaluating the impact of longer-term treatment with VX-864 to be initiated in the coming weeks - - Additional AAT correctors to enter the clinic starting in 2023 - BOSTON --(BUSINESS WIRE)--Oct.  ",
                "1d_change": -1.5200095088,
                "index_price": -0.5264165515,
                "norm_price": -0.9935929573
            },
            {
                "index": 29,
                "date": "2022-09-27",
                "press_title": "Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-global-exa-cel",
                "content": "  - Exa-cel will be submitted to the U.S. FDA for rolling review beginning in November, with completion of the U.S. submission package in Q1 2023 - - EMA and MHRA submissions are on track for Q4 2022 - - Exa-cel granted Fast Track, Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug  ",
                "1d_change": 4.267983595,
                "index_price": 0.8765729143,
                "norm_price": 3.3914106806
            },
            {
                "index": 30,
                "date": "2022-09-08",
                "press_title": "Vertex Appoints Jonathan Biller as Chief Legal Officer",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-appoints-jonathan-biller-chief-legal-officer",
                "content": "  BOSTON --(BUSINESS WIRE)--Sep. 8, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jonathan Biller has been appointed Chief Legal Officer, effective September 19, 2022 . Mr. Biller will report directly to Vertex’s Chief Executive Officer and President, Reshma  ",
                "1d_change": 2.5127509178,
                "index_price": 2.6410291486,
                "norm_price": -0.1282782308
            },
            {
                "index": 31,
                "date": "2022-09-02",
                "press_title": "Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-orkambir-lumacaftorivacaftor",
                "content": "  -With this approval, approximately 300 children with two copies of the F508del mutation will have a medicine to treat the underlying cause of their disease for the first time- BOSTON --(BUSINESS WIRE)--Sep. 2, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S.  ",
                "1d_change": -3.958026578,
                "index_price": -2.2125324511,
                "norm_price": -1.7454941269
            },
            {
                "index": 32,
                "date": "2022-08-31",
                "press_title": "Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-participate-wells-fargo-healthcare-conference-friday",
                "content": "  BOSTON --(BUSINESS WIRE)--Aug. 31, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will participate in a fireside chat at the Wells Fargo Healthcare Conference on Friday, September 9, 2022 at 11:00 a.m. ET . A live webcast of management’s remarks will be  ",
                "1d_change": 2.8738892159,
                "index_price": -0.8525611855,
                "norm_price": 3.7264504014
            },
            {
                "index": 33,
                "date": "2022-08-04",
                "press_title": "Vertex Reports Second Quarter 2022 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-second-quarter-2022-financial-results",
                "content": "  — Product revenues of $2.20 billion , a 22% increase compared to Q2 2021 — — Company raises full year 2022 product revenue guidance to $8.6 to $8.8 billion — — Recent exa-cel and VX-880 clinical data presentations demonstrate transformative potential for patients with sickle cell disease, beta  ",
                "1d_change": 3.6871142458,
                "index_price": -0.2330449602,
                "norm_price": 3.920159206
            },
            {
                "index": 34,
                "date": "2022-07-22",
                "press_title": "Vertex Advances VX-548 in Acute and Neuropathic Pain",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-advances-vx-548-acute-and-neuropathic-pain",
                "content": "  - VX-548 advances into pivotal development for people with acute pain ; Phase 3 program to initiate in Q4 2022 - - Phase 2 dose-ranging trial in neuropathic pain expected to initiate by year end - -Breakthrough Therapy Designation granted by FDA - BOSTON --(BUSINESS WIRE)--Jul.  ",
                "1d_change": -0.3066818738,
                "index_price": -0.7963477995,
                "norm_price": 0.4896659257
            },
            {
                "index": 35,
                "date": "2022-07-20",
                "press_title": "Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-verve-therapeutics-establish-collaboration-discover",
                "content": "  Verve to Receive $25 Million Upfront Payment and $35 Million Equity Investment, as Well as Potential Milestones and Royalties BOSTON and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated&nbsp;(Nasdaq: VRTX) and Verve Therapeutics, Inc.  ",
                "1d_change": -1.9745071332,
                "index_price": 1.5911647705,
                "norm_price": -3.5656719037
            },
            {
                "index": 36,
                "date": "2022-07-18",
                "press_title": "Vertex to Announce Second Quarter 2022 Financial Results on August 4",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-second-quarter-2022-financial-results-august-4",
                "content": "  BOSTON --(BUSINESS WIRE)--Jul. 18, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2022 financial results on Thursday, August 4, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  ",
                "1d_change": -1.129139829,
                "index_price": 1.3437660352,
                "norm_price": -2.4729058642
            },
            {
                "index": 37,
                "date": "2022-07-11",
                "press_title": "Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-acquire-viacyte-goal-accelerating-its-potentially",
                "content": "  - ViaCyte brings tools, technologies and assets with potential to accelerate development of VX-880, Vertex’s fully differentiated, insulin-producing, stem cell derived islets - - ViaCyte to be acquired for $320 million in cash- BOSTON --(BUSINESS WIRE)--Jul.  ",
                "1d_change": -1.3758112134,
                "index_price": -1.6272099032,
                "norm_price": 0.2513986898
            },
            {
                "index": 38,
                "date": "2022-07-05",
                "press_title": "Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-fda-has-lifted-clinical-hold-vx-880-phase-12",
                "content": "  BOSTON --(BUSINESS WIRE)--Jul. 5, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated  ",
                "1d_change": 1.799694384,
                "index_price": 1.3646002069,
                "norm_price": 0.4350941771
            },
            {
                "index": 39,
                "date": "2022-06-11",
                "press_title": "Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-present-new-data-more-patients",
                "content": "  –   Data from 75 patients with transfusion-dependent beta thalassemia or severe sickle cell disease with follow-up of up to 37.2 months continue to demonstrate that exa-cel has the potential to be a one-time functional cure – – Safety profile generally consistent with myeloablative conditioning and  ",
                "1d_change": -0.6945542456,
                "index_price": -2.748506816,
                "norm_price": 2.0539525705
            },
            {
                "index": 40,
                "date": "2022-06-10",
                "press_title": "Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-data-demonstrating-significant-benefits-long-term",
                "content": "  - TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) real-world safety and effectiveness interim results show   improved lung function and significant reductions in risk of pulmonary exacerbations, lung transplant and death for people with cystic fibrosis (CF) - - Study in people with CF  ",
                "1d_change": -4.531566243,
                "index_price": -5.9941918747,
                "norm_price": 1.4626256317
            },
            {
                "index": 41,
                "date": "2022-06-08",
                "press_title": "Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-participate-goldman-sachs-43rd-annual-healthcare",
                "content": "  BOSTON --(BUSINESS WIRE)--Jun. 8, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022 at 1:20 p.m. PT .  ",
                "1d_change": -4.8132458269,
                "index_price": -3.218164244,
                "norm_price": -1.5950815829
            },
            {
                "index": 42,
                "date": "2022-06-08",
                "press_title": "Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-inaxaplin-vx-147-granted-breakthrough-therapy",
                "content": "  - Vertex granted nine Breakthrough Therapy Designations and three PRIME designations across its pipeline programs to date – BOSTON --(BUSINESS WIRE)--Jun. 8, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has granted inaxaplin  ",
                "1d_change": -4.8132458269,
                "index_price": -3.218164244,
                "norm_price": -1.5950815829
            },
            {
                "index": 43,
                "date": "2022-06-06",
                "press_title": "Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-presents-new-data-vx-880-phase-12-clinical-trial-american",
                "content": "  –   Patient 1 showed blood glucose time-in-range change from 40.1% on 34.0 units per day of exogenous insulin at baseline to 99.9% and insulin independence at Day 270 – –   Patient 2 showed blood glucose time-in-range change from 35.9% on 25.9 units per day of exogenous insulin at baseline to 51.9%  ",
                "1d_change": 0.1544850043,
                "index_price": 0.6239355067,
                "norm_price": -0.4694505024
            },
            {
                "index": 44,
                "date": "2022-06-02",
                "press_title": "Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-acceptance-late-breaking",
                "content": "   - Vertex announces three additional abstracts on the burden of beta thalassemia and sickle cell disease accepted for poster presentation – BOSTON &amp; ZUG, Switzerland &amp; CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 2, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics  ",
                "1d_change": 0.3191864093,
                "index_price": 0.3195813313,
                "norm_price": -0.0003949219
            },
            {
                "index": 45,
                "date": "2022-05-31",
                "press_title": "Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-new-data-vx-880-clinical-trial-82nd-american",
                "content": "  BOSTON --(BUSINESS WIRE)--May 31, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabetes (T1D) and its Phase 1/2 trial of VX-880, a stem cell‑derived, fully differentiated  ",
                "1d_change": -1.7148565585,
                "index_price": -1.2157295133,
                "norm_price": -0.4991270452
            },
            {
                "index": 46,
                "date": "2022-05-18",
                "press_title": "Suketu Upadhyay Elected to Vertex Board of Directors",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/suketu-upadhyay-elected-vertex-board-directors",
                "content": "  BOSTON --(BUSINESS WIRE)--May 18, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Suketu (“Suky”) Upadhyay   has been elected to its board of directors as an independent director. Mr. Upadhyay is a global business executive with more than 20 years of experience in the  ",
                "1d_change": -2.0121352324,
                "index_price": -3.8758800113,
                "norm_price": 1.8637447789
            },
            {
                "index": 47,
                "date": "2022-05-17",
                "press_title": "Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey Leiden Center for Cell and Genetic Therapies",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-further-expansion-boston-seaport-dedication",
                "content": "  -New 344,000 square foot cell and genetic therapies research and manufacturing facility to be built- -Facility to support continued R&amp;D growth- BOSTON --(BUSINESS WIRE)--May 17, 2022-- At a dedication today of the new Jeffrey Leiden Center for Cell and Genetic Therapies in Boston’s Seaport, Vertex  ",
                "1d_change": -1.375074752,
                "index_price": -3.2704010163,
                "norm_price": 1.8953262642
            },
            {
                "index": 48,
                "date": "2022-05-17",
                "press_title": "Vertex Announces $50 Million Commitment to Health Equity With Three Initial Grants",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-50-million-commitment-health-equity-three",
                "content": "   – Vertex grant to JDRF supports efforts to improve clinical trial diversity in type 1 diabetes – – The Vertex Foundation grant supports the Mass General Comprehensive Sickle Cell Disease Treatment Center – – Additional Vertex Foundation grant to Year Up to support health care workforce training –  ",
                "1d_change": -1.375074752,
                "index_price": -3.2704010163,
                "norm_price": 1.8953262642
            },
            {
                "index": 49,
                "date": "2022-05-05",
                "press_title": "Vertex Reports First Quarter 2022 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-first-quarter-2022-financial-results",
                "content": "  — Product revenues of $2.10 billion , a 22% increase compared to Q1 2021 — — Company reiterates full year 2022 product revenue guidance of $8.4 to $8.6 billion — — Mid- and late-stage clinical pipeline now spans 6 disease areas — BOSTON --(BUSINESS WIRE)--May 5, 2022-- Vertex Pharmaceuticals  ",
                "1d_change": -6.9940575268,
                "index_price": -3.5672619189,
                "norm_price": -3.426795608
            },
            {
                "index": 50,
                "date": "2022-04-21",
                "press_title": "Vertex to Announce First Quarter 2022 Financial Results on May 5",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-first-quarter-2022-financial-results-may-5",
                "content": "  BOSTON --(BUSINESS WIRE)--Apr. 21, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2022 financial results on Thursday, May 5, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  ",
                "1d_change": -5.7614029283,
                "index_price": -5.0889827578,
                "norm_price": -0.6724201705
            },
            {
                "index": 51,
                "date": "2022-04-20",
                "press_title": "Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/health-canada-grants-marketing-authorization-trikaftar-0",
                "content": "  -Approximately 500 Canadians ages 6-11 are now eligible for TRIKAFTA ® - - Vertex has submitted this indication to CADTH &amp; INESSS for Health Technology Assessments- BOSTON --(BUSINESS WIRE)--Apr. 20, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has  ",
                "1d_change": -0.9335859439,
                "index_price": -1.7889323839,
                "norm_price": 0.85534644
            },
            {
                "index": 52,
                "date": "2022-03-31",
                "press_title": "Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-statistically-significant-and-clinically",
                "content": "  -  Treatment with the NaV1.8 inhibitor VX-548 met the primary endpoint in both Phase 2 proof-of-concept acute pain studies following abdominoplasty or bunionectomy surgery - - VX-548 was generally well tolerated - - Results further highlight NaV1.8 as a new mechanism that could create an  ",
                "1d_change": 2.3107247934,
                "index_price": -1.1694191605,
                "norm_price": 3.4801439538
            },
            {
                "index": 53,
                "date": "2022-03-26",
                "press_title": "Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-reimbursement-agreement-australia-trikaftar",
                "content": "  - With this reimbursement agreement in place, more than 2,200 people with CF will have PBS -funded access to TRIKAFTA ® , including more than 700 who will now have access to a CFTR modulator therapy for the first time - LONDON --(BUSINESS WIRE)--Mar. 26, 2022-- Vertex Pharmaceuticals Incorporated  ",
                "1d_change": 1.6086553138,
                "index_price": 1.95418974,
                "norm_price": -0.3455344262
            },
            {
                "index": 54,
                "date": "2022-03-22",
                "press_title": "Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-advances-vx-147-pivotal-clinical-development-people-apol1",
                "content": "  – Single pivotal trial to initiate later this month targets the broad patient population with two APOL1 mutations and proteinuric kidney disease – – Pathway for accelerated approval using an interim analysis at Week 48 of eGFR slope, supported by reduction in proteinuria – – Final analysis  ",
                "1d_change": -0.4030145409,
                "index_price": -0.2885810146,
                "norm_price": -0.1144335263
            },
            {
                "index": 55,
                "date": "2022-03-01",
                "press_title": "Vertex to Present at Cowen’s 42nd Annual Health Care Conference on March 8",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-cowens-42nd-annual-health-care-conference-march-8",
                "content": "  BOSTON --(BUSINESS WIRE)--Mar. 1, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at Cowen’s 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 2:50 p.m. ET . A live webcast of management's remarks will be available through Vertex  ",
                "1d_change": 2.1015753945,
                "index_price": 0.533447823,
                "norm_price": 1.5681275715
            },
            {
                "index": 56,
                "date": "2022-01-26",
                "press_title": "Vertex Reports Fourth Quarter 2021 and Full Year Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-fourth-quarter-2021-and-full-year-financial",
                "content": "  -Full year product revenues of $7.57 billion , a 22% increase compared to full year 2020- -Company provides full year 2022 product revenue guidance of $8.4 to $8.6 billion - - Advancing broad clinical pipeline across six disease areas; multiple programs in mid- and late-stage development with  ",
                "1d_change": 0.7010805779,
                "index_price": -1.8934525656,
                "norm_price": 2.5945331435
            },
            {
                "index": 57,
                "date": "2022-01-18",
                "press_title": "Vertex to Announce Fourth Quarter 2021 Financial Results on January 26",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-fourth-quarter-2021-financial-results-january-26",
                "content": "  BOSTON ----(BUSINESS WIRE)--Jan. 18, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  ",
                "1d_change": -0.2555867039,
                "index_price": -2.1946997832,
                "norm_price": 1.9391130793
            },
            {
                "index": 58,
                "date": "2022-01-11",
                "press_title": "European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/european-commission-approves-kaftrior-0",
                "content": "  - More than 1,500 children now eligible to receive a treatment targeting the underlying cause of cystic fibrosis for the first time - LONDON --(BUSINESS WIRE)--Jan. 11, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval for  ",
                "1d_change": 0.8578767342,
                "index_price": 1.2104469571,
                "norm_price": -0.3525702229
            },
            {
                "index": 59,
                "date": "2022-01-04",
                "press_title": "Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-40th-annual-jp-morgan-healthcare-conference",
                "content": "  BOSTON --(BUSINESS WIRE)--Jan. 4, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 40 th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 9:00 a.m. ET . A live webcast of management's remarks will be available  ",
                "1d_change": 0.3116260713,
                "index_price": -2.2109970636,
                "norm_price": 2.5226231349
            },
            {
                "index": 60,
                "date": "2021-12-01",
                "press_title": "Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis",
                "release_url": "https://investors.vrtx.com/node/29041",
                "content": "  – Treatment with VX-147 led to a statistically significant, substantial and clinically meaningful mean reduction in proteinuria of 47.6% at 13 weeks compared to baseline and was well tolerated – – Results provide clinical proof of concept for the first genetically targeted approach to treating  ",
                "1d_change": 4.3335782551,
                "index_price": -0.5619218722,
                "norm_price": 4.8955001274
            },
            {
                "index": 61,
                "date": "2021-11-19",
                "press_title": "Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-reimbursement-agreement-spain-kaftrior",
                "content": "  – With this reimbursement agreement approximately 700 people with cystic fibrosis now have access to a CFTR modulator therapy for the first time – LONDON --(BUSINESS WIRE)--Nov. 19, 2021-- Vertex Pharmaceuticals Incorporated   (Nasdaq: VRTX) today announced that the Spanish government has approved  ",
                "1d_change": -1.8292051373,
                "index_price": -0.5445297253,
                "norm_price": -1.284675412
            },
            {
                "index": 62,
                "date": "2021-11-12",
                "press_title": "Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-chmp-positive-opinion-kaftrior-0",
                "content": "  - If approved, more than 1,500 children would be eligible for a medicine   that can treat the underlying cause of their disease for the first time - LONDON --(BUSINESS WIRE)--Nov. 12, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Medicines Agency’s  ",
                "1d_change": -0.0802707353,
                "index_price": 0.5885276216,
                "norm_price": -0.6687983569
            },
            {
                "index": 63,
                "date": "2021-11-02",
                "press_title": "Vertex Reports Third-Quarter 2021 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-third-quarter-2021-financial-results",
                "content": "  -Product revenues of $1.98 billion , a 29% increase compared to Q3 2020- -Company raises full-year 2021 guidance for product revenues to $7.4 to $7.5 billion - -Broad pipeline advancing with recent progress marked by unprecedented VX-880 clinical results in T1D; Phase 2 clinical results for VX-147  ",
                "1d_change": 1.8035666843,
                "index_price": 1.0133949764,
                "norm_price": 0.7901717079
            },
            {
                "index": 64,
                "date": "2021-10-26",
                "press_title": "Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-mammoth-biosciences-announce-collaboration-develop",
                "content": "  Vertex to use Mammoth’s proprietary ultra-small CRISPR systems to discover and develop novel in vivo gene-editing therapies BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Mammoth Biosciences , a biotech company building the next generation  ",
                "1d_change": -2.2548921057,
                "index_price": -0.5934020973,
                "norm_price": -1.6614900084
            },
            {
                "index": 65,
                "date": "2021-10-22",
                "press_title": "Vertex to Announce Third-Quarter 2021 Financial Results on November 2",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-third-quarter-2021-financial-results-november-2",
                "content": "  BOSTON --(BUSINESS WIRE)--Oct. 22, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2021 financial results on Tuesday, November 2, 2021 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  ",
                "1d_change": -0.9622134853,
                "index_price": 0.4458546488,
                "norm_price": -1.4080681341
            },
            {
                "index": 66,
                "date": "2021-10-19",
                "press_title": "Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-long-term-data-demonstrating-significant-benefits",
                "content": "  - 96-week interim results of TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) study show no loss of pulmonary function in people with at least one F508del allele, a first for any CFTR modulator – - Real-world data from people treated with KALYDECO ® (ivacaftor) over approximately 6 years  ",
                "1d_change": 1.8491605116,
                "index_price": 0.8564477713,
                "norm_price": 0.9927127403
            },
            {
                "index": 67,
                "date": "2021-10-18",
                "press_title": "Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-positive-day-90-data-first-patient-phase-12",
                "content": "  - First patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 Visit - - 91% decrease in daily insulin requirement and simultaneous robust improvements in glucose control as measured by  ",
                "1d_change": 1.5694965777,
                "index_price": 1.2370408511,
                "norm_price": 0.3324557266
            },
            {
                "index": 68,
                "date": "2021-09-13",
                "press_title": "Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-morgan-stanley-virtual-19th-annual-global",
                "content": "  BOSTON --(BUSINESS WIRE)--Sep. 13, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Virtual 19 th Annual Global Healthcare Conference on Wednesday, September 15 th , 2021 at 11:00 a.m. ET .  ",
                "1d_change": -0.8810591953,
                "index_price": -0.7148300222,
                "norm_price": -0.1662291731
            },
            {
                "index": 69,
                "date": "2021-08-26",
                "press_title": "Vertex Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-publication-new-england-journal-medicine-phase",
                "content": "  BOSTON --(BUSINESS WIRE)--Aug. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced publication in The   New England Journal of Medicine   (NEJM) of results from a Phase 3 study of TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in people with cystic fibrosis  ",
                "1d_change": -0.5102062234,
                "index_price": 0.3463924402,
                "norm_price": -0.8565986636
            },
            {
                "index": 70,
                "date": "2021-08-24",
                "press_title": "Vertex and Arbor Biotechnologies Establish New Partnership  to Develop Novel ex vivo Engineered Cell Therapies ",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-arbor-biotechnologies-establish-new-partnership",
                "content": "  Vertex to use Arbor’s CRISPR gene-editing technology to enhance efforts in developing novel cell therapies for the treatment of serious diseases CAMBRIDGE, MA – August 24, 2021 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Arbor Biotechnologies (Arbor) today announced a new collaboration  ",
                "1d_change": 1.2467066428,
                "index_price": 0.2622228868,
                "norm_price": 0.984483756
            },
            {
                "index": 71,
                "date": "2021-08-04",
                "press_title": "Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-appoints-stuart-arbuckle-chief-operating-officer",
                "content": "  BOSTON --(BUSINESS WIRE)--Aug. 4, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Stuart A. Arbuckle has been appointed as the company’s Executive Vice President, Chief Operating Officer (COO), effective immediately. Mr. Arbuckle has served as Vertex’s Executive Vice  ",
                "1d_change": 1.4729816307,
                "index_price": 0.296897836,
                "norm_price": 1.1760837948
            },
            {
                "index": 72,
                "date": "2021-07-29",
                "press_title": "Vertex Reports Second-Quarter 2021 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-second-quarter-2021-financial-results",
                "content": "  - Product revenues of $1.79 billion , an 18% increase compared to Q2 2020 - - Company raises full-year 2021 guidance for product revenues to $7.2 to $7.4B -   - Phase 3 study of next-in-class triple combination for CF to begin in the second half of 2021; multiple additional clinical milestones  ",
                "1d_change": -0.5704900715,
                "index_price": -0.1895241367,
                "norm_price": -0.3809659348
            },
            {
                "index": 73,
                "date": "2021-07-28",
                "press_title": "Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-initiate-phase-3-development-program-new-once-daily",
                "content": "  - Phase 2 study met primary endpoint and all secondary endpoints - - Phase 2 data demonstrated that a once-daily triple combination of VX-121/ tezacaftor/VX-561 has potential for enhanced clinical benefit compared to TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) - - Initiation of  ",
                "1d_change": -1.2326585291,
                "index_price": 0.366579713,
                "norm_price": -1.5992382421
            },
            {
                "index": 74,
                "date": "2021-07-19",
                "press_title": "Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-initiates-phase-2-clinical-trial-program-vx-548-treatment",
                "content": "  - Proof-of-concept study of VX-548 in acute pain following bunionectomy surgery open for enrollment - - Second Phase 2 study of VX-548 in acute pain following abdominoplasty surgery to begin in the coming weeks - BOSTON --(BUSINESS WIRE)--Jul. 19, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq:  ",
                "1d_change": -2.8542358297,
                "index_price": 0.6166964115,
                "norm_price": -3.4709322412
            },
            {
                "index": 75,
                "date": "2021-07-16",
                "press_title": "Vertex to Announce Second-Quarter 2021 Financial Results on July 29",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-second-quarter-2021-financial-results-july-29",
                "content": "  BOSTON --(BUSINESS WIRE)--Jul. 16, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second-quarter 2021 financial results on Thursday, July 29, 2021 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m. ET .  ",
                "1d_change": -0.6825941442,
                "index_price": -2.5581822526,
                "norm_price": 1.8755881085
            },
            {
                "index": 76,
                "date": "2021-06-28",
                "press_title": "Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-national-reimbursement-agreement-france",
                "content": "  - With this reimbursement agreement more than 1,500 patients now have access to a CFTR modulator therapy for the first time - LONDON --(BUSINESS WIRE)--Jun. 28, 2021-- Vertex Pharmaceuticals Incorporated   (Nasdaq: VRTX) today announced a national reimbursement agreement with the French Health  ",
                "1d_change": -0.1118006007,
                "index_price": 0.1607694361,
                "norm_price": -0.2725700368
            },
            {
                "index": 77,
                "date": "2021-06-25",
                "press_title": "Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO®, SYMKEVI® and Additional Indications of ORKAMBI® and KALYDECO® for Eligible Patients With Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-new-portfolio-reimbursement-agreement-italy",
                "content": "  - Reimbursement agreement also includes certain future indication extensions across all Vertex CF medicines - - Approximately 1,400 patients will now have access to a CFTR modulator for the first time - LONDON --(BUSINESS WIRE)--Jun. 25, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)  ",
                "1d_change": 2.9420721407,
                "index_price": 0.3766286958,
                "norm_price": 2.5654434449
            },
            {
                "index": 78,
                "date": "2021-06-18",
                "press_title": "Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/health-canada-grants-marketing-authorization-trikaftar",
                "content": "  -Approximately 1,100 F/MF patients now eligible for a CFTR modulator to treat the underlying cause of their disease- BOSTON --(BUSINESS WIRE)--Jun. 18, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced Health Canada has granted Marketing Authorization for TRIKAFTA ®  ",
                "1d_change": -0.4368712507,
                "index_price": 0.4736390145,
                "norm_price": -0.9105102652
            },
            {
                "index": 79,
                "date": "2021-06-11",
                "press_title": "Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-present-new-data-22-patients",
                "content": "  - Beta thalassemia: All 15 patients were transfusion independent after CTX001 infusion - - Sickle cell disease: All seven patients were free of vaso-occlusive crises after CTX001 infusion - BOSTON &amp; ZUG, Switzerland &amp; CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun.  ",
                "1d_change": 0.3901487442,
                "index_price": 0.2878864501,
                "norm_price": 0.1022622941
            },
            {
                "index": 80,
                "date": "2021-06-10",
                "press_title": "Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-primary-endpoint-achieved-phase-2-study-vx-864",
                "content": "  - Treatment with VX-864 led to a statistically significant increase from baseline in plasma functional AAT levels as compared to placebo and was generally well tolerated - - Results provide proof-of-mechanism, although magnitude of treatment effect observed unlikely to translate into substantial  ",
                "1d_change": -10.7760867223,
                "index_price": 0.4445002889,
                "norm_price": -11.2205870112
            },
            {
                "index": 81,
                "date": "2021-06-09",
                "press_title": "Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-trikaftar",
                "content": "  - With this approval approximately 1,500 children with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease for the first time - BOSTON --(BUSINESS WIRE)--Jun. 9, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today  ",
                "1d_change": 2.2004909251,
                "index_price": 0.1460174173,
                "norm_price": 2.0544735079
            },
            {
                "index": 82,
                "date": "2021-05-12",
                "press_title": "Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-present-new-clinical-data",
                "content": "  CAMBRIDGE, Mass. and ZUG, Switzerland and BOSTON, May 12, 2021 (GLOBE NEWSWIRE) --&nbsp; Vertex Pharmaceuticals Incorporated &nbsp;(Nasdaq: VRTX) and&nbsp; CRISPR Therapeutics &nbsp;(Nasdaq: CRSP) today announced two abstracts detailing updated data from the ongoing CTX001 clinical trials have been accepted for  ",
                "1d_change": 1.0683501188,
                "index_price": -0.4389010258,
                "norm_price": 1.5072511447
            },
            {
                "index": 83,
                "date": "2021-05-10",
                "press_title": "Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-bank-america-securities-2021-virtual-health-care",
                "content": "  BOSTON --(BUSINESS WIRE)--May 10, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Bank of America Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 10:15 a.m. ET .  ",
                "1d_change": -1.2347440764,
                "index_price": -1.8349736185,
                "norm_price": 0.6002295421
            },
            {
                "index": 84,
                "date": "2021-04-29",
                "press_title": "Vertex Reports First-Quarter 2021 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-first-quarter-2021-financial-results",
                "content": "  -Product revenues of $1.72 billion , a 14% increase compared to Q1 2020- - Company advancing clinical programs in six additional diseases beyond cystic fibrosis- -Multiple Phase 2 proof-of-concept study results expected in 2021 - BOSTON --(BUSINESS WIRE)--Apr.  ",
                "1d_change": 2.1081534872,
                "index_price": -0.5972064114,
                "norm_price": 2.7053598986
            },
            {
                "index": 85,
                "date": "2021-04-28",
                "press_title": "Vertex Announces European Commission Approval for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older With At Least One F508del Mutation in the CFTR gene",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-european-commission-approval-kaftrior",
                "content": "  - New indication includes people ages 12 years and older who have one copy of the F508del mutation regardless of the other mutation type - - People with gating (F/G) or residual function (F/RF) mutations now eligible for the triple combination therapy - LONDON --(BUSINESS WIRE)--Apr.  ",
                "1d_change": -1.8030737536,
                "index_price": 0.6251992008,
                "norm_price": -2.4282729544
            },
            {
                "index": 86,
                "date": "2021-04-26",
                "press_title": "Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia ",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-priority-medicines-prime",
                "content": "  BOSTON and CAMBRIDGE, Mass. and ZUG, Switzerland, April 26, 2021 (GLOBE NEWSWIRE) -- Vertex &nbsp;Pharmaceuticals Incorporated (Nasdaq: VRTX) and&nbsp; CRISPR Therapeutics &nbsp;(Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an  ",
                "1d_change": -1.0253824184,
                "index_price": 0.0403759889,
                "norm_price": -1.0657584073
            },
            {
                "index": 87,
                "date": "2021-04-26",
                "press_title": "Vertex Announces NaV1.8 Inhibitor Advancing to Phase 2 Clinical Development",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-nav18-inhibitor-advancing-phase-2-clinical",
                "content": "  - Proof-of-concept studies of VX-548 in acute pain to initiate in the second half of the year - BOSTON --(BUSINESS WIRE)--Apr. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will advance the selective   NaV1.8 inhibitor, VX-548, into Phase 2 clinical  ",
                "1d_change": -1.0253824184,
                "index_price": 0.0403759889,
                "norm_price": -1.0657584073
            },
            {
                "index": 88,
                "date": "2021-04-22",
                "press_title": "Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-obsidian-therapeutics-establish-collaboration",
                "content": "  - Multi-year strategic research collaboration leverages Obsidian’s proprietary cytoDRiVE® platform to discover controllable genetic therapies to treat serious diseases - Vertex will pay Obsidian up to $75 million in equity, upfront payments and potential research milestones BOSTON &amp; CAMBRIDGE,  ",
                "1d_change": 0.3625485582,
                "index_price": 0.2322862735,
                "norm_price": 0.1302622847
            },
            {
                "index": 89,
                "date": "2021-04-20",
                "press_title": "Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-pharmaceuticals-and-crispr-therapeutics-amend",
                "content": "  - Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001- - Revised agreement provides Vertex with 60% and CRISPR with 40% of program economics- - CRISPR to receive $900 million upfront payment with potential for additional $200 million  ",
                "1d_change": 0.418637692,
                "index_price": 0.3412008942,
                "norm_price": 0.0774367978
            },
            {
                "index": 90,
                "date": "2021-04-19",
                "press_title": "Vertex to Announce First-Quarter 2021 Financial Results on April 29",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-first-quarter-2021-financial-results-april-29",
                "content": "  BOSTON --(BUSINESS WIRE)--Apr. 19, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2021 financial results on Thursday, April 29, 2021 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m. ET .  ",
                "1d_change": -0.31794919,
                "index_price": -1.0848975781,
                "norm_price": 0.7669483882
            },
            {
                "index": 91,
                "date": "2021-03-26",
                "press_title": "Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis With At Least One F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-chmp-positive-opinion-kaftrior",
                "content": "  - If approved, people ages 12 years and older who have one copy of the F508del mutation and a gating (F/G) or residual function (F/RF) mutation will now be eligible for triple combination therapy - LONDON --(BUSINESS WIRE)--Mar. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today  ",
                "1d_change": 1.9426914233,
                "index_price": 1.3590719301,
                "norm_price": 0.5836194932
            },
            {
                "index": 92,
                "date": "2021-03-24",
                "press_title": "Vertex Receives Australian TGA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-australian-tga-approval-trikaftar",
                "content": "  - With this approval approximately 750 people living with cystic fibrosis in Australia will be newly eligible for a CFTR modulator therapy - LONDON --(BUSINESS WIRE)--Mar. 24, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Australian Therapeutic Goods  ",
                "1d_change": -0.5886230912,
                "index_price": -0.266270848,
                "norm_price": -0.3223522432
            },
            {
                "index": 93,
                "date": "2021-03-10",
                "press_title": "Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-fda-fast-track-designation-and-initiation-phase",
                "content": "  – VX-880 is the first investigational stem cell-derived therapy utilizing fully differentiated, insulin-producing pancreatic islet cells for the treatment of type 1 diabetes – – VX-880 is the first and only pancreatic islet replacement therapy known to receive Fast Track Designation – BOSTON  ",
                "1d_change": -0.9993070956,
                "index_price": 1.2019804485,
                "norm_price": -2.2012875441
            },
            {
                "index": 94,
                "date": "2021-02-24",
                "press_title": "Vertex to Present at the Cowen Health Care Conference on March 2",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-cowen-health-care-conference-march-2",
                "content": "  BOSTON --(BUSINESS WIRE)--Feb. 24, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Health Care Conference on Tuesday, March 2, 2021 at 9:50 a.m. ET . The audio portion of management's remarks will be available live through Vertex  ",
                "1d_change": -1.3334640124,
                "index_price": -1.1586819668,
                "norm_price": -0.1747820456
            },
            {
                "index": 95,
                "date": "2021-02-01",
                "press_title": "Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2020-financial",
                "content": "  -Full-year 2020 GAAP product revenues of $6.20 billion - -Full-year 2020 non-GAAP product revenues of $6.20 billion , a 55% increase compared to full-year 2019- -Company provides full-year 2021 product revenue guidance of $6.7 to $6.9 billion - BOSTON --(BUSINESS WIRE)--Feb.  ",
                "1d_change": -6.2899728771,
                "index_price": 2.4864722216,
                "norm_price": -8.7764450987
            },
            {
                "index": 96,
                "date": "2021-01-28",
                "press_title": "Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-fda-clearance-investigational-new-drug-ind",
                "content": "  - Vertex will initiate a Phase 1/2 clinical trial in first half of 2021 - - VX-880 is the first stem cell-derived therapy evaluating fully differentiated pancreatic islet cells for the treatment of T1D - BOSTON --(BUSINESS WIRE)--Jan. 28, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)  ",
                "1d_change": 0.995284949,
                "index_price": -1.1175909439,
                "norm_price": 2.1128758929
            },
            {
                "index": 97,
                "date": "2021-01-26",
                "press_title": "Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-acceptance-supplemental-new-drug",
                "content": "  -FDA grants Priority Review of the application and sets a PDUFA target action date of June 8, 2021 - BOSTON --(BUSINESS WIRE)--Jan. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug  ",
                "1d_change": -6.7391754387,
                "index_price": -2.9911175791,
                "norm_price": -3.7480578596
            },
            {
                "index": 98,
                "date": "2021-01-22",
                "press_title": "Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-fourth-quarter-2020-financial-results-february-1",
                "content": "  BOSTON --(BUSINESS WIRE)--Jan. 22, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth-quarter 2020 financial results on Monday, February 1, 2021 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  ",
                "1d_change": 1.6824821183,
                "index_price": 0.2884326464,
                "norm_price": 1.3940494719
            },
            {
                "index": 99,
                "date": "2021-01-07",
                "press_title": "Vertex to Present at the J.P. Morgan Healthcare Conference on January 11",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-jp-morgan-healthcare-conference-january-11",
                "content": "  BOSTON --(BUSINESS WIRE)--Jan. 7, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 a.m. ET ( 6:10 a.m. PT ). The audio portion of management’s remarks can be accessed  ",
                "1d_change": 3.8396650226,
                "index_price": 1.5679735762,
                "norm_price": 2.2716914464
            },
            {
                "index": 100,
                "date": "2020-12-28",
                "press_title": "Vertex Announces New Drug Submission for Investigational Triple Combination Medicine for the Treatment of Cystic Fibrosis Has Been Accepted for Priority Review by Health Canada",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-new-drug-submission-investigational-triple",
                "content": "  BOSTON , Dec. 28, 2020 /CNW/ -  Vertex Pharmaceuticals Incorporated   (Nasdaq: VRTX) today announced its New Drug Submission for TRIKAFTA®, Vertex 's investigational triple combination medicine, has been accepted for Priority Review by Health Canada for the treatment of cystic fibrosis (CF) in  ",
                "1d_change": -0.8180171992,
                "index_price": 0.1075923447,
                "norm_price": -0.9256095439
            },
            {
                "index": 101,
                "date": "2020-12-22",
                "press_title": "Skyhawk and Vertex Establish a Strategic Collaboration to Discover and Develop Novel Small Molecules that Modulate RNA Splicing for Serious Diseases",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/skyhawk-and-vertex-establish-strategic-collaboration-discover",
                "content": "  Vertex receives exclusive options to license a number of Skyhawk’s product candidates directed at serious diseases Skyhawk receives $40 million upfront as well as potential milestones and royalty payments on future sales WALTHAM, Mass. &amp; BOSTON --(BUSINESS WIRE)--Dec.  ",
                "1d_change": 0.3519342961,
                "index_price": -0.2187004463,
                "norm_price": 0.5706347424
            },
            {
                "index": 102,
                "date": "2020-12-21",
                "press_title": "Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Use in People With CF With Certain Rare Mutations",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-fda-approvals-trikaftar",
                "content": "  - More than 600 people with certain rare CF mutations are now eligible for TRIKAFTA, SYMDEKO or KALYDECO - BOSTON --(BUSINESS WIRE)--Dec. 21, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) expanded the eligibility for TRIKAFTA ®  ",
                "1d_change": 0.8003361741,
                "index_price": 0.0808182895,
                "norm_price": 0.7195178846
            },
            {
                "index": 103,
                "date": "2020-12-05",
                "press_title": "CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/crispr-therapeutics-and-vertex-present-new-data-investigational",
                "content": "  - Beta thalassemia: All seven patients were transfusion independent with 3 to 18 months of follow-up after CTX001 infusion - - Sickle cell disease: All three patients were free of vaso-occlusive crises with 3 to 15 months of follow-up after CTX001 infusion - - Nineteen patients have been dosed with  ",
                "1d_change": -0.509071122,
                "index_price": 0.203120252,
                "norm_price": -0.712191374
            },
            {
                "index": 104,
                "date": "2020-12-01",
                "press_title": "CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ in Sickle Cell Disease and Beta Thalassemia",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/crispr-therapeutics-and-vertex-host-investor-webcast-review-data",
                "content": "  ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON , Dec. 01, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the companies will host an investor webcast on December 9, 2020 at 8:00 a.m.  ",
                "1d_change": -0.3396578222,
                "index_price": 0.6306849127,
                "norm_price": -0.9703427349
            },
            {
                "index": 105,
                "date": "2020-11-27",
                "press_title": "Vertex Announces European Commission Approval for SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-european-commission-approval-symkevir",
                "content": "  - The combination therapy is a new treatment option for CF patients who are homozygous for F508del - - The only medicine to treat the underlying cause of CF in this age group with one F508del mutation and one of 14 residual function mutations - LONDON --(BUSINESS WIRE)--Nov.  ",
                "1d_change": 3.5740941338,
                "index_price": -0.4671975482,
                "norm_price": 4.0412916819
            },
            {
                "index": 106,
                "date": "2020-11-13",
                "press_title": "Vertex Recommends Rejection of ‘Mini-Tender’ Offer From TRC Capital Investment Corporation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-recommends-rejection-mini-tender-offer-trc-capital",
                "content": "  BOSTON --(BUSINESS WIRE)--Nov. 13, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that it has been notified of an unsolicited “mini-tender” offer dated November 9, 2020 , made by TRC Capital Investment Corporation , an Ontario, Canada , corporation to purchase up to  ",
                "1d_change": 0.8873257481,
                "index_price": 2.0496743937,
                "norm_price": -1.1623486456
            },
            {
                "index": 107,
                "date": "2020-11-12",
                "press_title": "Vertex to Present at the Jefferies Virtual London Health Care Conference on November 19",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-jefferies-virtual-london-health-care-conference",
                "content": "  BOSTON --(BUSINESS WIRE)--Nov. 12, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Jefferies Virtual London Health Care Conference on Thursday, November 19, 2020 at 9:05 a.m. ET ( 2:05 p.m. GMT ).  ",
                "1d_change": 3.7557649256,
                "index_price": 0.6270304194,
                "norm_price": 3.1287345062
            },
            {
                "index": 108,
                "date": "2020-11-05",
                "press_title": "Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With Cystic Fibrosis as Early as Four Months of Age",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-european-commission-approval-kalydecor-2",
                "content": "  - Approval provides opportunity to treat the underlying cause of cystic fibrosis earlier than ever before in Europe - LONDON --(BUSINESS WIRE)--Nov. 5, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the label extension  ",
                "1d_change": 0.0907921506,
                "index_price": 0.6753200387,
                "norm_price": -0.5845278881
            },
            {
                "index": 109,
                "date": "2020-11-04",
                "press_title": "CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/crisprcas9-gene-editing-therapy-ctx001tm-severe",
                "content": "  ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data in seven patients from two ongoing Phase 1/2 clinical trials of the investigational CRISPR/Cas9  ",
                "1d_change": 0.5512991975,
                "index_price": 2.9622980439,
                "norm_price": -2.4109988464
            },
            {
                "index": 110,
                "date": "2020-10-29",
                "press_title": "Vertex Reports Third-Quarter 2020 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-third-quarter-2020-financial-results",
                "content": "  -Product revenues of $1.54 billion , a 62% increase compared to Q3 2019- -Company raises revenue guidance; now expects 2020 product revenues of $6.0 to $6.2 billion - BOSTON --(BUSINESS WIRE)--Oct. 29, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial  ",
                "1d_change": -0.3119571389,
                "index_price": -0.2204908018,
                "norm_price": -0.0914663371
            },
            {
                "index": 111,
                "date": "2020-10-19",
                "press_title": "Vertex to Announce Third-Quarter 2020 Financial Results on October 29",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-third-quarter-2020-financial-results-october-29",
                "content": "  BOSTON --(BUSINESS WIRE)--Oct. 19, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2020 financial results on Thursday, October 29, 2020 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  ",
                "1d_change": -2.1161595446,
                "index_price": -1.4678487303,
                "norm_price": -0.6483108143
            },
            {
                "index": 112,
                "date": "2020-10-14",
                "press_title": "Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-provides-update-its-clinical-programs-targeting-alpha-1",
                "content": "  - Phase 2 study of VX-814 in patients with alpha-1 antitrypsin deficiency discontinued based upon safety and pharmacokinetic data - - Phase 2 study of VX-864 continues to enroll and dose patients; data expected in H1 2021 - - AATD research program continues to progress - BOSTON --(BUSINESS  ",
                "1d_change": -27.8288758834,
                "index_price": -0.9223871917,
                "norm_price": -26.9064886918
            },
            {
                "index": 113,
                "date": "2020-09-25",
                "press_title": "FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/fda-approves-kalydecor-ivacaftor-first-and-only-cftr-modulator-0",
                "content": "  -Approval provides opportunity to treat the underlying cause of CF earlier than ever before- -Safety data from a cohort of the Phase 3 ARRIVAL study support treatment with KALYDECO in children ages four to   ",
                "1d_change": 1.3558453419,
                "index_price": 3.4294122866,
                "norm_price": -2.0735669447
            },
            {
                "index": 114,
                "date": "2020-09-24",
                "press_title": "Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-new-data-european-and-north-american-virtual",
                "content": "  - Oral presentation of interim results from TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) open-label safety extension study to be presented at the ECFS Digital Conference - - Six presentations highlighting data from KALYDECO ® (ivacaftor), ORKAMBI ® (lumacaftor/ivacaftor) and TRIKAFTA  ",
                "1d_change": 2.2522105274,
                "index_price": 2.1925404345,
                "norm_price": 0.0596700929
            },
            {
                "index": 115,
                "date": "2020-09-22",
                "press_title": "CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/crispr-therapeutics-and-vertex-pharmaceuticals-announce-priority",
                "content": "  ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Sept. 22, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Inco r porated &nbsp;(Nasdaq: VRTX) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an  ",
                "1d_change": 0.0606487975,
                "index_price": -1.8174709151,
                "norm_price": 1.8781197126
            },
            {
                "index": 116,
                "date": "2020-09-16",
                "press_title": "Moderna and Vertex Establish New Collaboration to Treat Cystic Fibrosis Using Gene Editing",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/moderna-and-vertex-establish-new-collaboration-treat-cystic",
                "content": "  Second collaboration between Moderna and Vertex based on Moderna’s proprietary mRNA and LNP technology Collaboration will leverage Vertex’s investments and capabilities in genetic technologies for CF Moderna to receive $75 million upfront, with potential for additional development, regulatory and  ",
                "1d_change": 0.1694509208,
                "index_price": -1.6151268702,
                "norm_price": 1.784577791
            },
            {
                "index": 117,
                "date": "2020-09-14",
                "press_title": "Vertex Announces European Medicines Agency Type II Variation Marketing Authorization Application Validation for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination with ivacaftor in People with One Copy of the F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-european-medicines-agency-type-ii-variation",
                "content": "  LONDON --(BUSINESS WIRE)--Sep. 14, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the European Medicines Agency (EMA) has validated a Type II Variation Marketing Authorization Application (MAA) for the expanded indication of KAFTRIO ®* (ivacaftor/tezacaftor/elexacaftor)  ",
                "1d_change": 2.1023105643,
                "index_price": 1.1066650923,
                "norm_price": 0.995645472
            },
            {
                "index": 118,
                "date": "2020-09-10",
                "press_title": "Vertex Announces Positive Phase 3 Study for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children Ages 6-11 Years With Cystic Fibrosis to Support Submissions for Global Regulatory Approvals",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-positive-phase-3-study-trikaftar",
                "content": "  BOSTON --(BUSINESS WIRE)--Sep. 10, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the company has completed a global Phase 3 study of TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)   in children ages 6 through 11 years old with cystic fibrosis (CF) who have  ",
                "1d_change": -1.9344165441,
                "index_price": -2.1427935156,
                "norm_price": 0.2083769715
            },
            {
                "index": 119,
                "date": "2020-09-10",
                "press_title": "The Vertex Foundation Announces €1 Million Donation to Ronald McDonald House Charities at the New Children’s Hospital in Ireland",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-foundation-announces-eu1-million-donation-ronald-mcdonald",
                "content": "  LONDON --(BUSINESS WIRE)--Sep. 10, 2020-- The Vertex Foundation , a nonprofit charitable foundation, today announced a €1 million donation to Ronald McDonald House Charities (RMHC) to support the construction of a Ronald McDonald House at the new children’s hospital in Dublin, Ireland .  ",
                "1d_change": -1.9344165441,
                "index_price": -2.1427935156,
                "norm_price": 0.2083769715
            },
            {
                "index": 120,
                "date": "2020-09-01",
                "press_title": "FDA Accepts Vertex’s Supplemental New Drug Applications for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Additional CFTR Mutations",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/fda-accepts-vertexs-supplemental-new-drug-applications-trikaftar",
                "content": "  - More than 600 people with certain rare CF mutations could become newly eligible for TRIKAFTA, SYMDEKO or KALYDECO - BOSTON --(BUSINESS WIRE)--Sep. 1, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) accepted three supplemental  ",
                "1d_change": 1.426095045,
                "index_price": 2.0498024118,
                "norm_price": -0.6237073668
            },
            {
                "index": 121,
                "date": "2020-08-21",
                "press_title": "European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis in People Ages 12 Years and Older",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/european-commission-approves-kaftrior",
                "content": "  – For the first time, up to 10,000 people in Europe ages 12 years and older with one F508del mutation and one minimal function mutation will be eligible for a medicine that treats the underlying cause of cystic fibrosis – – People 12 years of age and older who have two F508del mutations will also  ",
                "1d_change": -1.6079042846,
                "index_price": 1.3193332851,
                "norm_price": -2.9272375697
            },
            {
                "index": 122,
                "date": "2020-07-30",
                "press_title": "Vertex Reports Second-Quarter 2020 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-second-quarter-2020-financial-results",
                "content": "  -Product revenues of $1.52 billion , a 62% increase compared to Q2 2019- -Company raises revenue guidance; now expects 2020 CF revenues of $5.7 to $5.9 billion - BOSTON --(BUSINESS WIRE)--Jul. 30, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial  ",
                "1d_change": -1.1323480045,
                "index_price": 1.2032608407,
                "norm_price": -2.3356088452
            },
            {
                "index": 123,
                "date": "2020-07-20",
                "press_title": "Positive Phase 3 Study Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older With Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating or Residual Function Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/positive-phase-3-study-results-trikaftar",
                "content": "  -Phase 3 study met primary endpoint and all secondary endpoints- -Study is a U.S. post-marketing commitment and will be submitted to FDA- -Data also will be submitted to the European Medicines Agency to support indication expansion of the EU label following triple combination approval- BOSTON  ",
                "1d_change": -0.4426934015,
                "index_price": 1.013416304,
                "norm_price": -1.4561097055
            },
            {
                "index": 124,
                "date": "2020-07-16",
                "press_title": "Vertex to Announce Second-Quarter 2020 Financial Results on July 30",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-second-quarter-2020-financial-results-july-30",
                "content": "  BOSTON --(BUSINESS WIRE)--Jul. 16, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second-quarter 2020 financial results on Thursday, July 30, 2020 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m. ET .  ",
                "1d_change": 0.8555967216,
                "index_price": 0.5076354655,
                "norm_price": 0.3479612561
            },
            {
                "index": 125,
                "date": "2020-06-30",
                "press_title": "Vertex Announces Expansion of Reimbursement Agreement With NHS England to Include KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor)",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-expansion-reimbursement-agreement-nhs-england",
                "content": "  -CF patients in England will be among the first in Europe to benefit from access to KAFTRIO ® , if the medicine is approved by the European Commission - LONDON --(BUSINESS WIRE)--Jun. 30, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has expanded its  ",
                "1d_change": -0.4890295873,
                "index_price": 2.1072883245,
                "norm_price": -2.5963179117
            },
            {
                "index": 126,
                "date": "2020-06-26",
                "press_title": "CHMP Grants Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor) in People Ages 12 and Older With Cystic Fibrosis With the Most Common Genotypes",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/chmp-grants-positive-opinion-kaftrior",
                "content": "  – If granted Marketing Authorization, people ages 12 and older in Europe who have one F508del mutation and one minimal function mutation will for the first time be able to benefit from a medicine that treats the underlying cause of the disease – – People 12 years of age and older who have two  ",
                "1d_change": -2.6299180141,
                "index_price": -0.6537304962,
                "norm_price": -1.9761875179
            },
            {
                "index": 127,
                "date": "2020-06-25",
                "press_title": "Vertex and the Vertex Foundation Commit $4 Million to Support Racial Equity and Social Justice",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-vertex-foundation-commit-4-million-support-racial",
                "content": "  - Vertex Foundation Announces $1.5 Million Gift to Boston University’s New Center for Antiracist Research - -Biotechnology-focused curriculum established in partnership with Year Up- -Additional commitments made to STEAM education- BOSTON --(BUSINESS WIRE)--Jun.  ",
                "1d_change": -2.180747157,
                "index_price": -1.2479037643,
                "norm_price": -0.9328433927
            },
            {
                "index": 128,
                "date": "2020-06-12",
                "press_title": "CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-new-clinical-data",
                "content": "  -Beta thalassemia: Two patients are transfusion independent at 5 and 15 months after CTX001 infusion; data demonstrate clinical proof-of-concept for CTX001 in transfusion-dependent beta thalassemia- -Sickle cell disease: Patient is free of vaso-occlusive crises at 9 months after CTX001 infusion-  ",
                "1d_change": -0.1307114755,
                "index_price": -0.145110727,
                "norm_price": 0.0143992516
            },
            {
                "index": 129,
                "date": "2020-06-10",
                "press_title": "Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages of 6 Months and 18 Years With the R117H Mutation in the CFTR Gene",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-european-commission-approval-kalydecor-1",
                "content": "  - KALYDECO ® (ivacaftor) is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis in patients with the R117H mutation, the most common residual function mutation, in children as young as 6 months of age - LONDON --(BUSINESS WIRE)--Jun.  ",
                "1d_change": -4.4980842238,
                "index_price": -7.0390665649,
                "norm_price": 2.5409823411
            },
            {
                "index": 130,
                "date": "2020-06-03",
                "press_title": "Vertex Appoints Diana McKenzie to its Board of Directors",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-appoints-diana-mckenzie-its-board-directors",
                "content": "  BOSTON --(BUSINESS WIRE)--Jun. 3, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Diana McKenzie has been appointed to its board of directors as an independent director. Ms. McKenzie is a senior technology leader and innovator with deep experience across pharma,  ",
                "1d_change": -3.9953059174,
                "index_price": 0.4321556024,
                "norm_price": -4.4274615198
            },
            {
                "index": 131,
                "date": "2020-05-14",
                "press_title": "New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/new-data-investigational-crisprcas9-gene-editing-therapy",
                "content": "  ZUG, Switzerland&nbsp;and&nbsp;CAMBRIDGE, Mass.&nbsp;and&nbsp;BOSTON,&nbsp;May 14, 2020&nbsp;(GLOBE NEWSWIRE) --&nbsp; CRISPR Therapeutics &nbsp;(Nasdaq: CRSP) and&nbsp; Vertex Pharmaceuticals Incorporated &nbsp;(Nasdaq: VRTX) today announced that new data from two ongoing Phase 1/2 clinical trials of the CRISPR/Cas9 gene-editing therapy CTX001 in  ",
                "1d_change": 3.8553482243,
                "index_price": 2.4150544152,
                "norm_price": 1.4402938091
            },
            {
                "index": 132,
                "date": "2020-05-11",
                "press_title": "CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/crispr-therapeutics-and-vertex-pharmaceuticals-announce-fda",
                "content": "  CTX001 has received Orphan Drug Designation from the U.S. Food and Drug Administration for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia ZUG, Switzerland&nbsp;and&nbsp;CAMBRIDGE, Mass.&nbsp;and&nbsp;BOSTON,&nbsp;May 11,  ",
                "1d_change": 1.8157445623,
                "index_price": -1.579719381,
                "norm_price": 3.3954639434
            },
            {
                "index": 133,
                "date": "2020-05-01",
                "press_title": "Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages 6 Months and 18 Years With the R117H Mutation in the CFTR Gene",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-european-chmp-positive-opinion-kalydecor-1",
                "content": "  - If approved, KALYDECO ® (ivacaftor) will be the first and only medicine in Europe to treat the underlying cause of cystic fibrosis in patients with the R117H mutation, the most common residual function mutation, as young as 6 months of age - LONDON --(BUSINESS WIRE)--May 1, 2020-- Vertex  ",
                "1d_change": 5.8294638227,
                "index_price": -0.9269260554,
                "norm_price": 6.7563898781
            },
            {
                "index": 134,
                "date": "2020-04-29",
                "press_title": "Vertex Reports First-Quarter 2020 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-first-quarter-2020-financial-results",
                "content": "  -Product revenues of $1.52 billion , a 77% increase compared to Q1 2019- -Company raises revenue guidance; now expects 2020 CF revenues of $5.3 to $5.6 billion - BOSTON --(BUSINESS WIRE)--Apr. 29, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial  ",
                "1d_change": -3.8893329583,
                "index_price": -0.2070446135,
                "norm_price": -3.6822883447
            },
            {
                "index": 135,
                "date": "2020-04-28",
                "press_title": "Vertex Announces Virtual 2020 Annual Meeting and Internet Access to Proxy Materials",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-virtual-2020-annual-meeting-and-internet-access",
                "content": "  BOSTON --(BUSINESS WIRE)--Apr. 28, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that, due to public health and travel safety concerns related to the ongoing COVID-19 pandemic, its 2020 Annual Meeting of Shareholders will be held as a virtual meeting.  ",
                "1d_change": -6.7516418013,
                "index_price": 1.0052712435,
                "norm_price": -7.7569130448
            },
            {
                "index": 136,
                "date": "2020-04-27",
                "press_title": "Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-pharmaceuticals-and-affinia-therapeutics-establish-multi",
                "content": "  Affinia Therapeutics’ proprietary AAV vector technology to be used in Vertex’s genetic therapy efforts with focus on Duchenne muscular dystrophy, myotonic dystrophy type 1 and cystic fibrosis BOSTON &amp; WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 27, 2020-- Vertex Pharmaceuticals Incorporated  ",
                "1d_change": -7.0205515041,
                "index_price": 0.3052322793,
                "norm_price": -7.3257837834
            },
            {
                "index": 137,
                "date": "2020-04-24",
                "press_title": "The Vertex Foundation Announces Donation to Food Banks Canada to Help With COVID-19 Response",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-foundation-announces-donation-food-banks-canada-help",
                "content": "  TORONTO , April 24, 2020 /CNW/ - Vertex Pharmaceuticals Incorporated announced that the Vertex Foundation , a nonprofit charitable foundation, will donate $50,000 CAD to Food Banks Canada to support their COVID-19 Response Fund . Food banks across Canada have been severely impacted by COVID-19.  ",
                "1d_change": -0.5995997516,
                "index_price": 2.2873213758,
                "norm_price": -2.8869211274
            },
            {
                "index": 138,
                "date": "2020-04-21",
                "press_title": "Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-innovative-reimbursement-agreement-switzerland",
                "content": "  Agreement also enables the possibility of rapid patient access to future triple combination regimen (elexacaftor/tezacaftor/ivacaftor and ivacaftor) once approved in Switzerland LONDON --(BUSINESS WIRE)--Apr. 21, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has  ",
                "1d_change": -1.3475906555,
                "index_price": 0.5179847783,
                "norm_price": -1.8655754337
            },
            {
                "index": 139,
                "date": "2020-04-20",
                "press_title": "Vertex to Announce First-Quarter 2020 Financial Results on April 29",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-first-quarter-2020-financial-results-april-29",
                "content": "  BOSTON --(BUSINESS WIRE)--Apr. 20, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2020 financial results on Wednesday, April 29, 2020 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  ",
                "1d_change": -3.4893507815,
                "index_price": -3.9852974632,
                "norm_price": 0.4959466817
            },
            {
                "index": 140,
                "date": "2020-04-07",
                "press_title": "The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-foundation-commits-5-million-support-global-covid-19",
                "content": "  BOSTON --(BUSINESS WIRE)--Apr. 7, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Vertex Foundation , a nonprofit charitable foundation, commits to make donations totaling $5 million in 2020 to support global COVID-19 relief efforts, including doubling its match  ",
                "1d_change": -5.4033445632,
                "index_price": 0.4120058402,
                "norm_price": -5.8153504034
            },
            {
                "index": 141,
                "date": "2020-03-27",
                "press_title": "Vertex Confirms Supply Chain Continuity and Business Outlook for Its Cystic Fibrosis Medicines and Provides Initial Update on Development Programs",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-confirms-supply-chain-continuity-and-business-outlook-its",
                "content": "  BOSTON --(BUSINESS WIRE)--Mar. 27, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today confirmed its 2020 business outlook and the continuity of the company’s supply chain for its approved cystic fibrosis (CF) medicines and provided an update on its development programs given the ongoing  ",
                "1d_change": 5.385480162,
                "index_price": 2.6946790698,
                "norm_price": 2.6908010922
            },
            {
                "index": 142,
                "date": "2020-03-13",
                "press_title": "The Vertex Foundation Donates $500,000 to Partners HealthCare to Support COVID-19 Outbreak Response",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-foundation-donates-500000-partners-healthcare-support",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Vertex Foundation , a nonprofit charitable foundation, is making a $500,000 gift to Partners HealthCare , a Boston -based nonprofit hospital and physician network, to support the needs of patients  ",
                "1d_change": -9.2406222457,
                "index_price": -7.705368796,
                "norm_price": -1.5352534497
            },
            {
                "index": 143,
                "date": "2020-03-09",
                "press_title": "Vertex Confirms Supply Chain Continuity and 2020 Business Outlook",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-confirms-supply-chain-continuity-and-2020-business",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirmed that the global coronavirus outbreak has not had any impact on the company’s supply chain or its 2020 business outlook. “The challenges facing the world with the spread of COVID-19 are significant, but it  ",
                "1d_change": 5.3967235604,
                "index_price": 0.6363159087,
                "norm_price": 4.7604076517
            },
            {
                "index": 144,
                "date": "2020-03-02",
                "press_title": "Vertex Announces Cancellation of its March 3 Presentation at the Cowen Health Care Conference",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-cancellation-its-march-3-presentation-cowen",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the cancellation of its planned March 3 presentation and webcast at the Cowen Health Care Conference . Following implementation of a companywide travel and meetings policy that is designed to reduce  ",
                "1d_change": 1.6779119965,
                "index_price": 0.9685815186,
                "norm_price": 0.7093304779
            },
            {
                "index": 145,
                "date": "2020-02-25",
                "press_title": "Vertex Announces Availability of Cystic Fibrosis Medicine KALYDECO® (ivacaftor) in New Zealand",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-availability-cystic-fibrosis-medicine-kalydecor",
                "content": "  LONDON --(BUSINESS WIRE)--Feb. 25, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that KALYDECO ® (ivacaftor) will be available to eligible patients with cystic fibrosis (CF) in New Zealand from March 1 . Clinicians are able to apply for patient access using the  ",
                "1d_change": -2.6460953143,
                "index_price": -3.9324363463,
                "norm_price": 1.286341032
            },
            {
                "index": 146,
                "date": "2020-02-25",
                "press_title": "Vertex to Present at the Cowen Health Care Conference on March 3",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-cowen-health-care-conference-march-3",
                "content": "  BOSTON --(BUSINESS WIRE)--Feb. 25, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Health Care Conference on Tuesday, March 3, 2020 at 10:00 a.m. ET . The audio portion of management's remarks will be available live through Vertex  ",
                "1d_change": -2.6460953143,
                "index_price": -3.9324363463,
                "norm_price": 1.286341032
            },
            {
                "index": 147,
                "date": "2020-01-30",
                "press_title": "Vertex Reports Full-Year and Fourth-Quarter 2019 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2019-financial",
                "content": "  - Full-year 2019 total GAAP product revenues of $4.16 billion - - Full-year 2019 total non-GAAP product revenues of $4.00 billion , a 32% increase compared to the full-year 2018 - - Company provides full-year 2020 total product revenue guidance of $5.1 billion to $5.3 billion - BOSTON --(BUSINESS  ",
                "1d_change": -1.6692328717,
                "index_price": -0.9589130265,
                "norm_price": -0.7103198452
            },
            {
                "index": 148,
                "date": "2020-01-21",
                "press_title": "Vertex to Announce Full-Year and Fourth-Quarter 2019 Financial Results on January 30",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-full-year-and-fourth-quarter-2019-financial",
                "content": "  BOSTON --(BUSINESS WIRE)--Jan. 21, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its full-year and fourth-quarter 2019 financial results on Thursday, January 30, 2020 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  ",
                "1d_change": -0.5242725052,
                "index_price": 0.0216744398,
                "norm_price": -0.5459469449
            },
            {
                "index": 149,
                "date": "2020-01-08",
                "press_title": "Vertex to Present at the J.P. Morgan Healthcare Conference on January 13",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-jp-morgan-healthcare-conference-january-13",
                "content": "  BOSTON --(BUSINESS WIRE)--Jan. 8, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 2:30 p.m. ET ( 11:30 a.m. PT ). The audio portion of management’s remarks can be accessed  ",
                "1d_change": 1.8978525239,
                "index_price": 1.1026922716,
                "norm_price": 0.7951602522
            },
            {
                "index": 150,
                "date": "2019-12-13",
                "press_title": "Vertex and Republic of Ireland Expand Long-Term Cystic Fibrosis Medicines Reimbursement Agreement to Include Triple Combination Therapy for All Eligible Patients Ages 12 and Over Once Licensed",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-republic-ireland-expand-long-term-cystic-fibrosis",
                "content": "  LONDON --(BUSINESS WIRE)--Dec. 13, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirmed that, following recent collaborative discussions, it has negotiated an agreement with the Health Service Executive (HSE) in the Republic of Ireland to expand the existing long-term cystic  ",
                "1d_change": -0.3143519095,
                "index_price": 0.7770777925,
                "norm_price": -1.091429702
            },
            {
                "index": 151,
                "date": "2019-12-10",
                "press_title": "Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) in Infants With Cystic Fibrosis Ages 6 Months to Less Than 12 Months With Certain Mutations in the CFTR Gene",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-european-commission-approval-kalydecor-0",
                "content": "  - Ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis in children this young - LONDON --(BUSINESS WIRE)--Dec. 10, 2019-- Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label  ",
                "1d_change": 0.2636371959,
                "index_price": 0.1995707841,
                "norm_price": 0.0640664118
            },
            {
                "index": 152,
                "date": "2019-11-20",
                "press_title": "French Authorities Approve National Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) for Eligible People Ages Two and Older With Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/french-authorities-approve-national-reimbursement-orkambi",
                "content": "  LONDON --(BUSINESS WIRE)--Nov. 20, 2019-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the French Authorities (Comité économique des produits de santé, or CEPS ) have approved national reimbursement of ORKAMBI ® (lumacaftor/ivacaftor) for people ages two and older with  ",
                "1d_change": 0.334107295,
                "index_price": -0.3582964262,
                "norm_price": 0.6924037212
            },
            {
                "index": 153,
                "date": "2019-11-19",
                "press_title": "CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-positive-safety-and",
                "content": "  -Two patients treated with CTX001 successfully engrafted and demonstrated an initial safety profile consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell transplant- -Beta thalassemia: Patient is transfusion independent with total hemoglobin level of 11.9 g/dL  ",
                "1d_change": 0.9764290845,
                "index_price": -0.6109131362,
                "norm_price": 1.5873422207
            },
            {
                "index": 154,
                "date": "2019-11-18",
                "press_title": "Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-molecular-templates-establish-collaboration-discover",
                "content": "  -Molecular Templates to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future sales- BOSTON and AUSTIN, Texas, Nov. 18, 2019&nbsp;-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Molecular Templates, Inc.  ",
                "1d_change": 2.3860487827,
                "index_price": 0.0727528406,
                "norm_price": 2.3132959421
            },
            {
                "index": 155,
                "date": "2019-11-13",
                "press_title": "Vertex Confirms Wales Offer Accepted for Access to All Licensed Cystic Fibrosis Medicines",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-confirms-wales-offer-accepted-access-all-licensed-cystic",
                "content": "  -Eligible patients in Wales will soon have access to ORKAMBI ® (lumacaftor/ivacaftor) and SYMKEVI ® (tezacaftor/ivacaftor), expanded access to KALYDECO ® (ivacaftor) under same terms as NHS England agreement- LONDON --(BUSINESS WIRE)--Nov. 13, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq:  ",
                "1d_change": 0.0,
                "index_price": 0.4020484089,
                "norm_price": -0.4020484089
            },
            {
                "index": 156,
                "date": "2019-11-12",
                "press_title": "Vertex Confirms Northern Ireland Offer Accepted for Cystic Fibrosis Medicines",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-confirms-northern-ireland-offer-accepted-cystic-fibrosis",
                "content": "  -Eligible patients in Northern Ireland will soon have access to ORKAMBI ® (lumacaftor/ivacaftor) and SYMKEVI ® (tezacaftor/ivacaftor), expanded access to KALYDECO ® (ivacaftor) under same terms as NHS England agreement- LONDON --(BUSINESS WIRE)--Nov. 12, 2019-- Vertex Pharmaceuticals Incorporated  ",
                "1d_change": 2.3949814426,
                "index_price": 0.1538444786,
                "norm_price": 2.241136964
            },
            {
                "index": 157,
                "date": "2019-11-07",
                "press_title": "Vertex to Present at the Credit Suisse Healthcare Conference on November 12",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-credit-suisse-healthcare-conference-november-12",
                "content": "  BOSTON --(BUSINESS WIRE)--Nov. 7, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 12, 2019 at 1:30 p.m. ET . Management’s remarks will be available live through Vertex’s website at  ",
                "1d_change": 2.439026239,
                "index_price": 0.1959231071,
                "norm_price": 2.2431031319
            },
            {
                "index": 158,
                "date": "2019-10-31",
                "press_title": "Phase 3 Results from Two Studies of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Triple Combination Treatment for Cystic Fibrosis Concurrently Published in The New England Journal of Medicine and The Lancet",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/phase-3-results-two-studies-trikafta",
                "content": "  - Both studies met primary and all key secondary endpoints demonstrating significant improvements in lung function and other measures of the disease - - Results of both studies to be presented today at the 33rd Annual North American Cystic Fibrosis Conference as part of six presentations from  ",
                "1d_change": 1.9309270607,
                "index_price": 0.6524485668,
                "norm_price": 1.2784784939
            },
            {
                "index": 159,
                "date": "2019-10-31",
                "press_title": "Vertex Announces European Medicines Agency Marketing Authorization Application Validation for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Triple Combination Treatment in Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-european-medicines-agency-marketing",
                "content": "  - Application supported by positive results from two global Phase 3 studies in people with cystic fibrosis ages 12 and older with one F508del mutation and one minimal function mutation and in people with two F508del mutations - LONDON --(BUSINESS WIRE)--Oct.  ",
                "1d_change": 1.9309270607,
                "index_price": 0.6524485668,
                "norm_price": 1.2784784939
            },
            {
                "index": 160,
                "date": "2019-10-30",
                "press_title": "Vertex Reports Third-Quarter 2019 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-third-quarter-2019-financial-results",
                "content": "  - Product revenues of $950 million , a 21% increase compared to Q3 2018 - - Continued progression of pipeline of investigational medicines in multiple diseases - BOSTON --(BUSINESS WIRE)--Oct. 30, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial  ",
                "1d_change": -1.3454087069,
                "index_price": -0.0717658778,
                "norm_price": -1.2736428291
            },
            {
                "index": 161,
                "date": "2019-10-24",
                "press_title": "Vertex Announces Agreement with NHS England for Access to All Licensed Cystic Fibrosis Medicines",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-agreement-nhs-england-access-all-licensed",
                "content": "  -Eligible patients in England will have access to ORKAMBI ® (lumacaftor/ivacaftor) and SYMKEVI ® (tezacaftor/ivacaftor), expanded access to KALYDECO ® (ivacaftor)- LONDON --(BUSINESS WIRE)--Oct. 24, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an access agreement with  ",
                "1d_change": 1.4345254081,
                "index_price": 0.2570683498,
                "norm_price": 1.1774570583
            },
            {
                "index": 162,
                "date": "2019-10-21",
                "press_title": "Vertex to Announce Third-Quarter 2019 Financial Results on October 30",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-third-quarter-2019-financial-results-october-30",
                "content": "  BOSTON --(BUSINESS WIRE)--Oct. 21, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2019 financial results on Wednesday, October 30, 2019 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  ",
                "1d_change": 7.2385648528,
                "index_price": -0.0163548689,
                "norm_price": 7.2549197217
            },
            {
                "index": 163,
                "date": "2019-10-21",
                "press_title": "ADDING MULTIMEDIA FDA Approves TRIKAFTA™ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/adding-multimedia-fda-approves-trikafta",
                "content": "  - For the first time, approximately 6,000 patients with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease– -12,000 people with one or two F508del mutations who are currently eligible for one of Vertex’s three other FDA -approved  ",
                "1d_change": 7.2385648528,
                "index_price": -0.0163548689,
                "norm_price": 7.2549197217
            },
            {
                "index": 164,
                "date": "2019-10-21",
                "press_title": "FDA Approves TRIKAFTA™ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/fda-approves-trikafta-elexacaftortezacaftorivacaftor-and",
                "content": "  - For the first time, approximately 6,000 patients with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease– -12,000 people with one or two F508del mutations who are currently eligible for one of Vertex’s three other FDA -approved  ",
                "1d_change": 7.2385648528,
                "index_price": -0.0163548689,
                "norm_price": 7.2549197217
            },
            {
                "index": 165,
                "date": "2019-10-21",
                "press_title": "Spanish Government Approves National Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in Combination With KALYDECO® (ivacaftor)",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/spanish-government-approves-national-reimbursement-orkambir",
                "content": "  LONDON --(BUSINESS WIRE)--Oct. 21, 2019-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the Spanish Government has approved terms for the national reimbursement of ORKAMBI ® (lumacaftor/ivacaftor) and SYMKEVI ® (tezacaftor/ivacaftor) in combination with KALYDECO ®  ",
                "1d_change": 7.2385648528,
                "index_price": -0.0163548689,
                "norm_price": 7.2549197217
            },
            {
                "index": 166,
                "date": "2019-10-19",
                "press_title": "Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-reimbursement-cystic-fibrosis-medicines",
                "content": "  LONDON --(BUSINESS WIRE)--Oct. 19, 2019-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that SYMDEKO ® (tezacaftor/ivacaftor and ivacaftor) is reimbursed in Australia for people with cystic fibrosis (CF) ages 12 years and older who are homozygous for the F508del mutation or who  ",
                "1d_change": 7.2385648528,
                "index_price": -0.0163548689,
                "norm_price": 7.2549197217
            },
            {
                "index": 167,
                "date": "2019-10-18",
                "press_title": "Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Eligible Infants with Cystic Fibrosis as Early as 6 Months of Age",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-european-chmp-positive-opinion-kalydecor-0",
                "content": "  - If approved, ivacaftor will be the first and only medicine to treat the underlying cause of cystic fibrosis for children this young - LONDON --(BUSINESS WIRE)--Oct. 18, 2019-- Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for  ",
                "1d_change": 1.7871731058,
                "index_price": 0.3285933811,
                "norm_price": 1.4585797247
            },
            {
                "index": 168,
                "date": "2019-10-01",
                "press_title": "Vertex Appoints Carmen Bozic, M.D., as New Chief Medical Officer and Nia Tatsis, Ph.D., as New Chief Regulatory Officer",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-appoints-carmen-bozic-md-new-chief-medical-officer-and",
                "content": "    BOSTON --(BUSINESS WIRE)--Oct. 1, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Carmen Bozic , M.D., has been appointed as the company’s Executive Vice President, Global Medicines Development and Medical Affairs. Dr.  ",
                "1d_change": -1.5176046292,
                "index_price": -3.3273132594,
                "norm_price": 1.8097086302
            },
            {
                "index": 169,
                "date": "2019-09-30",
                "press_title": "Vertex and Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-ribometrix-establish-strategic-collaboration-discover",
                "content": "  &nbsp; -Partnership will leverage Ribometrix’s discovery platform for up to three therapeutic programs- &nbsp; &nbsp; -Ribometrix to receive $20 million in upfront payment and Vertex equity investment; potential for additional milestones and royalty payments- &nbsp; &nbsp; BOSTON &amp; DURHAM, N.C. --(BUSINESS WIRE)--Sep.  ",
                "1d_change": -1.1755586581,
                "index_price": -0.9121696577,
                "norm_price": -0.2633890004
            },
            {
                "index": 170,
                "date": "2019-09-12",
                "press_title": "Vertex Announces New Access Agreement with Scottish Government for ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor)",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-new-access-agreement-scottish-government",
                "content": "  Eligible patients in Scotland will immediately have access to ORKAMBI (lumacaftor/ivacaftor) and SYMKEVI (tezacaftor/ivacaftor) in combination with ivacaftor LONDON --(BUSINESS WIRE)--Sep. 12, 2019-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that eligible cystic fibrosis  ",
                "1d_change": 0.3143952464,
                "index_price": -0.0562010783,
                "norm_price": 0.3705963247
            },
            {
                "index": 171,
                "date": "2019-09-10",
                "press_title": "Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 11",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-morgan-stanley-global-healthcare-conference-0",
                "content": "  BOSTON --(BUSINESS WIRE)--Sep. 10, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019 at 12:15 p.m. ET . The audio portion of management’s remarks can be accessed  ",
                "1d_change": -0.5314529292,
                "index_price": 0.9970216752,
                "norm_price": -1.5284746043
            },
            {
                "index": 172,
                "date": "2019-09-03",
                "press_title": "Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-acquire-semma-therapeutics-goal-developing-curative-cell",
                "content": "  -Semma’s unique investigational approach combines robust production process of pancreatic islet cells with proprietary delivery system to restore insulin secretion in type 1 diabetes patients- -Semma to be acquired for $950 million in cash- BOSTON &amp; CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep.  ",
                "1d_change": -2.1037161014,
                "index_price": 0.9793115633,
                "norm_price": -3.0830276647
            },
            {
                "index": 173,
                "date": "2019-08-20",
                "press_title": "FDA Accepts New Drug Application for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Combination Treatment",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/fda-accepts-new-drug-application-vx-445-elexacaftor-tezacaftor",
                "content": "  -FDA Grants Priority Review of the application and sets a PDUFA target action date of March 19, 2020 - -Application supported by positive results from two global Phase 3 studies in people with cystic fibrosis ages 12 and older with one F508del mutation and one minimal function mutation and in  ",
                "1d_change": -0.3433473233,
                "index_price": 0.1853325948,
                "norm_price": -0.5286799181
            },
            {
                "index": 174,
                "date": "2019-07-31",
                "press_title": "Vertex Reports Second-Quarter 2019 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-second-quarter-2019-financial-results",
                "content": "  - Product revenues of $940 million , a 25% increase compared to 2018 - - Company increases full-year 2019 total product revenue guidance to $3.6 to $3.7 billion - - Company advancing programs in 5 additional diseases beyond cystic fibrosis - BOSTON --(BUSINESS WIRE)--Jul.  ",
                "1d_change": 5.8564339301,
                "index_price": -2.1215045865,
                "norm_price": 7.9779385166
            },
            {
                "index": 175,
                "date": "2019-07-25",
                "press_title": "Vertex Announces Dr. Jeffrey Leiden to Transition to Role of Executive Chairman, Effective April 1, 2020 and Dr. Reshma Kewalramani Appointed as New Chief Executive Officer",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-dr-jeffrey-leiden-transition-role-executive",
                "content": "  BOSTON --(BUSINESS WIRE)--Jul. 25, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that its Board of Directors has approved the planned transition of Chairman, President and Chief Executive Officer Jeffrey Leiden , M.D., Ph.D, into the role of Executive Chairman of the  ",
                "1d_change": -3.2308333816,
                "index_price": 0.3172683903,
                "norm_price": -3.5481017719
            },
            {
                "index": 176,
                "date": "2019-07-22",
                "press_title": "Vertex Submits New Drug Application to the U.S. FDA for Triple Combination Regimen of VX-445 (Elexacaftor), Tezacaftor and Ivacaftor in Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-submits-new-drug-application-us-fda-triple-combination",
                "content": "  -Application supported by positive results from two global Phase 3 studies in people with CF ages 12 and older with one F508del mutation and one minimal function mutation and in people with two F508del mutations- BOSTON --(BUSINESS WIRE)--Jul. 22, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq:  ",
                "1d_change": 1.0842325358,
                "index_price": 0.783239869,
                "norm_price": 0.3009926668
            },
            {
                "index": 177,
                "date": "2019-07-17",
                "press_title": "Vertex to Announce Second-Quarter 2019 Financial Results on July 31",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-second-quarter-2019-financial-results-july-31",
                "content": "  BOSTON --(BUSINESS WIRE)--Jul. 17, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2019 financial results on Wednesday, July 31, 2019 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  ",
                "1d_change": 0.6513581256,
                "index_price": -0.3335433382,
                "norm_price": 0.9849014638
            },
            {
                "index": 178,
                "date": "2019-06-21",
                "press_title": "FDA Approves SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of CF in Children Ages 6-11 Years with Certain Mutations in the CFTR Gene",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/fda-approves-symdekor-tezacaftorivacaftor-and-ivacaftor-treat",
                "content": "  -SYMDEKO is now approved for patients 6 years of age and older with two copies of the F508del mutation or one copy of a responsive mutation- -Vertex's third medicine approved to treat the underlying cause of CF in eligible patients in this age range- BOSTON --(BUSINESS WIRE)--Jun.  ",
                "1d_change": -1.2816219261,
                "index_price": -0.2498807625,
                "norm_price": -1.0317411637
            },
            {
                "index": 179,
                "date": "2019-06-06",
                "press_title": "Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-expands-new-disease-areas-and-enhances-gene-editing",
                "content": "  -Provides Vertex with leading gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1- -CRISPR to receive an upfront payment of $175 million , with potential for additional milestone and royalty payments- -Exonics to be acquired for an  ",
                "1d_change": 0.1671334766,
                "index_price": 1.560207868,
                "norm_price": -1.3930743913
            },
            {
                "index": 180,
                "date": "2019-06-04",
                "press_title": "Vertex to Present Data at ECFS Conference on Potential Impact of Early Treatment and Long-Term Treatment with CFTR Modulators on the Underlying Cause of CF",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-data-ecfs-conference-potential-impact-early",
                "content": "  BOSTON --(BUSINESS WIRE)--Jun. 4, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from six scientific abstracts from the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the 42 nd European Cystic Fibrosis Conference , taking place June  ",
                "1d_change": 2.9491547783,
                "index_price": 2.2472272158,
                "norm_price": 0.7019275625
            },
            {
                "index": 181,
                "date": "2019-05-30",
                "press_title": "Vertex Selects Triple Combination Regimen of VX-445, Tezacaftor and Ivacaftor to Submit for Global Regulatory Approvals in Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-selects-triple-combination-regimen-vx-445-tezacaftor-and",
                "content": "  -Mean absolute improvement in ppFEV 1 of 14.3 percentage points from baseline through week 24 of treatment compared to placebo (p  ",
                "1d_change": -0.6498988318,
                "index_price": -1.2674099427,
                "norm_price": 0.6175111109
            },
            {
                "index": 182,
                "date": "2019-05-15",
                "press_title": "Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-kymera-therapeutics-establish-strategic-collaboration",
                "content": "  -Multi-year collaboration leveraging Kymera’s proprietary targeted protein degradation platform to develop novel medicines- -Kymera to receive $70 million upfront, including equity investment, and potential additional milestone and royalty payments for up to six programs in the collaboration-  ",
                "1d_change": 2.8314587243,
                "index_price": 1.944852597,
                "norm_price": 0.8866061273
            },
            {
                "index": 183,
                "date": "2019-04-30",
                "press_title": "Vertex Reports First-Quarter 2019 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-first-quarter-2019-financial-results",
                "content": "  - First-quarter 2019 product revenues of $857 million , a 34% increase compared to $638 million in 2018- - First-quarter 2019 GAAP operating income increased 115% to $277 million ; non-GAAP operating income increased 81% to $377 million - - On track to choose best triple combination regimen in Q2  ",
                "1d_change": -0.7705599799,
                "index_price": -0.4586576804,
                "norm_price": -0.3119022995
            },
            {
                "index": 184,
                "date": "2019-04-30",
                "press_title": "FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants with CF as Early as Six Months of Age",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/fda-approves-kalydecor-ivacaftor-first-and-only-cftr-modulator",
                "content": "  -Opportunity to treat the underlying cause of CF earlier than ever before- -Safety data from Phase 3 ARRIVAL study support treatment with KALYDECO in children ages six to   ",
                "1d_change": -0.7705599799,
                "index_price": -0.4586576804,
                "norm_price": -0.3119022995
            },
            {
                "index": 185,
                "date": "2019-04-16",
                "press_title": "CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-fda-fast-track-0",
                "content": "  ZUG, Switzerland and CAMBRIDGE and BOSTON, Mass. – April 16, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CTX001 for the  ",
                "1d_change": -9.9778424509,
                "index_price": -0.4071802235,
                "norm_price": -9.5706622274
            },
            {
                "index": 186,
                "date": "2019-04-12",
                "press_title": "Vertex to Announce First-Quarter 2019 Financial Results on April 30",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-first-quarter-2019-financial-results-april-30",
                "content": "  BOSTON --(BUSINESS WIRE)--Apr. 12, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2019 financial results on Tuesday, April 30, 2019 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  ",
                "1d_change": -1.6055633665,
                "index_price": 0.1624450394,
                "norm_price": -1.7680084059
            },
            {
                "index": 187,
                "date": "2019-04-02",
                "press_title": "Vertex Appoints Charles Wagner as Chief Financial Officer",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-appoints-charles-wagner-chief-financial-officer",
                "content": "  BOSTON --(BUSINESS WIRE)--Apr. 2, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Charles (Charlie) Wagner as Executive Vice President and Chief Financial Officer (CFO), effective April 10, 2019 . Mr. Wagner will report directly to Vertex Chairman,  ",
                "1d_change": 1.0271928693,
                "index_price": 0.1795751474,
                "norm_price": 0.8476177219
            },
            {
                "index": 188,
                "date": "2019-03-12",
                "press_title": "Vertex Receives Approval for SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) in Australia, to Treat the Underlying Cause of Cystic Fibrosis in People aged 12 and Older with Certain CFTR Gene Mutations",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-approval-symdekor-tezacaftorivacaftor-and",
                "content": "  -A new treatment option for patients with two copies of the F508del mutation, the most common mutation in cystic fibrosis- -First medicine in Australia to treat the underlying cause of cystic fibrosis in patients who have certain mutations that result in residual CFTR function- BOSTON --(BUSINESS  ",
                "1d_change": 2.429176816,
                "index_price": 0.8388653765,
                "norm_price": 1.5903114396
            },
            {
                "index": 189,
                "date": "2019-03-06",
                "press_title": "Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/two-phase-3-studies-triple-combination-vx-445-tezacaftor-and",
                "content": "  -Mean absolute improvement in ppFEV 1 of 13.8 percentage points from baseline at week 4 in people with one F508del mutation and one minimal function mutation (F/MF) compared to placebo (p  ",
                "1d_change": -5.3580382021,
                "index_price": -1.5038610994,
                "norm_price": -3.8541771027
            },
            {
                "index": 190,
                "date": "2019-02-25",
                "press_title": "CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-progress-clinical",
                "content": "  -First patient infused with CTX001 in a Phase 1/2 clinical trial for patients with beta thalassemia- -First patient enrolled in a Phase 1/2 clinical trial of CTX001 for patients with sickle cell disease- ZUG, Switzerland and CAMBRIDGE and BOSTON, Mass., Feb.  ",
                "1d_change": 1.1539237227,
                "index_price": -0.3740361387,
                "norm_price": 1.5279598613
            },
            {
                "index": 191,
                "date": "2019-02-21",
                "press_title": "Vertex Appoints Lloyd Carney to its Board of Directors",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-appoints-lloyd-carney-its-board-directors",
                "content": "  BOSTON --(BUSINESS WIRE)--Feb. 21, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Lloyd Carney has been appointed to its board of directors as an independent director. Mr. Carney is a prominent technology executive with experience leading innovative, high-growth  ",
                "1d_change": -1.044359657,
                "index_price": 0.445091328,
                "norm_price": -1.4894509849
            },
            {
                "index": 192,
                "date": "2019-02-14",
                "press_title": "Positive Phase 3 Study for Tezacaftor/Ivacaftor Combination in Children Aged 6-11 Years with Cystic Fibrosis Supports European Medicines Agency Submission",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/positive-phase-3-study-tezacaftorivacaftor-combination-children",
                "content": "  -Study met primary endpoint with a statistically significant improvement in absolute change in lung clearance index (LCI 2.5 ) through 8 weeks of tezacaftor/ivacaftor treatment- -Tezacaftor in combination with ivacaftor was generally well tolerated and safety data were consistent with previous  ",
                "1d_change": 1.8875965936,
                "index_price": 1.1565101789,
                "norm_price": 0.7310864146
            },
            {
                "index": 193,
                "date": "2019-02-05",
                "press_title": "Vertex Reports Full-Year and Fourth-Quarter 2018 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2018-financial",
                "content": "  - Full-year 2018 CF product revenues of $3.04 billion , a 40% increase compared to $2.17 billion in 2017; fourth-quarter 2018 CF product revenues of $868 million - - Full-year 2018 GAAP operating income increased 415% to $635 million ; non-GAAP operating income increased 97% to $1.11 billion - -  ",
                "1d_change": -1.875101804,
                "index_price": 0.1197103321,
                "norm_price": -1.9948121361
            },
            {
                "index": 194,
                "date": "2019-01-28",
                "press_title": "Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) in Children Ages 12 to <24 months with Certain Mutations in the CFTR Gene",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/health-canada-grants-market-authorization-kalydecor-ivacaftor",
                "content": "  -KALYDECO is the first and only approved medicine in Canada to treat the underlying cause of cystic fibrosis in these young patients- BOSTON --(BUSINESS WIRE)--Jan. 28, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Market Authorization for  ",
                "1d_change": -1.3735365874,
                "index_price": -0.188256466,
                "norm_price": -1.1852801213
            },
            {
                "index": 195,
                "date": "2019-01-23",
                "press_title": "Vertex Announces Departure of Ian Smith, Names Interim CFO",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-departure-ian-smith-names-interim-cfo",
                "content": "  BOSTON --(BUSINESS WIRE)--Jan. 23, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Ian Smith has been terminated as Chief Operating Officer and interim Chief Financial Officer (CFO) effective immediately. Mr. Smith’s termination is the result of personal behavior that  ",
                "1d_change": -4.3359396819,
                "index_price": -0.0435184973,
                "norm_price": -4.2924211846
            },
            {
                "index": 196,
                "date": "2019-01-22",
                "press_title": "Vertex to Announce Full-Year and Fourth-Quarter 2018 Financial Results on February 5",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-full-year-and-fourth-quarter-2018-financial",
                "content": "  BOSTON --(BUSINESS WIRE)--Jan. 22, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its full year and fourth quarter 2018 financial results on Tuesday, February 5, 2019 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  ",
                "1d_change": -1.8905663012,
                "index_price": -0.7268705042,
                "norm_price": -1.163695797
            },
            {
                "index": 197,
                "date": "2019-01-21",
                "press_title": "Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-european-commission-approval-orkambir",
                "content": "  Lumacaftor/ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis for approximately 1,500 children aged 2 to 5 with two copies of the F508del mutation LONDON --(BUSINESS WIRE)--Jan. 21, 2019-- Vertex Pharmaceuticals (Europe) Limited today  ",
                "1d_change": -1.8905663012,
                "index_price": -0.7268705042,
                "norm_price": -1.163695797
            },
            {
                "index": 198,
                "date": "2019-01-04",
                "press_title": "CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-fda-fast-track",
                "content": "  ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Jan. 04, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics&nbsp;(NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CTX001 for the  ",
                "1d_change": 5.6582381926,
                "index_price": 2.9556481381,
                "norm_price": 2.7025900545
            },
            {
                "index": 199,
                "date": "2019-01-03",
                "press_title": "Vertex and Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-arbor-biotechnologies-establish-collaboration",
                "content": "  -Multi-year research collaboration funded by Vertex using Arbor’s proprietary research platform to enhance efforts in developing gene-editing therapies in five diseases- -Arbor to receive up-front cash payment and convertible note investment, research funding, and potential for additional  ",
                "1d_change": 3.9779937687,
                "index_price": 1.5806069835,
                "norm_price": 2.3973867852
            },
            {
                "index": 200,
                "date": "2019-01-02",
                "press_title": "Vertex to Present at the J.P. Morgan Healthcare Conference on January 7",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-jp-morgan-healthcare-conference-january-7",
                "content": "  BOSTON --(BUSINESS WIRE)--Jan. 2, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 2:30 p.m. ET ( 11:30 a.m. PT ). The audio portion of management’s remarks can be accessed  ",
                "1d_change": 1.5391126119,
                "index_price": -1.187556207,
                "norm_price": 2.7266688189
            },
            {
                "index": 201,
                "date": "2018-12-19",
                "press_title": "Vertex Announces it will Submit Cystic Fibrosis Medicines ORKAMBI® (lumacaftor/ivacaftor) as well as SYMKEVI® (tezacaftor/ivacaftor) to be Used in Combination with ivacaftor, to the Scottish Medicines Consortium for Appraisal",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-it-will-submit-cystic-fibrosis-medicines",
                "content": "  - If accepted by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland , eligible patients could have access to these precision cystic fibrosis medicines in 2019 - - While the SMC reviews the submissions, clinicians can apply for access to these CF medicines via the PACS Tier 2  ",
                "1d_change": -1.0787292011,
                "index_price": -3.2272628687,
                "norm_price": 2.1485336675
            },
            {
                "index": 202,
                "date": "2018-12-18",
                "press_title": "Vertex Announces Positive Phase 2 Data in Third Proof-of-Concept Study with the NaV1.8 Inhibitor VX-150",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-positive-phase-2-data-third-proof-concept-study",
                "content": "  -Treatment with the NaV1.8 inhibitor VX-150 showed significant relief of pain in patients with small fiber neuropathy and was generally well tolerated- -Third positive Phase 2 proof-of-concept study for VX-150 further validates the potential role of NaV1.8 inhibition for the treatment of multiple  ",
                "1d_change": -5.9246146978,
                "index_price": -2.1117186645,
                "norm_price": -3.8128960333
            },
            {
                "index": 203,
                "date": "2018-12-13",
                "press_title": "Health Canada Grants Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) for Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/health-canada-grants-market-authorization-orkambir",
                "content": "  - ORKAMBI is the first medicine in Canada to treat the underlying cause of CF in young children with two copies of the F508del mutation - BOSTON --(BUSINESS WIRE)--Dec. 13, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that Health Canada has granted Market Authorization  ",
                "1d_change": -2.9401388168,
                "index_price": -2.259658882,
                "norm_price": -0.6804799347
            },
            {
                "index": 204,
                "date": "2018-11-29",
                "press_title": "Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) to Treat Patients with Cystic Fibrosis Aged 12 to <24 months with Certain Mutations in the CFTR Gene",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-european-commission-approval-kalydecor",
                "content": "  Ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis in these young patients LONDON --(BUSINESS WIRE)--Nov. 29, 2018-- Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label  ",
                "1d_change": 2.1571956642,
                "index_price": 0.8405261933,
                "norm_price": 1.3166694709
            },
            {
                "index": 205,
                "date": "2018-11-27",
                "press_title": "Two Phase 3 Studies of the Triple Combination of VX-659, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/two-phase-3-studies-triple-combination-vx-659-tezacaftor-and",
                "content": "  -Mean absolute improvement in ppFEV 1 of 14.0 percentage points from baseline at week 4 in people with one F508del mutation and one minimal function mutation compared to placebo (p  ",
                "1d_change": 5.5779862847,
                "index_price": 2.9171342531,
                "norm_price": 2.6608520316
            },
            {
                "index": 206,
                "date": "2018-11-16",
                "press_title": "Vertex Receives European CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-european-chmp-positive-opinion-orkambir",
                "content": "  - If approved, lumacaftor/ivacaftor will be the first medicine in Europe to treat the underlying cause of cystic fibrosis for approximately 1,500 young children with two copies of the F508del mutation - LONDON --(BUSINESS WIRE)--Nov. 16, 2018-- Vertex Pharmaceuticals (Europe) Limited today  ",
                "1d_change": -3.2221934231,
                "index_price": -1.0335507017,
                "norm_price": -2.1886427214
            },
            {
                "index": 207,
                "date": "2018-11-01",
                "press_title": "Vertex Announces European Authorization for Third Cystic Fibrosis Medicine SYMKEVI® (tezacaftor/ivacaftor), to be used in combination with ivacaftor (KALYDECO®), for People with CF Aged 12 and Older with Certain Mutations in the CFTR gene",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-european-authorization-third-cystic-fibrosis",
                "content": "  - A new treatment option for patients with two copies of the F508del mutation, the most common mutation in cystic fibrosis - - First medicine in the EU to treat the CFTR protein defect in patients who have one copy of the F508del mutation and one copy of one of 14 mutations that result in residual  ",
                "1d_change": 2.1813139395,
                "index_price": 0.2012434669,
                "norm_price": 1.9800704726
            },
            {
                "index": 208,
                "date": "2018-10-24",
                "press_title": "Vertex Reports Third-Quarter 2018 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-third-quarter-2018-financial-results",
                "content": "  -Third-quarter 2018 total CF product revenues of $783 million , a 42% increase compared to $550 million in the third quarter of 2017- -Company reiterates full-year 2018 total CF product revenue guidance of $2.9 to $3.0 billion ; reiterates full-year 2018 combined non-GAAP R&amp;D and SG&amp;A expense  ",
                "1d_change": -5.6820262227,
                "index_price": -1.1938352366,
                "norm_price": -4.4881909861
            },
            {
                "index": 209,
                "date": "2018-10-19",
                "press_title": "Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene ",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-european-chmp-positive-opinion-kalydecor",
                "content": "  If approved, ivacaftor will be the first and only medicine to treat the underlying cause of cystic fibrosis for these young children LONDON --(BUSINESS WIRE)--Oct. 19, 2018-- Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal  ",
                "1d_change": -1.0992177419,
                "index_price": -0.7177391664,
                "norm_price": -0.3814785755
            },
            {
                "index": 210,
                "date": "2018-10-18",
                "press_title": "Vertex Data Presented at North American Cystic Fibrosis Conference (NACFC) Demonstrate Rapid Progress Toward Expanding and Enhancing Options for Treating the Underlying Cause of Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-data-presented-north-american-cystic-fibrosis-conference",
                "content": "  - Phase 2 results of VX-659 and VX-445 triple combination regimens concurrently published in The New England Journal of Medicine - - Phase 3 ARRIVAL data support treating the underlying cause of cystic fibrosis with KALYDECO ® (ivacaftor) as early as six months of age - - Patient-reported outcomes  ",
                "1d_change": -4.8949802067,
                "index_price": -1.2363688711,
                "norm_price": -3.6586113356
            },
            {
                "index": 211,
                "date": "2018-10-16",
                "press_title": "Vertex to Announce Third Quarter 2018 Financial Results on October 24",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-third-quarter-2018-financial-results-october-24",
                "content": "  BOSTON --(BUSINESS WIRE)--Oct. 16, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2018 financial results on Wednesday, October 24, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  ",
                "1d_change": 3.5637269585,
                "index_price": 1.5007746909,
                "norm_price": 2.0629522675
            },
            {
                "index": 212,
                "date": "2018-10-10",
                "press_title": "CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-fda-has-lifted-clinical",
                "content": "  ZUG, Switzerland &nbsp; and &nbsp; BOSTON &nbsp; and &nbsp; CAMBRIDGE, Mass. , &nbsp; Oct. 10, 2018 &nbsp; (GLOBE NEWSWIRE) -- &nbsp; CRISPR Therapeutics&nbsp; (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and &nbsp; Vertex Pharmaceuticals Incorporated &nbsp; (NASDAQ:VRTX)  ",
                "1d_change": -5.2715440702,
                "index_price": -5.333945869,
                "norm_price": 0.0624017987
            },
            {
                "index": 213,
                "date": "2018-10-01",
                "press_title": "Vertex Announces Access Contract in Denmark for Current and Future Cystic Fibrosis Medicines",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-access-contract-denmark-current-and-future",
                "content": "  - First-of-its-kind contract with the Danish pharmaceutical and procurement organization, Amgros, is effective from today - - Vertex also announces reimbursement in Austria for ORKAMBI ® (lumacaftor/ivacaftor) to treat patients ages 6 through 11 with two copies of the F508del mutation - LONDON  ",
                "1d_change": -0.6825472138,
                "index_price": -0.0978339652,
                "norm_price": -0.5847132486
            },
            {
                "index": 214,
                "date": "2018-09-11",
                "press_title": "Vertex to Present at the Morgan Stanley Healthcare Conference on September 14",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-morgan-stanley-healthcare-conference-september-14",
                "content": "  BOSTON --(BUSINESS WIRE)--Sep. 11, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Healthcare Conference on Friday, September 14, 2018 at 12:15 p.m. ET . The audio portion of management’s remarks will be available live  ",
                "1d_change": -0.3308267074,
                "index_price": 0.6005654011,
                "norm_price": -0.9313921085
            },
            {
                "index": 215,
                "date": "2018-09-10",
                "press_title": "Vertex Appoints Katharine Jensen as Head of Corporate Social Responsibility",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-appoints-katharine-jensen-head-corporate-social",
                "content": "  -- Ms. Jensen to oversee global CSR efforts and lead The Vertex Foundation -- BOSTON --(BUSINESS WIRE)--Sep. 10, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Katharine Jensen has been appointed Head of Corporate Social Responsibility (CSR). In this role, Ms.  ",
                "1d_change": -0.7782315575,
                "index_price": 0.2250778334,
                "norm_price": -1.0033093909
            },
            {
                "index": 216,
                "date": "2018-09-06",
                "press_title": "Vertex Completes Enrollment of Two Phase 3 Studies of VX-659 in Triple Combination with Tezacaftor and Ivacaftor for the Treatment of Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-completes-enrollment-two-phase-3-studies-vx-659-triple",
                "content": "  -Data expected in late 2018 from Phase 3 studies of VX-659, tezacaftor and ivacaftor in people with one F508del mutation and one minimal function mutation and in people with two F508del mutations- -Enrollment of two Phase 3 studies of VX-445 in triple combination with tezacaftor and ivacaftor  ",
                "1d_change": -1.6938726614,
                "index_price": -0.5905937062,
                "norm_price": -1.1032789553
            },
            {
                "index": 217,
                "date": "2018-09-03",
                "press_title": "Vertex Announces Reimbursement Agreement in Australia for ORKAMBI® (lumacaftor/ivacaftor) for People with Cystic Fibrosis Ages Six Years and Older with Two Copies of the F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-reimbursement-agreement-australia-orkambir",
                "content": "  - Approximately 1,300 patients in Australia join the thousands of patients worldwide who already have access to lumacaftor/ivacaftor - - A pathway to access for future Vertex CF medicine, tezacaftor/ivacaftor, has also been established - LONDON --(BUSINESS WIRE)--Sep.  ",
                "1d_change": -0.0109104377,
                "index_price": -0.2894088139,
                "norm_price": 0.2784983762
            },
            {
                "index": 218,
                "date": "2018-08-30",
                "press_title": "Vertex and Genomics plc Establish Collaboration to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-genomics-plc-establish-collaboration-use-human",
                "content": "  Multi-year collaboration combines expertise in genomics, machine learning and drug discovery to identify novel targets for innovative medicines BOSTON &amp; OXFORD, United Kingdom --(BUSINESS WIRE)--Aug. 30, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Genomics plc today announced a  ",
                "1d_change": -0.3253829302,
                "index_price": -0.2557253379,
                "norm_price": -0.0696575923
            },
            {
                "index": 219,
                "date": "2018-08-23",
                "press_title": "Vertex Appoints Ludovic Fenaux as Senior Vice President, International Commercial Operations",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-appoints-ludovic-fenaux-senior-vice-president",
                "content": "  – Ludovic Fenaux to lead Vertex’s expanding International organization – – Simon Bedson announces retirement – LONDON --(BUSINESS WIRE)--Aug. 23, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Ludovic Fenaux has been appointed Senior Vice President, International  ",
                "1d_change": -0.4976277432,
                "index_price": 0.500920191,
                "norm_price": -0.9985479341
            },
            {
                "index": 220,
                "date": "2018-08-20",
                "press_title": "Vertex Receives a Positive PBAC Recommendation for Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) to Treat Australians Ages Six and Over with Cystic Fibrosis and Two Copies of the F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-positive-pbac-recommendation-reimbursement",
                "content": "  - PBAC recommendation moves approximately 1,300 patients in Australia closer to access to lumacaftor/ivacaftor and Vertex is now working with the Australian Government to finalize a reimbursement agreement as soon as possible - LONDON --(BUSINESS WIRE)--Aug.  ",
                "1d_change": 0.1357036596,
                "index_price": 0.3154088573,
                "norm_price": -0.1797051977
            },
            {
                "index": 221,
                "date": "2018-08-16",
                "press_title": "Vertex Awards Two College Students Full Scholarships to the University of Massachusetts",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-awards-two-college-students-full-scholarships-university",
                "content": "  -- Boston Public High School Students Nora Nguyen and Sonny Mei Receive Vertex Science Leaders Scholarship to Pursue STEAM Degrees at UMass -- BOSTON --(BUSINESS WIRE)--Aug. 16, 2018-- Vertex today announced the recipients of the annual Vertex Science Leaders Scholarship, a four-year, full-ride  ",
                "1d_change": 1.0790601633,
                "index_price": 0.655757533,
                "norm_price": 0.4233026303
            },
            {
                "index": 222,
                "date": "2018-08-15",
                "press_title": "FDA Approves KALYDECO® (ivacaftor) as First and Only Medicine to Treat the Underlying Cause of CF in Children Ages 12 to <24 Months with Certain Mutations in the CFTR Gene ",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/fda-approves-kalydecor-ivacaftor-first-and-only-medicine-treat",
                "content": "  -Data from Phase 3 ARRIVAL study support treatment with KALYDECO in children ages 12 to  ",
                "1d_change": 0.3315053777,
                "index_price": 0.4484822525,
                "norm_price": -0.1169768748
            },
            {
                "index": 223,
                "date": "2018-08-07",
                "press_title": "FDA Approves ORKAMBI® (lumacaftor/ivacaftor) as First Medicine to Treat the Underlying Cause of Cystic Fibrosis for Children Ages 2-5 Years with Most Common Form of the Disease",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/fda-approves-orkambir-lumacaftorivacaftor-first-medicine-treat",
                "content": "  - Approximately 1,300 people in the U.S. ages 2 through 5 years have two copies of the F508del mutation, the most common genetic form of the disease - BOSTON --(BUSINESS WIRE)--Aug. 7, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S.  ",
                "1d_change": -0.3650880653,
                "index_price": 0.0622888801,
                "norm_price": -0.4273769454
            },
            {
                "index": 224,
                "date": "2018-07-27",
                "press_title": "Vertex Receives European CHMP Positive Opinion for SYMKEVI® (tezacaftor/ivacaftor) for People with Cystic Fibrosis Aged 12 and Older with Certain Mutations in the CFTR Gene",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-european-chmp-positive-opinion-symkevir",
                "content": "  If approved, SYMKEVI ® (tezacaftor/ivacaftor) will be Vertex’s third medicine to treat the CFTR protein defect in patients with cystic fibrosis – a rare life-shortening disease LONDON --(BUSINESS WIRE)--Jul. 27, 2018-- Vertex Pharmaceuticals (Europe) Limited , today announced that the European  ",
                "1d_change": -0.4357267027,
                "index_price": -1.4183257909,
                "norm_price": 0.9825990882
            },
            {
                "index": 225,
                "date": "2018-07-25",
                "press_title": "Vertex Reports Second-Quarter 2018 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-second-quarter-2018-financial-results",
                "content": "  -Second-quarter 2018 total CF product revenues of $750 million , a 46% increase compared to $514 million in the second quarter of 2017- -Company increases full-year 2018 total CF product revenue guidance to $2.9 to $3.0 billion ; reiterates full-year 2018 combined non-GAAP R&amp;D and SG&amp;A expense  ",
                "1d_change": 0.6197739058,
                "index_price": 0.6946388768,
                "norm_price": -0.0748649709
            },
            {
                "index": 226,
                "date": "2018-07-12",
                "press_title": "Vertex to Announce Second Quarter 2018 Financial Results on July 25",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-second-quarter-2018-financial-results-july-25",
                "content": "  BOSTON --(BUSINESS WIRE)--Jul. 12, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2018 financial results on Wednesday, July 25, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  ",
                "1d_change": 3.0360087133,
                "index_price": 0.6486310203,
                "norm_price": 2.387377693
            },
            {
                "index": 227,
                "date": "2018-06-28",
                "press_title": "Health Canada Approves PrSYMDEKO™ (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/health-canada-approves-prsymdekotm-tezacaftorivacaftor-and",
                "content": "  -SYMDEKO is Vertex’s third medicine to treat the underlying cause of CF- -Approximately 2,000 people in Canada are ages 12 and older and have two copies of the F508del mutation or at least one mutation in the CF gene that is responsive to treatment with SYMDEKO- BOSTON --(BUSINESS WIRE)--Jun.  ",
                "1d_change": 13.0442530901,
                "index_price": 0.7239696926,
                "norm_price": 12.3202833975
            },
            {
                "index": 228,
                "date": "2018-06-21",
                "press_title": "Vertex’s Paul Negulescu Awarded the Warren Alpert Foundation Prize for Pioneering Discoveries in Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertexs-paul-negulescu-awarded-warren-alpert-foundation-prize",
                "content": "  BOSTON --(BUSINESS WIRE)--Jun. 21, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named one of the winners of this year’s Warren Alpert Foundation Prize for “transformative discoveries in the fields of genetics,  ",
                "1d_change": 0.822914466,
                "index_price": -0.5227141326,
                "norm_price": 1.3456285987
            },
            {
                "index": 229,
                "date": "2018-06-18",
                "press_title": "Vertex Opens Expanded Research Site in San Diego",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-opens-expanded-research-site-san-diego",
                "content": "  BOSTON --(BUSINESS WIRE)--Jun. 18, 2018-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the opening of its new 170,000 square foot research facility in Torrey Pines , San Diego . The new site represents a significant expansion of the Company’s research presence in the area, and  ",
                "1d_change": 0.3883534651,
                "index_price": -0.1158315592,
                "norm_price": 0.5041850242
            },
            {
                "index": 230,
                "date": "2018-06-18",
                "press_title": "Vertex Announces Long-Term Access Agreement in Sweden for Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor)",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-long-term-access-agreement-sweden-cystic",
                "content": "  - The agreement allows for reimbursement of ORKAMBI for people with cystic fibrosis who have two copies of the F508del mutation from July 1 - - A framework for assessment and access to our future cystic fibrosis medicines is included as part of the agreement - LONDON --(BUSINESS WIRE)--Jun.  ",
                "1d_change": 0.3883534651,
                "index_price": -0.1158315592,
                "norm_price": 0.5041850242
            },
            {
                "index": 231,
                "date": "2018-06-14",
                "press_title": "The Vertex Foundation and Employees Donate $1 Million Through Matching Gift Program",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-foundation-and-employees-donate-1-million-through",
                "content": "  BOSTON --(BUSINESS WIRE)--Jun. 14, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Vertex employees and The Vertex Foundation have together donated over $1 million through the Company’s new dollar-for-dollar matching gift program.  ",
                "1d_change": 1.6643025158,
                "index_price": -0.127715222,
                "norm_price": 1.7920177378
            },
            {
                "index": 232,
                "date": "2018-06-07",
                "press_title": "Vertex Data Presented at European Cystic Fibrosis Society (ECFS) Conference Demonstrate Early and Long-Term Disease-Modifying Potential of Treating the Underlying Cause of CF",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-data-presented-european-cystic-fibrosis-society-ecfs",
                "content": "  - Data from KALYDECO ® (ivacaftor) studies show the potential to modify the long-term progression of the disease - - Interim analysis of the ongoing extension study of tezacaftor/ivacaftor combination (approved in the U.S. as SYMDEKO TM ) continues to demonstrate consistent safety and sustained  ",
                "1d_change": 2.2915954024,
                "index_price": 0.150769922,
                "norm_price": 2.1408254804
            },
            {
                "index": 233,
                "date": "2018-06-06",
                "press_title": "Vertex to Present at the Goldman Sachs Healthcare Conference on June 13",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-goldman-sachs-healthcare-conference-june-13-0",
                "content": "  BOSTON --(BUSINESS WIRE)--Jun. 6, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference on Wednesday, June 13, 2018 at 5:40 p.m. ET ( 2:40 p.m. PT ). The audio portion of management’s remarks will be  ",
                "1d_change": 0.0205823529,
                "index_price": 0.6179722009,
                "norm_price": -0.5973898481
            },
            {
                "index": 234,
                "date": "2018-05-30",
                "press_title": "CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/crispr-therapeutics-and-vertex-provide-update-fda-review",
                "content": "  BOSTON and ZUG, Switzerland and CAMBRIDGE, Mass. , May 30, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Investigational New Drug  ",
                "1d_change": -1.3896099933,
                "index_price": 0.1049835273,
                "norm_price": -1.4945935206
            },
            {
                "index": 235,
                "date": "2018-05-01",
                "press_title": "Vertex Awards $400,000 in Scholarships to People Living with Cystic Fibrosis and Their Immediate Family Members",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-awards-400000-scholarships-people-living-cystic-fibrosis",
                "content": "  All in for CF Scholarship Program Doubles to Help 80 Recipients Pursue Higher Education BOSTON --(BUSINESS WIRE)--May 1, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the recipients of scholarships as part of its second All in for CF Scholarship program.  ",
                "1d_change": -2.4553409641,
                "index_price": -0.2765915034,
                "norm_price": -2.1787494606
            },
            {
                "index": 236,
                "date": "2018-04-26",
                "press_title": "Vertex Reports First-Quarter 2018 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-first-quarter-2018-financial-results",
                "content": "  -First-quarter 2018 total CF product revenues of $638 million , a 33% increase compared to $481 million in the first quarter of 2017- -Company reiterates full-year 2018 total CF product revenue guidance of $2.65 to $2.80 billion and combined non-GAAP R&amp;D and SG&amp;A expense guidance of $1.50 to $1.55  ",
                "1d_change": -0.3524530862,
                "index_price": 0.6839185728,
                "norm_price": -1.036371659
            },
            {
                "index": 237,
                "date": "2018-04-26",
                "press_title": "Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-initiates-phase-3-studies-vx-445-tezacaftor-and-ivacaftor",
                "content": "  -VX-445 triple combination regimen is the second of two different triple combination regimens to enter Phase 3 development in 2018- -Phase 3 study in approximately 360 patients with one F508del mutation and one minimal function mutation designed to support New Drug Application based on 4-week  ",
                "1d_change": -0.3524530862,
                "index_price": 0.6839185728,
                "norm_price": -1.036371659
            },
            {
                "index": 238,
                "date": "2018-04-17",
                "press_title": "Vertex to Announce First Quarter 2018 Financial Results on April 26",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-first-quarter-2018-financial-results-april-26",
                "content": "  BOSTON --(BUSINESS WIRE)--Apr. 17, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2018 financial results on Thursday, April 26, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  ",
                "1d_change": 1.7262532527,
                "index_price": 0.5870068734,
                "norm_price": 1.1392463794
            },
            {
                "index": 239,
                "date": "2018-03-29",
                "press_title": "Vertex Appoints Kimberly A. White as Senior Vice President and Chief Communications Officer",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-appoints-kimberly-white-senior-vice-president-and-chief",
                "content": "  BOSTON --(BUSINESS WIRE)--Mar. 29, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Kimberly A. White has been appointed Senior Vice President and Chief Communications Officer. Ms. White will begin her role with Vertex on May 21, 2018 , and will report to Michael J.  ",
                "1d_change": -2.2519380254,
                "index_price": -1.2599358132,
                "norm_price": -0.9920022122
            },
            {
                "index": 240,
                "date": "2018-03-29",
                "press_title": "Vertex Appoints Kimberly A. White as Senior Vice President and Chief Communications Officer",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-appoints-kimberly-white-senior-vice-president-and-chief-0",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Kimberly A. White has been appointed Senior Vice President and Chief Communications Officer. Ms. White will begin her role with Vertex on May 21, 2018 , and will report to Michael J.  ",
                "1d_change": -2.2519380254,
                "index_price": -1.2599358132,
                "norm_price": -0.9920022122
            },
            {
                "index": 241,
                "date": "2018-03-12",
                "press_title": "Vertex to Present at the Cowen Healthcare Conference on March 13",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-cowen-healthcare-conference-march-13",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Healthcare Conference on Tuesday, March 13, 2018 at 12:00 p.m. ET . The audio portion of management's remarks will be available live through Vertex's website,  ",
                "1d_change": -0.8801973177,
                "index_price": -0.9123743788,
                "norm_price": 0.0321770611
            },
            {
                "index": 242,
                "date": "2018-03-01",
                "press_title": "Vertex Initiates Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-initiates-phase-3-study-vx-659-tezacaftor-and-ivacaftor",
                "content": "  -Global Phase 3 study to enroll approximately 100 patients with the most common genetic form of the disease- -Phase 2 data showed mean absolute improvement in ppFEV 1 &nbsp;of 9.7 percentage points when VX-659 was added in people with CF who have two F508del mutations who were already receiving  ",
                "1d_change": 2.5755644747,
                "index_price": -0.8906631009,
                "norm_price": 3.4662275756
            },
            {
                "index": 243,
                "date": "2018-02-26",
                "press_title": "Vertex Appoints Reshma Kewalramani, M.D., as Chief Medical Officer",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-appoints-reshma-kewalramani-md-chief-medical-officer",
                "content": "  - Jeffrey Chodakewitz , M.D., to retire and serve as senior advisor through early 2019- - Dr. Kewalramani to become CMO and Executive Vice President, Global Medicines Development and Medical Affairs, on April 1, 2018 - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)  ",
                "1d_change": -0.6269551818,
                "index_price": -0.4769953413,
                "norm_price": -0.1499598405
            },
            {
                "index": 244,
                "date": "2018-02-21",
                "press_title": "Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-initiates-first-phase-3-study-vx-659-tezacaftor-and",
                "content": "  -Global Phase 3 study to enroll 360 patients with one F508del mutation and one minimal function mutation- -Study designed to support submission of New Drug Application in the U.S. based on 4-week primary efficacy endpoint and 12-week safety data- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals  ",
                "1d_change": -1.9290618793,
                "index_price": -0.6128074601,
                "norm_price": -1.3162544192
            },
            {
                "index": 245,
                "date": "2018-02-14",
                "press_title": "Vertex Announces Treatment with the NaV1.8 Inhibitor VX-150 Showed Significant Relief of Acute Pain in Phase 2 Study",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-treatment-nav18-inhibitor-vx-150-showed",
                "content": "  -VX-150 was generally well tolerated and showed statistically significant relief of acute pain compared to placebo; study included an active reference arm of the opioid pain medicine hydrocodone+acetaminophen to support evaluation of VX-150 treatment effect- -Phase 2 study in acute pain is the  ",
                "1d_change": 5.1634133419,
                "index_price": 2.9287489625,
                "norm_price": 2.2346643794
            },
            {
                "index": 246,
                "date": "2018-02-12",
                "press_title": "FDA Approves SYMDEKOTM (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/fda-approves-symdekotm-tezacaftorivacaftor-and-ivacaftor-treat",
                "content": "  - SYMDEKO is Vertex's third medicine to treat the underlying cause of CF - - SYMDEKO to begin shipping to pharmacies this week - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) approved SYMDEKO ™  ",
                "1d_change": 0.4735926628,
                "index_price": 0.9834972618,
                "norm_price": -0.509904599
            },
            {
                "index": 247,
                "date": "2018-02-01",
                "press_title": "Vertex Selects Two Next-Generation Correctors, VX-659 and VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-selects-two-next-generation-correctors-vx-659-and-vx-445",
                "content": "  - Phase 2 data showed mean absolute improvements in ppFEV 1 of up to 13.3 and 13.8 percentage points for VX-659 and VX-445, respectively, in triple combination with tezacaftor and ivacaftor in people with CF who have one F508del mutation and one minimal function mutation (F508del/Min); triple  ",
                "1d_change": -4.7341162519,
                "index_price": -1.9666007995,
                "norm_price": -2.7675154524
            },
            {
                "index": 248,
                "date": "2018-01-31",
                "press_title": "Vertex Reports Full-Year and Fourth-Quarter 2017 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2017-financial",
                "content": "  -Total 2017 CF product revenues of $2.17 billion , a 29% increase compared to $1.68 billion in 2016; 2017 KALYDECO revenues of $845 million and 2017 ORKAMBI revenues of $1.32 billion - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated  ",
                "1d_change": 3.6244893192,
                "index_price": -0.3695962308,
                "norm_price": 3.99408555
            },
            {
                "index": 249,
                "date": "2018-01-10",
                "press_title": "Vertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-eu-approval-orkambir-lumacaftorivacaftor",
                "content": "  - In Europe, there are approximately 3,400 children ages 6-11 who have two copies of the F508del mutation - - Existing reimbursement agreements in countries like Ireland will enable rapid access to ORKAMBI; country-by-country reimbursement processes will now begin in other countries- LONDON  ",
                "1d_change": 1.5151477203,
                "index_price": 0.7952857138,
                "norm_price": 0.7198620065
            },
            {
                "index": 250,
                "date": "2018-01-03",
                "press_title": "Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth-Quarter and Full-Year 2017 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-upcoming-presentation-jp-morgan-healthcare-2",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:30 p.m. ET ( 9:30 a.m. PT ). The audio portion of management's remarks can be accessed live through  ",
                "1d_change": -0.2809124291,
                "index_price": 0.9596177912,
                "norm_price": -1.2405302203
            },
            {
                "index": 251,
                "date": "2017-12-12",
                "press_title": "Vertex and CRISPR Therapeutics to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease and β-Thalassemia",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-co-develop-and-co-commercialize",
                "content": "  -Vertex selects CTX001 as first gene edited treatment to be developed as part of collaboration with CRISPR Therapeutics - -Clinical Trial Application for CTX001 submitted in Europe to support initiation of Phase 1/2 clinical study in β-thalassemia in 2018- -Preclinical data for CTX001 presented  ",
                "1d_change": 3.2872994926,
                "index_price": 0.0420645979,
                "norm_price": 3.2452348947
            },
            {
                "index": 252,
                "date": "2017-12-07",
                "press_title": "Vertex Announces Positive Results from Open-Label Phase 3 Study of KALYDECO® (ivacaftor) in Children with Cystic Fibrosis Ages 1 to 2 Years",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-open-label-phase-3-study",
                "content": "  -Study met primary safety endpoint and showed improvements across multiple endpoints, including measures of pancreatic function- -Potential to modify the course of CF in children as young as one year of age- -Results support FDA and EMA filings in the first quarter of 2018- BOSTON --(BUSINESS  ",
                "1d_change": 3.9621213127,
                "index_price": 0.871963688,
                "norm_price": 3.0901576247
            },
            {
                "index": 253,
                "date": "2017-11-10",
                "press_title": "Vertex Receives CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation in the European Union",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-chmp-positive-opinion-orkambir",
                "content": "  - In Europe, there are approximately 3,400 children ages 6-11 who have two copies of the F508del mutation - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Union Committee for Medicinal Products for Human Use (CHMP) issued a positive  ",
                "1d_change": -0.1553710258,
                "index_price": 0.1802879904,
                "norm_price": -0.3356590162
            },
            {
                "index": 254,
                "date": "2017-11-03",
                "press_title": "Vertex Announces Presentations of Data at North American Cystic Fibrosis Conference that Demonstrate Important Progress Toward Goal of Helping All People with CF",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-presentations-data-north-american-cystic",
                "content": "  - Data from ongoing extension study of ORKAMBI ® (lumacaftor/ivacaftor) in children ages 6-11 and real-world KALYDECO ® (ivacaftor) data demonstrate long-term safety and other benefits of these medicines - - New data from ongoing extension study of tezacaftor/ivacaftor combination demonstrate  ",
                "1d_change": 3.9803952516,
                "index_price": 0.3550555776,
                "norm_price": 3.625339674
            },
            {
                "index": 255,
                "date": "2017-11-03",
                "press_title": "Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis Ages 12 and Older Published in the New England Journal of Medicine",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/phase-3-studies-tezacaftorivacaftor-combination-treatment-people",
                "content": "  - Data showed significant improvements in lung function (ppFEV 1 ) with a favorable safety profile across multiple patient groups - - Tezacaftor/ivacaftor currently under review by the FDA and EMA; FDA Priority Review action date of February 28, 2018 - BOSTON --(BUSINESS WIRE)-- Vertex  ",
                "1d_change": 3.9803952516,
                "index_price": 0.3550555776,
                "norm_price": 3.625339674
            },
            {
                "index": 256,
                "date": "2017-11-02",
                "press_title": "Vertex to Present at the Credit Suisse Healthcare Conference on November 7",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-credit-suisse-healthcare-conference-november-7",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 7, 2017 at 10:35 a.m. ET . Management's remarks will be available live through Vertex's website at www.vrtx.com  ",
                "1d_change": 5.3077326459,
                "index_price": 0.3238270785,
                "norm_price": 4.9839055674
            },
            {
                "index": 257,
                "date": "2017-11-01",
                "press_title": "Vertex Announces New $750,000 Program to Support the Work of the Next Generation of Cystic Fibrosis Researchers",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-new-750000-program-support-work-next-generation",
                "content": "  The Vertex Research Innovation Award (RIA) Program Will Now Provide up to $10M in Grants Over the Next Five Years to New Postdoctoral and Faculty Researchers from Around the World BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated  (Nasdaq: VRTX) announced today a new $750,000 program  ",
                "1d_change": -1.6908297517,
                "index_price": -0.1302348258,
                "norm_price": -1.5605949259
            },
            {
                "index": 258,
                "date": "2017-10-25",
                "press_title": "Vertex Reports Third-Quarter 2017 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-third-quarter-2017-financial-results",
                "content": "  -Third-quarter 2017 cystic fibrosis product revenues of $550 million , up 34% versus Q3 2016; $336 million for ORKAMBI and $213 million for KALYDECO- -Company increases total 2017 CF product revenue guidance to $2.10 to $2.15 billion ; increases ORKAMBI revenue guidance to $1.29 to $1.32 billion  ",
                "1d_change": -4.3962211782,
                "index_price": -0.2390297384,
                "norm_price": -4.1571914398
            },
            {
                "index": 259,
                "date": "2017-10-23",
                "press_title": "Vertex Doubles Scholarship Program to Support the Academic and Professional Advancement of People Living with Cystic Fibrosis and Their Families",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-doubles-scholarship-program-support-academic-and",
                "content": "  Now Accepting Applications for the \"All in for CF\" Scholarship Program Through Jan. 3, 2018 BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has doubled the number of scholarships for people living with cystic fibrosis (CF) and their immediate family members.  ",
                "1d_change": -2.7860543292,
                "index_price": -0.3483745751,
                "norm_price": -2.4376797541
            },
            {
                "index": 260,
                "date": "2017-10-17",
                "press_title": "Vertex Announces 10-Year, $500 Million Corporate Giving Commitment",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-10-year-500-million-corporate-giving-commitment",
                "content": "  Dedicates $50M to science, technology, engineering, arts and math (STEAM) education for underserved students and establishes The Vertex Foundation Expands global efforts for providing patient and caregiver support including access to our medicines; developing young scientists and physicians; and  ",
                "1d_change": 0.1356884612,
                "index_price": 0.15969046,
                "norm_price": -0.0240019988
            },
            {
                "index": 261,
                "date": "2017-10-16",
                "press_title": "Vertex to Announce Third Quarter 2017 Financial Results on October 25",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-third-quarter-2017-financial-results-october-25",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2017 financial results on Wednesday, October 25, 2017 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  ",
                "1d_change": 1.2512108373,
                "index_price": 0.148085416,
                "norm_price": 1.1031254213
            },
            {
                "index": 262,
                "date": "2017-09-21",
                "press_title": "Vertex to Present at the Leerink Partners Roundtable Series on September 27",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-leerink-partners-roundtable-series-september-27",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Leerink Partners Roundtable Series: Rare Disease &amp; Immuno-Oncology on Wednesday, September 27, 2017 at 11:30 a.m. ET Management's remarks will be available live through  ",
                "1d_change": -1.2957865827,
                "index_price": -0.1974223475,
                "norm_price": -1.0983642352
            },
            {
                "index": 263,
                "date": "2017-09-19",
                "press_title": "Vertex Announces Upcoming Presentations of Data at 2017 North American Cystic Fibrosis Conference",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-upcoming-presentations-data-2017-north-american",
                "content": "  -Eleven abstracts from Vertex's CF program accepted for presentation- -Late-breaking abstract submitted with data from three different triple combination regimens in CF patients- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 11 abstracts from its  ",
                "1d_change": -0.3601381924,
                "index_price": 0.0777418102,
                "norm_price": -0.4378800025
            },
            {
                "index": 264,
                "date": "2017-09-07",
                "press_title": "Vertex to Present at the Morgan Stanley Healthcare Conference on September 11",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-morgan-stanley-healthcare-conference-september-11",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Healthcare Conference on Monday, September 11, 2017 at 1:40 p.m. ET . Management's remarks will be available live through Vertex's website at www.vrtx.com  ",
                "1d_change": 1.1018069507,
                "index_price": -0.2693607837,
                "norm_price": 1.3711677344
            },
            {
                "index": 265,
                "date": "2017-09-06",
                "press_title": "Vertex Appoints Tom Graney as Senior Vice President and Chief Financial Officer",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-appoints-tom-graney-senior-vice-president-and-chief",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Tom Graney to the role of Senior Vice President and Chief Financial Officer (CFO). Mr. Graney will begin his role with Vertex on September 13, 2017 and will report to Executive Vice  ",
                "1d_change": -0.056455891,
                "index_price": 0.0515199984,
                "norm_price": -0.1079758894
            },
            {
                "index": 266,
                "date": "2017-08-24",
                "press_title": "Vertex Announces Acceptance of its Applications for Review of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis by the FDA and EMA",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-acceptance-its-applications-review",
                "content": "  - FDA grants Priority Review of the application and sets action date of February 28, 2018 - -Applications supported by positive results from two global Phase 3 studies in people with CF ages 12 and older who have two copies of the F508del mutation or one F508del mutation and one residual function  ",
                "1d_change": -0.2153075108,
                "index_price": -0.1989260631,
                "norm_price": -0.0163814478
            },
            {
                "index": 267,
                "date": "2017-08-01",
                "press_title": "FDA Approves KALYDECO® (ivacaftor) for More Than 600 People Ages 2 and Older With Cystic Fibrosis Who Have Certain Residual Function Mutations",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/fda-approves-kalydecor-ivacaftor-more-600-people-ages-2-and",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved KALYDECO ® (ivacaftor) for use in more than 600 people with cystic fibrosis (CF) ages 2 and older who have one of five residual function  ",
                "1d_change": 2.8689331545,
                "index_price": 0.0189690176,
                "norm_price": 2.8499641369
            },
            {
                "index": 268,
                "date": "2017-07-26",
                "press_title": "Vertex Reports Second-Quarter 2017 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-second-quarter-2017-financial-results",
                "content": "  -Second-quarter 2017 cystic fibrosis product revenues of $514 million ; $324 million for ORKAMBI and $190 million for KALYDECO- -Vertex reiterates 2017 guidance for ORKAMBI and KALYDECO product revenues; updates guidance for combined GAAP and non-GAAP R&amp;D and SG&amp;A expenses- -Pipeline of  ",
                "1d_change": -3.8158597618,
                "index_price": -0.1838091706,
                "norm_price": -3.6320505911
            },
            {
                "index": 269,
                "date": "2017-07-25",
                "press_title": "Vertex and Concert Pharmaceuticals Complete Asset Purchase Agreement for CTP-656",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-concert-pharmaceuticals-complete-asset-purchase",
                "content": "  BOSTON &amp; LEXINGTON, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the completion of their previously announced asset purchase agreement. Under the completed agreement, Vertex now has worldwide  ",
                "1d_change": -2.1539617623,
                "index_price": -0.0020100122,
                "norm_price": -2.15195175
            },
            {
                "index": 270,
                "date": "2017-07-18",
                "press_title": "Vertex Announces Positive Phase 1 & Phase 2 Data from Three Different Triple Combination Regimens in People with Cystic Fibrosis Who Have One F508del Mutation and One Minimal Function Mutation (F508del/Min)",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-positive-phase-1-phase-2-data-three-different",
                "content": "  -Phase 2 data showed mean absolute improvements in ppFEV 1 of 9.7 and 12.0 percentage points for VX-152 and VX-440, respectively, in triple combination with tezacaftor and ivacaftor in F508del/Min patients; Initial data from Phase 1 study showed mean absolute improvement in ppFEV 1 of 9.6  ",
                "1d_change": 19.0869780585,
                "index_price": 0.7256034063,
                "norm_price": 18.3613746522
            },
            {
                "index": 271,
                "date": "2017-07-17",
                "press_title": "Vertex Awards Two First-Generation College Students Full Scholarships to the University of Massachusetts",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-awards-two-first-generation-college-students-full",
                "content": "  Boston Public High School Students Hannah Mei and Sayed Shah Receive Vertex Science Leaders Scholarship to Pursue STEM Degrees at UMass BOSTON --(BUSINESS WIRE)-- Vertex , Boston Public Schools (BPS) and the University of Massachusetts today announced the recipients of the annual Vertex Science  ",
                "1d_change": 1.3014536721,
                "index_price": 0.0451151289,
                "norm_price": 1.2563385432
            },
            {
                "index": 272,
                "date": "2017-07-13",
                "press_title": "Vertex to Announce Second Quarter 2017 Financial Results on July 26",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-second-quarter-2017-financial-results-july-26",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2017 financial results on Wednesday, July 26, 2017 after the financial markets close. The company will host a conference call and webcast at 5:15 p.m. ET .  ",
                "1d_change": -0.572562767,
                "index_price": 0.5806613013,
                "norm_price": -1.1532240683
            },
            {
                "index": 273,
                "date": "2017-07-13",
                "press_title": "Vertex Announces Reimbursement Agreement in Italy for ORKAMBI® (Lumacaftor/Ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-reimbursement-agreement-italy-orkambir",
                "content": "  - Effective immediately, agreement enables hundreds of people in Italy to access this important medicine - - Recent pricing and reimbursement agreements have enabled broad access to ORKAMBI for thousands of eligible patients in multiple European countries; negotiations continue in a number of other  ",
                "1d_change": -0.572562767,
                "index_price": 0.5806613013,
                "norm_price": -1.1532240683
            },
            {
                "index": 274,
                "date": "2017-06-09",
                "press_title": "Vertex to Present at the Goldman Sachs Healthcare Conference on June 13",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-goldman-sachs-healthcare-conference-june-13",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference on Tuesday, June 13, 2017 at 12:20 p.m. ET . Management's remarks will be available live through Vertex's website at www.vrtx.com in  ",
                "1d_change": -3.3755659455,
                "index_price": -0.2881381873,
                "norm_price": -3.0874277582
            },
            {
                "index": 275,
                "date": "2017-06-09",
                "press_title": "Vertex Announces Nine Presentations of Data on ORKAMBI® (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) at the European Cystic Fibrosis Society (ECFS) Conference",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-nine-presentations-data-orkambir",
                "content": "  - Presentation of data from a Phase 3 study of ORKAMBI in children ages 6-11 with two copies of the F508del mutation demonstrated improvements in lung function and sweat chloride; study also published online in The Lancet Respiratory Medicine today - - ECFS data presentations demonstrate that  ",
                "1d_change": -3.3755659455,
                "index_price": -0.2881381873,
                "norm_price": -3.0874277582
            },
            {
                "index": 276,
                "date": "2017-06-08",
                "press_title": "Vertex Names Dr. Alan Garber, Provost of Harvard University, to its Board of Directors",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-names-dr-alan-garber-provost-harvard-university-its-board",
                "content": "  BOSTON --(BUSINESS WIRE)-- Shareholders of Vertex Pharmaceuticals Incorporated  (Nasdaq: VRTX) today elected Alan M. Garber , M.D., Ph.D. as an independent member of its board of directors. Dr. Garber is Provost of Harvard University , the Mallinckrodt Professor of Health Care Policy at Harvard  ",
                "1d_change": -1.9077093331,
                "index_price": -0.1028057744,
                "norm_price": -1.8049035587
            },
            {
                "index": 277,
                "date": "2017-06-01",
                "press_title": "Vertex Announces Long-Term Reimbursement Agreement with the Republic of Ireland for ORKAMBI® (lumacaftor/ivacaftor), KALYDECO® (ivacaftor) and Future Cystic Fibrosis Medicines",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-long-term-reimbursement-agreement-republic",
                "content": "  -Agreement provides access to ORKAMBI for people who have two copies of the F508del mutation and expands access to KALYDECO for all eligible patients- LONDON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced it has reached an agreement with the Health Service  ",
                "1d_change": 4.5419508651,
                "index_price": 0.9602088238,
                "norm_price": 3.5817420412
            },
            {
                "index": 278,
                "date": "2017-05-19",
                "press_title": "Vertex Awards 40 Scholarships Totaling $200,000 to People Living with Cystic Fibrosis and Their Immediate Family Members",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-awards-40-scholarships-totaling-200000-people-living",
                "content": "  - New Program Helps CF Families Pursue Higher Education - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated  (Nasdaq: VRTX) today announced the first recipients of the company's All in for CF Scholarship program. Each of the 40 scholarship recipients will be awarded $5,000 for the  ",
                "1d_change": 0.9836941099,
                "index_price": 0.9461032973,
                "norm_price": 0.0375908126
            },
            {
                "index": 279,
                "date": "2017-05-18",
                "press_title": "Vertex to Present at the UBS Healthcare Conference on May 23",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-ubs-healthcare-conference-may-23",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the UBS Healthcare Conference on Tuesday, May 23, 2017 at 11:00 a.m. ET . Management's remarks will be available live through Vertex's website at www.vrtx.com in the  ",
                "1d_change": 2.0928602454,
                "index_price": 1.1353108574,
                "norm_price": 0.9575493879
            },
            {
                "index": 280,
                "date": "2017-05-17",
                "press_title": "FDA Approves KALYDECO® (ivacaftor) for More Than 900 People Ages 2 and Older with Cystic Fibrosis Who Have Certain Residual Function Mutations",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/fda-approves-kalydecor-ivacaftor-more-900-people-ages-2-and",
                "content": "  - Precision medicine decision based on in vitro data and supported by more than five years of real-world clinical data that demonstrate KALYDECO's strong safety and efficacy profile for eligible patients - - Vertex working with FDA to obtain rapid approval for more than 600 additional people who  ",
                "1d_change": 0.4154989083,
                "index_price": -0.7283186802,
                "norm_price": 1.1438175885
            },
            {
                "index": 281,
                "date": "2017-05-04",
                "press_title": "Vertex Grants $1 Million to 15 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-grants-1-million-15-non-profit-organizations-advance",
                "content": "  Third Annual CF \"Circle of Care\" Grants Connect CF Community Members Around the World to Share Their Ideas and Inspiration BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the grant recipients for its 2017 Cystic Fibrosis (CF) Circle of Care program, an  ",
                "1d_change": -4.1361896129,
                "index_price": 0.3959504622,
                "norm_price": -4.5321400751
            },
            {
                "index": 282,
                "date": "2017-04-27",
                "press_title": "Vertex Reports First-Quarter 2017 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-first-quarter-2017-financial-results",
                "content": "  -First-quarter 2017 cystic fibrosis product revenues of $481 million ; $295 million for ORKAMBI and $186 million for KALYDECO- -Company reiterates 2017 guidance for ORKAMBI product revenues of $1.1 to $1.3 billion and increases 2017 guidance for KALYDECO product revenues to $710 to $730 million -  ",
                "1d_change": 1.944212166,
                "index_price": -0.2306853499,
                "norm_price": 2.174897516
            },
            {
                "index": 283,
                "date": "2017-04-12",
                "press_title": "Vertex to Announce First Quarter 2017 Financial Results on April 27",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-first-quarter-2017-financial-results-april-27",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2017 financial results on Thursday, April 27, 2017 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  ",
                "1d_change": -0.3778561456,
                "index_price": -0.9961549908,
                "norm_price": 0.6182988452
            },
            {
                "index": 284,
                "date": "2017-03-28",
                "press_title": "Two Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment Met Primary Endpoints with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/two-phase-3-studies-tezacaftorivacaftor-combination-treatment",
                "content": "    - Study in people who have two copies of the F508del mutation demonstrated a mean absolute improvement in ppFEV 1 of 4.0 percentage points compared to placebo (p   ",
                "1d_change": 16.3873754537,
                "index_price": 0.9037979615,
                "norm_price": 15.4835774922
            },
            {
                "index": 285,
                "date": "2017-03-06",
                "press_title": "Vertex to Acquire CTP-656 from Concert Pharmaceuticals for the Treatment of Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-acquire-ctp-656-concert-pharmaceuticals-treatment-cystic",
                "content": "  -Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating the underlying cause of CF- -Concert to receive $160 million in cash with potential for $90 million in future regulatory approval milestone payments- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals  ",
                "1d_change": 1.7192287561,
                "index_price": -0.2888075106,
                "norm_price": 2.0080362667
            },
            {
                "index": 286,
                "date": "2017-03-02",
                "press_title": "Vertex to Present at the Cowen Healthcare Conference on March 6",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-cowen-healthcare-conference-march-6",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Healthcare Conference on Monday, March 6 th at 2:00 p.m. ET Management's remarks will be available live through Vertex's website at www.vrtx.com in the \"Investors\"  ",
                "1d_change": 0.2771925859,
                "index_price": -0.4880107691,
                "norm_price": 0.765203355
            },
            {
                "index": 287,
                "date": "2017-01-25",
                "press_title": "Vertex Reports Full-Year and Fourth-Quarter 2016 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2016-financial",
                "content": "  -2016 total CF product revenues of $1.68 billion compared to $982 million in 2015; $980 million for ORKAMBI and $703 million for KALYDECO- -Fourth-quarter 2016 total CF product revenues of $454 million ; $277 million for ORKAMBI and $177 million for KALYDECO- -Company reiterates 2017 financial  ",
                "1d_change": 3.2579382628,
                "index_price": 0.339622806,
                "norm_price": 2.9183154568
            },
            {
                "index": 288,
                "date": "2017-01-11",
                "press_title": "Merck KGaA, Darmstadt, Germany Licenses Four Oncology Research and Development Programs from Vertex",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/merck-kgaa-darmstadt-germany-licenses-four-oncology-research-and",
                "content": "  -Merck KGaA, Darmstadt, Germany licenses two promising clinical-stage programs targeting DNA damage and repair, and two novel pre-clinical programs- -Vertex receives upfront payment of $230 million plus royalties on future sales- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated  ",
                "1d_change": -0.94671536,
                "index_price": 0.0810346804,
                "norm_price": -1.0277500404
            },
            {
                "index": 289,
                "date": "2017-01-08",
                "press_title": "Vertex Provides Update on Business and Financial Performance and Research and Development Programs",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-provides-update-business-and-financial-performance-and",
                "content": "  -Full-year 2016 product revenues of approximately $703 million for KALYDECO and $979 million for ORKAMBI; total 2016 CF product revenues of $1.68 billion compared to $983 million in 2015- -Company provides 2017 financial guidance for KALYDECO product revenues of $690 to $710 million and ORKAMBI  ",
                "1d_change": 3.7742641287,
                "index_price": -0.2067162832,
                "norm_price": 3.9809804118
            },
            {
                "index": 290,
                "date": "2017-01-04",
                "press_title": "Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2016 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-upcoming-presentation-jp-morgan-healthcare-1",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 35 th Annual J.P. Morgan Healthcare Conference on Monday, January 9 at 12:30 p.m. ET ( 9:30 a.m. PT ).  ",
                "1d_change": 4.8570660972,
                "index_price": 0.3261305572,
                "norm_price": 4.53093554
            },
            {
                "index": 291,
                "date": "2016-12-19",
                "press_title": "Vertex Announces German Reimbursement Agreement for ORKAMBI® (Lumacaftor/Ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-german-reimbursement-agreement-orkambir",
                "content": "  LONDON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced it has reached a pricing and reimbursement agreement for ORKAMBI ® (lumacaftor/ivacaftor) with the German Federal Association of the Statutory Health Insurances (GKV-SV).  ",
                "1d_change": -0.0261599195,
                "index_price": 0.5073199934,
                "norm_price": -0.5334799128
            },
            {
                "index": 292,
                "date": "2016-11-07",
                "press_title": "Positive Phase 3 Study of ORKAMBI® in Children With Cystic Fibrosis Ages 6-11 Who Have Two Copies of the F508del Mutation Supports a Submission to the European Medicines Agency in the First Half of 2017",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/positive-phase-3-study-orkambir-children-cystic-fibrosis-ages-6",
                "content": "  - Study met primary endpoint with a statistically significant improvement in absolute change in lung clearance index (LCI 2.5 ) compared to placebo through 24 weeks of treatment - - ORKAMBI was well tolerated with safety data that were similar to data from previous Phase 3 open-label safety study -  ",
                "1d_change": 3.1449580402,
                "index_price": 1.8214011122,
                "norm_price": 1.323556928
            },
            {
                "index": 293,
                "date": "2016-11-02",
                "press_title": "Vertex to Present at the Credit Suisse Healthcare Conference on November 8",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-credit-suisse-healthcare-conference-november-8",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 8 th at 3:30 p.m. ET Management's remarks will be available live through Vertex's website at www.vrtx.com in the  ",
                "1d_change": 0.115850128,
                "index_price": -0.9944184504,
                "norm_price": 1.1102685784
            },
            {
                "index": 294,
                "date": "2016-10-27",
                "press_title": "Vertex Presents Long-Term Data Demonstrating that ORKAMBI® (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) Show the Potential to Modify the Progression of CF",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-presents-long-term-data-demonstrating-orkambir",
                "content": "  - 12 abstracts presented at 30 th Annual North American Cystic Fibrosis Conference highlight data from Vertex's CF program - ORLANDO, Fla. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of long-term data demonstrating that ORKAMBI ®  ",
                "1d_change": -2.3330723329,
                "index_price": -0.8300444041,
                "norm_price": -1.5030279288
            },
            {
                "index": 295,
                "date": "2016-10-25",
                "press_title": "Vertex Reports Third Quarter 2016 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-third-quarter-2016-financial-results",
                "content": "  -Third quarter 2016 cystic fibrosis product revenues of $410 million ; $234 million for ORKAMBI ® (lumacaftor/ivacaftor) and $176 million for KALYDECO ® (ivacaftor)- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the  ",
                "1d_change": -0.2159803976,
                "index_price": -0.4809710713,
                "norm_price": 0.2649906738
            },
            {
                "index": 296,
                "date": "2016-10-25",
                "press_title": "Vertex Announces Planned Initiation of Phase 2 Studies Evaluating the Next-Generation Correctors VX-440 and VX-152 in Triple Combination Regimens to Treat the Underlying Cause of Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-planned-initiation-phase-2-studies-evaluating",
                "content": "  -VX-440 to be evaluated as part of 4-week triple combination dosing with tezacaftor (VX-661) and ivacaftor; VX-152 to be evaluated as part of 2-week triple combination dosing- -Studies to enroll people with cystic fibrosis who have one copy of the F508del mutation and a minimal function mutation  ",
                "1d_change": -0.2159803976,
                "index_price": -0.4809710713,
                "norm_price": 0.2649906738
            },
            {
                "index": 297,
                "date": "2016-10-07",
                "press_title": "Vertex to Announce Third Quarter 2016 Financial Results on October 25",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-third-quarter-2016-financial-results-october-25",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2016 financial results on Tuesday, October 25, 2016 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  ",
                "1d_change": 0.721101096,
                "index_price": -0.0244968858,
                "norm_price": 0.7455979818
            },
            {
                "index": 298,
                "date": "2016-09-28",
                "press_title": "U.S. Food and Drug Administration Approves ORKAMBI® (lumacaftor/ivacaftor) for Use in Children with Cystic Fibrosis Ages 6 through 11 who have Two Copies of the F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/us-food-and-drug-administration-approves-orkambir",
                "content": "  -Approximately 2,400 children ages 6 through 11 have two copies of the F508del mutation in the U.S. - - Vertex revises ORKAMBI revenue guidance for 2016 - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S.  ",
                "1d_change": -6.4823554544,
                "index_price": -0.4983527461,
                "norm_price": -5.9840027083
            },
            {
                "index": 299,
                "date": "2016-09-09",
                "press_title": "Vertex to Present at Upcoming Investor Conferences",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-upcoming-investor-conferences-1",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated  (Nasdaq: VRTX) today announced that management will present at The Morgan Stanley Global Healthcare Conference in New York, NY on Wednesday, September 14 th at 11:40 a.m. ET . Vertex will also present at The Leerink Partners Roundtable  ",
                "1d_change": 1.5838984693,
                "index_price": -0.4650232919,
                "norm_price": 2.0489217612
            },
            {
                "index": 300,
                "date": "2016-08-15",
                "press_title": "Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-provides-update-ongoing-phase-3-program-vx-661",
                "content": "  -Results from Part A of Phase 3 study in people with a mutation that results in minimal cystic fibrosis transmembrane conductance regulator (CFTR) protein function do not support continuation of the study- -Enrollment complete in Phase 3 study in people with two copies of the F508del mutation-  ",
                "1d_change": -1.9599990845,
                "index_price": -0.3640785133,
                "norm_price": -1.5959205712
            },
            {
                "index": 301,
                "date": "2016-07-27",
                "press_title": "Vertex Reports Second Quarter 2016 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-second-quarter-2016-financial-results",
                "content": "  -Second quarter 2016 cystic fibrosis product revenues of $426 million ; $245 million for ORKAMBI ® (lumacaftor/ivacaftor) and $180 million for KALYDECO ® (ivacaftor)- -Vertex reiterates 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion and KALYDECO product revenues of $685 to $705  ",
                "1d_change": 1.6214505493,
                "index_price": 0.0115204185,
                "norm_price": 1.6099301308
            },
            {
                "index": 302,
                "date": "2016-07-14",
                "press_title": "Vertex to Announce Second Quarter 2016 Financial Results on July 27",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-second-quarter-2016-financial-results-july-27",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2016 financial results on Wednesday, July 27, 2016 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  ",
                "1d_change": 1.3634804789,
                "index_price": 0.1785648339,
                "norm_price": 1.1849156451
            },
            {
                "index": 303,
                "date": "2016-07-06",
                "press_title": "Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mRNA Therapeutics™ for Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-moderna-establish-exclusive-collaboration-discover",
                "content": "  -Collaboration to explore use of mRNA Therapeutics to treat the underlying cause of CF by enabling cells to produce functional CFTR proteins in the lungs- - Moderna to receive $40 million upfront, made up of a $20 million cash payment and a $20 million convertible note investment, with potential  ",
                "1d_change": 4.3198214967,
                "index_price": 0.6420692755,
                "norm_price": 3.6777522213
            },
            {
                "index": 304,
                "date": "2016-06-10",
                "press_title": "Vertex Announces Presentations of Data for KALYDECO® (ivacaftor) and ORKAMBI® (lumacaftor/ivacaftor) at European Cystic Fibrosis Society (ECFS) Conference",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-presentations-data-kalydecor-ivacaftor-and",
                "content": "  -Real-world data presented at ECFS show long-term impact of KALYDECO across multiple measures of disease- -Data from Phase 3 safety study of ORKAMBI in children ages 6-11 presented today at ECFS- BASEL, Switzerland --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today  ",
                "1d_change": -2.1427020342,
                "index_price": -1.4674905441,
                "norm_price": -0.6752114901
            },
            {
                "index": 305,
                "date": "2016-05-31",
                "press_title": "Vertex to Present at the Goldman Sachs Healthcare Conference on June 7",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-goldman-sachs-healthcare-conference-june-7",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference in Rancho Palos Verde , CA on Tuesday, June 7 th at 1:40 p.m. ET ( 10:40 a.m. PT ). Management's remarks will be accessible live  ",
                "1d_change": 3.4930763855,
                "index_price": -0.0380980912,
                "norm_price": 3.5311744767
            },
            {
                "index": 306,
                "date": "2016-05-31",
                "press_title": "U.S. FDA Accepts for Priority Review Supplemental New Drug Application for the Use of ORKAMBI® (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6 to 11 who have Two Copies of the F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/us-fda-accepts-priority-review-supplemental-new-drug-application",
                "content": "  -Approximately 2,400 children ages 6 to 11 have two copies of the F508del mutation in the U.S. - -Target review date of September 30, 2016 set for the FDA's decision on the application- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that the U.S.  ",
                "1d_change": 3.4930763855,
                "index_price": -0.0380980912,
                "norm_price": 3.5311744767
            },
            {
                "index": 307,
                "date": "2016-04-27",
                "press_title": "Vertex Reports First Quarter 2016 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-first-quarter-2016-financial-results",
                "content": "  -First quarter 2016 cystic fibrosis product revenues of $394 million ; $223 million for ORKAMBI ® (lumacaftor/ivacaftor) and $171 million for KALYDECO ® (ivacaftor)- -Provides 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion ; increases 2016 guidance for KALYDECO product revenues  ",
                "1d_change": 3.412102691,
                "index_price": -0.7958348339,
                "norm_price": 4.2079375249
            },
            {
                "index": 308,
                "date": "2016-04-15",
                "press_title": "Vertex to Announce First Quarter 2016 Financial Results on April 27",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-first-quarter-2016-financial-results-april-27",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2016 financial results on Wednesday, April 27, 2016 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  ",
                "1d_change": -5.0468599936,
                "index_price": 0.5366840992,
                "norm_price": -5.5835440927
            },
            {
                "index": 309,
                "date": "2016-03-10",
                "press_title": "Vertex to Present at the Barclays Healthcare Conference on March 15",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-barclays-healthcare-conference-march-15",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Barclays Healthcare Conference in Miami, FL on Tuesday, March 15 th at 10:15 a.m. ET . Management's remarks will be accessible live through Vertex's website at  ",
                "1d_change": 1.2752126674,
                "index_price": 1.5438693499,
                "norm_price": -0.2686566826
            },
            {
                "index": 310,
                "date": "2016-03-08",
                "press_title": "Vertex Receives Australian Approval for ORKAMBI® (lumacaftor/ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-australian-approval-orkambir-lumacaftorivacaftor",
                "content": "  -In Australia, approximately 1,000 people with CF ages 12 and older have two copies of the F508del mutation- -ORKAMBI reimbursement process already underway in Australia - LONDON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Therapeutic Goods  ",
                "1d_change": -7.0896847391,
                "index_price": -0.3830567688,
                "norm_price": -6.7066279703
            },
            {
                "index": 311,
                "date": "2016-02-24",
                "press_title": "Vertex Awards $1 Million in Grants to 18 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-awards-1-million-grants-18-non-profit-organizations",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated  (Nasdaq: VRTX) today announced it has awarded the company's 2016 Cystic Fibrosis (CF) Circle of Care grants , totaling approximately $1 million, to 18 non-profit medical, academic, patient and community organizations.  ",
                "1d_change": 1.6485397555,
                "index_price": 1.7492387884,
                "norm_price": -0.1006990329
            },
            {
                "index": 312,
                "date": "2016-02-09",
                "press_title": "Vertex to Present at Upcoming Investor Conferences",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-upcoming-investor-conferences-0",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that it will present at the Leerink Healthcare Conference in New York, NY on Thursday, February 11 th at 11:10 a.m. ET . Vertex will also present at the Cowen Healthcare Conference in Boston, MA on Tuesday,  ",
                "1d_change": 1.8108446056,
                "index_price": 0.183600512,
                "norm_price": 1.6272440936
            },
            {
                "index": 313,
                "date": "2016-02-05",
                "press_title": "Vertex Receives Complete Response Letter from U.S. FDA for Use of KALYDECO® (ivacaftor) in People with Cystic Fibrosis Ages 2 and Older with One of 23 Residual Function Mutations",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-complete-response-letter-us-fda-use-kalydecor",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for the use of KALYDECO ® (ivacaftor) in people with cystic  ",
                "1d_change": -9.4878033894,
                "index_price": -3.2172612422,
                "norm_price": -6.2705421472
            },
            {
                "index": 314,
                "date": "2016-01-27",
                "press_title": "Vertex Reports Full-Year and Fourth Quarter 2015 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2015-financial",
                "content": "  -Full-year 2015 total non-GAAP revenues of $1.01 billion , including net product revenues of $351 million for ORKAMBI ® (lumacaftor/ivacaftor) and $632 million for KALYDECO ® (ivacaftor) in cystic fibrosis- -Vertex reiterates 2016 financial guidance for KALYDECO net product revenues of $670 to $690  ",
                "1d_change": 0.4420048002,
                "index_price": -0.4837978119,
                "norm_price": 0.9258026121
            },
            {
                "index": 315,
                "date": "2016-01-26",
                "press_title": "Health Canada Approves PrORKAMBI® (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/health-canada-approves-prorkambir-lumacaftorivacaftor-first",
                "content": "  -Approximately 1,500 people in Canada are ages 12 and older and have two copies of the F508del mutation, the most common genetic form of the disease- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has approved Pr ORKAMBI ®  ",
                "1d_change": -0.216212917,
                "index_price": 0.2209252618,
                "norm_price": -0.4371381788
            },
            {
                "index": 316,
                "date": "2016-01-10",
                "press_title": "Vertex Outlines 2016 Business Priorities to Support the Discovery and Development of New Transformative Medicines for the Treatment of Cystic Fibrosis and Other Serious Diseases",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-outlines-2016-business-priorities-support-discovery-and",
                "content": "  -Approximately 25,000 people with cystic fibrosis worldwide currently eligible for treatment with ORKAMBI ® (lumacaftor/ivacaftor) or KALYDECO ® (ivacaftor); Vertex advancing the development of multiple medicines with the goal of treating all people with cystic fibrosis- -Fourth quarter 2015 net  ",
                "1d_change": -6.0208393482,
                "index_price": 0.6478664992,
                "norm_price": -6.6687058474
            },
            {
                "index": 317,
                "date": "2016-01-05",
                "press_title": "Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2015 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-upcoming-presentation-jp-morgan-healthcare-0",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 34 th Annual J.P. Morgan Healthcare Conference on Monday, January 11 at 12:30 p.m. ET ( 9:30 a.m. PT ).  ",
                "1d_change": -1.3580921109,
                "index_price": -1.1817561231,
                "norm_price": -0.1763359878
            },
            {
                "index": 318,
                "date": "2015-11-23",
                "press_title": "Vertex to Present at the Piper Jaffray Healthcare Conference on December 1",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-piper-jaffray-healthcare-conference-december-1",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Piper Jaffray Healthcare Conference in New York on Tuesday, December 1 at 11:00 a.m. ET . Management's remarks will be available live through  ",
                "1d_change": 1.7651964376,
                "index_price": -0.0129249138,
                "norm_price": 1.7781213514
            },
            {
                "index": 319,
                "date": "2015-11-23",
                "press_title": "Vertex Appoints Michael J. Parini as Executive Vice President and Chief Legal Officer",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-appoints-michael-j-parini-executive-vice-president-and",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Michael J. Parini to the role of Executive Vice President and Chief Legal Officer. Mr. Parini will serve as a member of Vertex's Executive Committee, reporting directly to Jeffrey Leiden  ",
                "1d_change": 1.7651964376,
                "index_price": -0.0129249138,
                "norm_price": 1.7781213514
            },
            {
                "index": 320,
                "date": "2015-11-20",
                "press_title": "Vertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-eu-approval-orkambir-lumacaftorivacaftor-first",
                "content": "  -In Europe, approximately 12,000 people with CF ages 12 and older have two copies of the F508del mutation- -Positive CHMP Opinion was received in September 2015 - -Country-by-country reimbursement process will now begin- LONDON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)  ",
                "1d_change": -0.1889787684,
                "index_price": 0.1806784933,
                "norm_price": -0.3696572616
            },
            {
                "index": 321,
                "date": "2015-11-18",
                "press_title": "Vertex Receives Two EU Approvals for KALYDECO® (ivacaftor) for People with Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-two-eu-approvals-kalydecor-ivacaftor-people",
                "content": "  - European Commission approves expanded use of ivacaftor in children with cystic fibrosis ages 2 to 5 who have one of 9 gating mutations; approximately 125 children ages 2 to 5 have one of the approved gating mutations in Europe - - European Commission approves expanded use of ivacaftor in people  ",
                "1d_change": 1.5913340214,
                "index_price": 1.4054121647,
                "norm_price": 0.1859218567
            },
            {
                "index": 322,
                "date": "2015-11-04",
                "press_title": "Vertex to Present at the Credit Suisse Healthcare Conference on November 10",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-credit-suisse-healthcare-conference-november-10",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 10 th at 11:30 a.m. ET . Management's remarks will be available live through Vertex's website at www.vrtx.com in  ",
                "1d_change": -5.7173332879,
                "index_price": -0.5081200975,
                "norm_price": -5.2092131905
            },
            {
                "index": 323,
                "date": "2015-10-28",
                "press_title": "Vertex Reports Third Quarter 2015 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-third-quarter-2015-financial-results",
                "content": "  -Third quarter 2015 revenues of $310 million , including net product revenues of $131 million for ORKAMBI ® (lumacaftor/ivacaftor) and $166 million for KALYDECO ® (ivacaftor) in cystic fibrosis- -Vertex increases guidance for 2015 KALYDECO net revenues; now expects KALYDECO revenues of $605 to $620  ",
                "1d_change": 4.5731923015,
                "index_price": 1.0974357644,
                "norm_price": 3.4757565371
            },
            {
                "index": 324,
                "date": "2015-10-26",
                "press_title": "Vertex and CRISPR Therapeutics Establish Collaboration to Use CRISPR-Cas9 Gene Editing Technology to Discover and Develop New Treatments for Genetic Diseases",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-establish-collaboration-use",
                "content": "  -Gene editing technology to be used to discover treatments to address the mutations and genes known to cause and contribute to cystic fibrosis- -Vertex and CRISPR to utilize gene editing approach to discover treatments for genetic diseases, including sickle cell disease- -Companies establish  ",
                "1d_change": 5.5532609719,
                "index_price": -0.4448535994,
                "norm_price": 5.9981145713
            },
            {
                "index": 325,
                "date": "2015-10-09",
                "press_title": "Vertex to Announce Third Quarter 2015 Financial Results on October 28",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-third-quarter-2015-financial-results-october-28",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2015 financial results on Wednesday, October 28, 2015 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  ",
                "1d_change": 3.3819000716,
                "index_price": 0.1848849812,
                "norm_price": 3.1970150904
            },
            {
                "index": 326,
                "date": "2015-10-08",
                "press_title": "Vertex Announces Significant Progress in Its Development Efforts to Treat the Cause of Cystic Fibrosis in the Vast Majority of People with the Disease",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-significant-progress-its-development-efforts",
                "content": "  -Two next-generation correctors to enter clinical development in November; studies of a triple combination of a next-generation corrector with VX-661/ivacaftor planned for 2016 in people with CF- -Treating the underlying cause of CF with ORKAMBI ® (lumacaftor/ivacaftor) or KALYDECO ® (ivacaftor)  ",
                "1d_change": 0.6818181818,
                "index_price": 1.036285094,
                "norm_price": -0.3544669122
            },
            {
                "index": 327,
                "date": "2015-10-07",
                "press_title": "Supplemental New Drug Application for Use of KALYDECO® (ivacaftor) in People with Cystic Fibrosis Ages 2 and Older who have One of 23 Residual Function Mutations Accepted for Priority Review by U.S. FDA",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/supplemental-new-drug-application-use-kalydecor-ivacaftor-people",
                "content": "  -More than 1,500 people with CF are ages two and older and have one of these 23 residual function mutations in the U.S.- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a  ",
                "1d_change": -1.3849418996,
                "index_price": 1.5441354833,
                "norm_price": -2.9290773829
            },
            {
                "index": 328,
                "date": "2015-09-25",
                "press_title": "Vertex Receives CHMP Positive Opinions for ORKAMBI™ (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) in the European Union",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-chmp-positive-opinions-orkambitm",
                "content": "  -CHMP recommends Marketing Authorization for lumacaftor in combination with ivacaftor for people with cystic fibrosis ages 12 and older with two copies of the F508del mutation- -CHMP recommends Marketing Authorization for ivacaftor for children with cystic fibrosis ages 2 to 5 with 9 gating  ",
                "1d_change": -14.0203020899,
                "index_price": -2.8781431109,
                "norm_price": -11.1421589791
            },
            {
                "index": 329,
                "date": "2015-09-08",
                "press_title": "Vertex to Present at the Morgan Stanley Healthcare Conference on September 16",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-morgan-stanley-healthcare-conference-september-16",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Morgan Stanley Healthcare Conference in New York, NY on Wednesday, September 16 th at 11:40 a.m. ET .  ",
                "1d_change": 0.015393823,
                "index_price": 0.7589951771,
                "norm_price": -0.7436013542
            },
            {
                "index": 330,
                "date": "2015-08-19",
                "press_title": "Vertex Awards Two Boston Public High School Students the Vertex Science Leaders Scholarship to the University of Massachusetts",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-awards-two-boston-public-high-school-students-vertex",
                "content": "  Hosts August 19 th back to school event with Bottom Line for 200+ first-generation college students BOSTON --(BUSINESS WIRE)-- Vertex and the University of Massachusetts (UMass) today announced the recipients of the annual Vertex Science Leaders Scholarship , a four-year scholarship to pursue their  ",
                "1d_change": -5.6730066048,
                "index_price": -2.9453788819,
                "norm_price": -2.7276277228
            },
            {
                "index": 331,
                "date": "2015-07-29",
                "press_title": "Vertex Reports Second Quarter 2015 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-second-quarter-2015-financial-results",
                "content": "  -Second quarter 2015 total revenues of $166 million , including net product revenues of approximately $155 million for KALYDECO ® (ivacaftor) in cystic fibrosis- -Vertex increases guidance for total 2015 KALYDECO net revenues; now expects KALYDECO revenues of $575 to $590 million - -ORKAMBI™  ",
                "1d_change": 5.3004632945,
                "index_price": 0.6606153007,
                "norm_price": 4.6398479938
            },
            {
                "index": 332,
                "date": "2015-07-14",
                "press_title": "Vertex to Announce Second Quarter 2015 Financial Results on July 29",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-second-quarter-2015-financial-results-july-29",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2015 financial results on Wednesday, July 29, 2015 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  ",
                "1d_change": 6.3955672835,
                "index_price": 0.3644268766,
                "norm_price": 6.0311404069
            },
            {
                "index": 333,
                "date": "2015-07-02",
                "press_title": "FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/fda-approves-orkambitm-lumacaftorivacaftor-first-medicine-treat",
                "content": "  -Approximately 8,500 people in the U.S. are ages 12 and older and have two copies of the F508del mutation, the most common genetic form of the disease- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S.  ",
                "1d_change": 1.4049562697,
                "index_price": -0.4480954527,
                "norm_price": 1.8530517224
            },
            {
                "index": 334,
                "date": "2015-07-02",
                "press_title": "ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/adding-multimedia-fda-approves-orkambitm-lumacaftorivacaftor",
                "content": "  -Approximately 8,500 people in the U.S. are ages 12 and older and have two copies of the F508del mutation, the most common genetic form of the disease- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S.  ",
                "1d_change": 1.4049562697,
                "index_price": -0.4480954527,
                "norm_price": 1.8530517224
            },
            {
                "index": 335,
                "date": "2015-06-18",
                "press_title": "Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/sangeeta-n-bhatia-md-phd-joins-vertex-board-directors",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Sangeeta N. Bhatia , M.D., Ph.D., joined its board of directors as an independent director. Dr. Bhatia was elected to serve a three-year term ending in 2018. \" Dr.  ",
                "1d_change": 2.6710330513,
                "index_price": 0.3985759244,
                "norm_price": 2.2724571268
            },
            {
                "index": 336,
                "date": "2015-06-11",
                "press_title": "Vertex Announces Data Presentations at European Cystic Fibrosis Society (ECFS) Conference",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-data-presentations-european-cystic-fibrosis",
                "content": "  -Analysis from TRAFFIC and TRANSPORT extension study of lumacaftor in combination with ivacaftor showed that improvements in lung function and other measures of disease were maintained through 48 weeks in people with cystic fibrosis who have two copies of the F508del mutation- BRUSSELS --(BUSINESS  ",
                "1d_change": -1.2061756133,
                "index_price": -0.5792380625,
                "norm_price": -0.6269375508
            },
            {
                "index": 337,
                "date": "2015-06-04",
                "press_title": "Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-and-parion-sciences-establish-collaboration-develop",
                "content": "  -ENaC inhibition aims to restore or improve hydration of cell surfaces in the lungs to improve lung function- -Parion to receive $80 million up-front payment with potential for additional development and regulatory milestones and royalty payments- BOSTON &amp; DURHAM, N.C.  ",
                "1d_change": 1.1857103685,
                "index_price": -0.9327092407,
                "norm_price": 2.1184196093
            },
            {
                "index": 338,
                "date": "2015-06-03",
                "press_title": "Vertex to Present at the Goldman Sachs Healthcare Conference on June 11",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-goldman-sachs-healthcare-conference-june-11",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Goldman Sachs Healthcare Conference in Rancho Palos Verdes, CA on Thursday, June 11 th at 12:20 p.m. ET ( 9:20 a.m. PT ).  ",
                "1d_change": 2.0167048517,
                "index_price": -0.706151427,
                "norm_price": 2.7228562787
            },
            {
                "index": 339,
                "date": "2015-05-17",
                "press_title": "New England Journal of Medicine Publishes Data from Two Phase 3 Studies of ORKAMBITM (lumacaftor/ivacaftor) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/new-england-journal-medicine-publishes-data-two-phase-3-studies",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the  New England Journal of Medicine (NEJM)  published data from the two Phase 3 studies of ORKAMBI TM (lumacaftor/ivacaftor), an investigational medicine designed to treat the underlying cause of  ",
                "1d_change": 1.6366600531,
                "index_price": 0.3068867841,
                "norm_price": 1.329773269
            },
            {
                "index": 340,
                "date": "2015-05-13",
                "press_title": "Vertex to Present at the UBS Healthcare Conference on May 19",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-ubs-healthcare-conference-may-19",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jeffrey Leiden , M.D., Ph.D., Chairman, President &amp; CEO of Vertex will present at the UBS Healthcare Conference in New York, NY on Tuesday, May 19 th at 11:00 a.m. ET .  ",
                "1d_change": -6.7073170732,
                "index_price": 1.0126811315,
                "norm_price": -7.7199982046
            },
            {
                "index": 341,
                "date": "2015-05-12",
                "press_title": "Food and Drug Administration Advisory Panel Voted 12 to 1 to Recommend Approval of ORKAMBI™ (lumacaftor/ivacaftor) to Treat People with Cystic Fibrosis Ages 12 and Older Who Have Two Copies of the F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/food-and-drug-administration-advisory-panel-voted-12-1-recommend",
                "content": "  - FDA decision expected by July 5, 2015 PDUFA date- -Approximately 8,500 people with cystic fibrosis in the U.S. have two copies of the F508del mutation and are ages 12 and older- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S.  ",
                "1d_change": 1.1472234309,
                "index_price": -0.2092055564,
                "norm_price": 1.3564289873
            },
            {
                "index": 342,
                "date": "2015-04-29",
                "press_title": "Vertex Reports First Quarter 2015 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-first-quarter-2015-financial-results",
                "content": "  -First quarter 2015 total revenues of $139 million , including net product revenues of $130 million for KALYDECO ® (ivacaftor) in cystic fibrosis- -Cash, cash equivalents and marketable securities of approximately $1.2 billion on March 31, 2015 - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals  ",
                "1d_change": -1.0545125443,
                "index_price": -1.2936874118,
                "norm_price": 0.2391748675
            },
            {
                "index": 343,
                "date": "2015-04-09",
                "press_title": "Vertex to Announce First Quarter 2015 Financial Results on April 29",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-first-quarter-2015-financial-results-april-29",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2015 financial results on Wednesday, April 29, 2015 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  ",
                "1d_change": 3.7362831837,
                "index_price": 0.9880792628,
                "norm_price": 2.7482039209
            },
            {
                "index": 344,
                "date": "2015-03-23",
                "press_title": "Vertex Announces Data from 12-Week Phase 2 Safety Study of VX-661 in Combination with Ivacaftor in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-data-12-week-phase-2-safety-study-vx-661",
                "content": "  -The combination was generally well tolerated and all patients completed 12 weeks of treatment- -Mean within-group absolute improvement from baseline in lung function of 4.4 (p=0.009) and 3.0 (p=0.026) percentage points at week 4 and through 12 weeks of treatment, respectively, in patients who  ",
                "1d_change": 0.5790522861,
                "index_price": -0.78842889,
                "norm_price": 1.3674811761
            },
            {
                "index": 345,
                "date": "2015-03-18",
                "press_title": "Vertex Receives U.S. Food and Drug Administration Approval of KALYDECO® (ivacaftor) for Children with Cystic Fibrosis Ages 2 to 5 who have Specific Mutations in the CFTR Gene",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-us-food-and-drug-administration-approval",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) approved KALYDECO ® for use in children ages 2 to 5 with cystic fibrosis (CF) who have one of 10 mutations in the cystic fibrosis transmembrane conductance  ",
                "1d_change": 3.441337145,
                "index_price": 0.7863957979,
                "norm_price": 2.6549413471
            },
            {
                "index": 346,
                "date": "2015-02-11",
                "press_title": "Vertex to Present at Upcoming Investor Conferences",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-upcoming-investor-conferences",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the RBC Capital Market Healthcare Conference in New York, NY on Tuesday, February 24 th at 11:30 a.m. ET . Vertex will also present at the Cowen and Company Healthcare Conference in  ",
                "1d_change": 0.8665483645,
                "index_price": 0.9542792762,
                "norm_price": -0.0877309116
            },
            {
                "index": 347,
                "date": "2015-01-28",
                "press_title": "Vertex Reports Full-Year and Fourth Quarter 2014 Financial Results and Provides Guidance for 2015",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2014-financial",
                "content": "  -Full-year 2014 total revenues of $580 million , including net product revenues of $464 million for KALYDECO in cystic fibrosis- -Cash, cash equivalents and marketable securities of approximately $1.4 billion on December 31, 2014 - -Company expects total 2015 KALYDECO net revenues of $560 to $580  ",
                "1d_change": -9.304365519,
                "index_price": -0.5486686862,
                "norm_price": -8.7556968328
            },
            {
                "index": 348,
                "date": "2015-01-11",
                "press_title": "Vertex Outlines 2015 Business Priorities to Support the Development, Approval and Launch of New Medicines for the Treatment of People with Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-outlines-2015-business-priorities-support-development",
                "content": "  -Priority Review granted for combination of lumacaftor and ivacaftor in people with cystic fibrosis ages 12 and older who have two copies of the F508del mutation; PDUFA date of July 5, 2015 - -More than 3,700 people with CF expected to be eligible to receive KALYDECO by end of 2015 supporting  ",
                "1d_change": -1.9983446871,
                "index_price": -1.1418503557,
                "norm_price": -0.8564943313
            },
            {
                "index": 349,
                "date": "2015-01-06",
                "press_title": "Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2014 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-upcoming-presentation-jp-morgan-healthcare",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 33 rd Annual J.P. Morgan Healthcare Conference on Monday, January 12 at 12:30 p.m. ET ( 9:30 a.m. PT ).  ",
                "1d_change": -0.538698721,
                "index_price": 0.185102915,
                "norm_price": -0.723801636
            },
            {
                "index": 350,
                "date": "2014-12-29",
                "press_title": "U.S. Food and Drug Administration Approves KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/us-food-and-drug-administration-approves-kalydecor-ivacaftor-use",
                "content": "  --Approximately 500 people with cystic fibrosis ages 6 and older have the R117H mutation in the United States -- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated  (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug  ",
                "1d_change": 1.0407031875,
                "index_price": -0.349930772,
                "norm_price": 1.3906339594
            },
            {
                "index": 351,
                "date": "2014-12-15",
                "press_title": "David Altshuler, M.D., Ph.D., Joins Vertex as Executive Vice President of Global Research and Chief Scientific Officer",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/david-altshuler-md-phd-joins-vertex-executive-vice-president",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated today announced that David Altshuler , M.D., Ph.D., will join the company as Executive Vice President, Global Research and Chief Scientific Officer. Dr. Altshuler was one of the four founding members of the Broad Institute of Harvard  ",
                "1d_change": -8.397977185,
                "index_price": -1.6368117047,
                "norm_price": -6.7611654804
            },
            {
                "index": 352,
                "date": "2014-11-20",
                "press_title": "Vertex to Present at Deutsche Bank BioFEST on December 2",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-deutsche-bank-biofest-december-2",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Deutsche Bank BioFEST in Boston on December 2 at 8:45 a.m. ET . Management's remarks can be accessed live through Vertex's website at www.vrtx.com  ",
                "1d_change": -1.3285419275,
                "index_price": 0.8543738737,
                "norm_price": -2.1829158012
            },
            {
                "index": 353,
                "date": "2014-11-05",
                "press_title": "Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-submits-applications-us-and-europe-approval-lumacaftor",
                "content": "  -U.S. submission includes request for Priority Review; Accelerated Assessment has been granted in the EU- -Approximately 8,500 people in the U.S. and 12,000 in Europe ages 12 and older have two copies of the F508del mutation- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:  ",
                "1d_change": 2.2337818451,
                "index_price": 0.7837654492,
                "norm_price": 1.4500163959
            },
            {
                "index": 354,
                "date": "2014-10-30",
                "press_title": "Vertex to Present at the Credit Suisse Healthcare Conference on November 11",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-credit-suisse-healthcare-conference-november-11",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Credit Suisse Healthcare Conference on Tuesday, November 11 at 12:00 p.m. ET . Management's remarks can be accessed live through Vertex's website at www.vrtx.com in the  ",
                "1d_change": 3.0450997192,
                "index_price": 1.9107582895,
                "norm_price": 1.1343414298
            },
            {
                "index": 355,
                "date": "2014-10-28",
                "press_title": "Vertex Reports Third Quarter 2014 Financial Results",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-third-quarter-2014-financial-results",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended September 30, 2014 . Vertex reported total third quarter 2014 GAAP revenues of $179 million , including revenues of $127 million from KALYDECO ®  ",
                "1d_change": -2.2381939792,
                "index_price": 0.9161092535,
                "norm_price": -3.1543032327
            },
            {
                "index": 356,
                "date": "2014-10-21",
                "press_title": "FDA Advisory Committee Recommends Approval of KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/fda-advisory-committee-recommends-approval-kalydecor-ivacaftor",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration's Pulmonary Allergy Drugs Advisory Committee (PADAC) voted 13-2 to recommend approval of KALYDECO ® (ivacaftor) in people with cystic fibrosis (CF) ages 6 and  ",
                "1d_change": 0.2919822586,
                "index_price": 0.9200295055,
                "norm_price": -0.6280472469
            },
            {
                "index": 357,
                "date": "2014-10-14",
                "press_title": "Vertex to Announce Third Quarter 2014 Financial Results on October 28",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-third-quarter-2014-financial-results-october-28",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2014 financial results on Tuesday, October 28, 2014 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  ",
                "1d_change": -5.8555868035,
                "index_price": -0.7849703995,
                "norm_price": -5.0706164039
            },
            {
                "index": 358,
                "date": "2014-10-09",
                "press_title": "Vertex Reviews Recent Progress and Announces Upcoming Milestones in the Development of Multiple Combinations of Medicines that Target the Underlying Cause of Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reviews-recent-progress-and-announces-upcoming-milestones",
                "content": "  -Data from across Vertex's cystic fibrosis research and development programs to be presented at the 28 th Annual North American Cystic Fibrosis Conference (NACFC) beginning today- -Interim analysis of rollover study following the Phase 3 TRAFFIC and TRANSPORT studies showed sustained improvements  ",
                "1d_change": -1.0121240567,
                "index_price": -3.2290582841,
                "norm_price": 2.2169342274
            },
            {
                "index": 359,
                "date": "2014-09-08",
                "press_title": "Vertex Announces Upcoming Presentations of Data at North American Cystic Fibrosis Conference - October 9 to 11, 2014",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-upcoming-presentations-data-north-american",
                "content": "  -Data from Phase 3 TRAFFIC and TRANSPORT studies of lumacaftor in combination with ivacaftor and from Phase 3 rollover study of patients who completed TRAFFIC and TRANSPORT to be presented- -Other presentations include studies of ivacaftor in people with cystic fibrosis who have the R117H mutation,  ",
                "1d_change": -2.094068826,
                "index_price": -0.9419496234,
                "norm_price": -1.1521192026
            },
            {
                "index": 360,
                "date": "2014-09-02",
                "press_title": "Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 10",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-morgan-stanley-global-healthcare-conference",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10 at 8:35 a.m. ET . Management's remarks can be accessed live through Vertex's website at www.vrtx.com in  ",
                "1d_change": -1.5837117276,
                "index_price": -0.1674385039,
                "norm_price": -1.4162732237
            },
            {
                "index": 361,
                "date": "2014-07-31",
                "press_title": "Vertex Receives European Approval for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-european-approval-kalydecotm-ivacaftor-eight-non",
                "content": "  -In Europe, approximately 250 people ages 6 and older have one of 8 additional gating mutations- -KALYDECO is the first medicine to treat the underlying cause of CF in people with specific non-G551D gating mutations- EYSINS, Switzerland --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated  ",
                "1d_change": -3.5530682666,
                "index_price": -2.0772402009,
                "norm_price": -1.4758280657
            },
            {
                "index": 362,
                "date": "2014-07-29",
                "press_title": "Vertex Reports Second Quarter 2014 Financial Results and Provides Updates on Key Research and Development Programs",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-second-quarter-2014-financial-results-and",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2014. Vertex reported total second quarter 2014 revenues of $138 million , including revenues of $113 million from KALYDECO ® (ivacaftor).  ",
                "1d_change": -3.6843813835,
                "index_price": -0.5055700193,
                "norm_price": -3.1788113642
            },
            {
                "index": 363,
                "date": "2014-07-14",
                "press_title": "Vertex to Announce Second Quarter 2014 Financial Results on July 29",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announce-second-quarter-2014-financial-results-july-29",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2014 financial results on Tuesday, July 29, 2014 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  ",
                "1d_change": -2.7245466861,
                "index_price": 0.1733177195,
                "norm_price": -2.8978644055
            },
            {
                "index": 364,
                "date": "2014-07-10",
                "press_title": "Vertex Announces Retirement of Peter Mueller, Ph.D.",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-retirement-peter-mueller-phd",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Peter Mueller , Ph.D., Executive Vice President of Global Research and Development and Chief Scientific Officer, will retire after more than 10 years with the company. Dr.  ",
                "1d_change": 2.9474090824,
                "index_price": 0.0457367396,
                "norm_price": 2.9016723428
            },
            {
                "index": 365,
                "date": "2014-06-30",
                "press_title": "Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for Use of KALYDECO® (ivacaftor) in People 18 and Older with Cystic Fibrosis who have the R117H Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-submits-supplemental-new-drug-application-snda-us-food",
                "content": "  -Marketing Authorization Application (MAA) variation in Europe planned for third quarter of 2014- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S.  ",
                "1d_change": 2.1700593262,
                "index_price": 0.6349658225,
                "norm_price": 1.5350935038
            },
            {
                "index": 366,
                "date": "2014-06-27",
                "press_title": "Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-receives-european-chmp-positive-opinion-kalydecotm",
                "content": "  -In Europe, approximately 250 people ages 6 and older have one of 8 additional gating mutations- -KALYDECO is the first medicine to treat the underlying cause of CF in people with non-G551D gating mutations- EYSINS, Switzerland --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)  ",
                "1d_change": 1.6793451227,
                "index_price": 0.1872189443,
                "norm_price": 1.4921261784
            },
            {
                "index": 367,
                "date": "2014-06-24",
                "press_title": "Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/two-24-week-phase-3-studies-lumacaftor-combination-ivacaftor-met",
                "content": "  -Combination of lumacaftor and ivacaftor is the first regimen designed to treat the underlying cause of CF in people with two copies of the F508del mutation, the most common form of the disease- -All four 24-week treatment arms achieved primary endpoint of mean absolute improvement in FEV 1  ",
                "1d_change": -9.080787867,
                "index_price": -0.1245166632,
                "norm_price": -8.9562712038
            },
            {
                "index": 368,
                "date": "2014-06-18",
                "press_title": "Vertex Licenses VX-787 to Janssen Pharmaceuticals for the Treatment of Influenza",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-licenses-vx-787-janssen-pharmaceuticals-treatment",
                "content": "  -VX-787 is an investigational medicine discovered by Vertex that is designed to directly inhibit replication of the influenza virus- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into a licensing agreement with Janssen  ",
                "1d_change": -2.4756400611,
                "index_price": 0.8548186339,
                "norm_price": -3.330458695
            },
            {
                "index": 369,
                "date": "2014-06-16",
                "press_title": "Vertex Announces a Signed Letter of Intent to Enable Public Reimbursement of KALYDECO® (ivacaftor) in Canada for Eligible People with Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-signed-letter-intent-enable-public",
                "content": "  -Before patients can get access through public reimbursement, each participating province or territory must decide to reimburse KALYDECO through its individual drug program- -Approximately 100 people ages 6 and older in Canada have the G551D mutation - BOSTON --(BUSINESS WIRE)-- Vertex  ",
                "1d_change": -4.9628233461,
                "index_price": 0.3681802919,
                "norm_price": -5.331003638
            },
            {
                "index": 370,
                "date": "2014-06-12",
                "press_title": "Vertex Announces Presentation of New KALYDECO™ (ivacaftor) Data at European Cystic Fibrosis Society Conference",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-presentation-new-kalydecotm-ivacaftor-data",
                "content": "  -New data showed that KALYDECO reduced the loss of lung function by half over 3 years in people with CF who have the G551D mutation compared to similar untreated patients- -New data from rollover study of ivacaftor in people with the R117H mutation support earlier results from Phase 3 study that  ",
                "1d_change": -0.394612769,
                "index_price": -0.3713505743,
                "norm_price": -0.0232621947
            },
            {
                "index": 371,
                "date": "2014-06-04",
                "press_title": "Proof-of-Concept Study of Ivacaftor Monotherapy Showed Improvements in Lung Function After Two Weeks of Treatment in People with Cystic Fibrosis who have a Residual Function Mutation",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/proof-concept-study-ivacaftor-monotherapy-showed-improvements",
                "content": "  -Data are consistent with in vitro observations in residual function mutations showing that ivacaftor improved CFTR activity- -8-week open-label period showed improvements in lung function- -Data support plans to initiate a Phase 3 study of ivacaftor in people with CF who have a residual function  ",
                "1d_change": 0.6296182588,
                "index_price": 0.8966895836,
                "norm_price": -0.2670713249
            },
            {
                "index": 372,
                "date": "2014-06-03",
                "press_title": "Vertex to Present at the Goldman Sachs Global Healthcare Conference on June 10",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-goldman-sachs-global-healthcare-conference-june",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 10 at 11:00 a.m. ET . Management's remarks can be accessed live through Vertex's website at www.vrtx.com in the  ",
                "1d_change": 1.2940562353,
                "index_price": 0.2494998953,
                "norm_price": 1.04455634
            },
            {
                "index": 373,
                "date": "2014-05-13",
                "press_title": "Vertex to Present at the UBS Global Healthcare Conference on May 20",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-present-ubs-global-healthcare-conference-may-20",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the UBS Global Healthcare Conference on Tuesday, May 20 at 11:00 a.m. ET . The audio portion of the remarks will be accessible live through Vertex's website at www.vrtx.com in the  ",
                "1d_change": 0.1034121618,
                "index_price": -0.4352576118,
                "norm_price": 0.5386697735
            },
            {
                "index": 374,
                "date": "2014-05-07",
                "press_title": "William Young Joins Vertex Board of Directors",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/william-young-joins-vertex-board-directors",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that William Young joined its board of directors as an independent director. Mr. Young was elected to the class of directors whose term expires in 2017. The Vertex board now consists of 10 members. \"Mr.  ",
                "1d_change": -4.2162988384,
                "index_price": 0.3785381748,
                "norm_price": -4.5948370131
            },
            {
                "index": 375,
                "date": "2014-05-01",
                "press_title": "Addition of VX-661 to KALYDECO® (ivacaftor) Improves Lung Function in People with CF Who Are Heterozygous for the F508del and G551D Mutations in 28-day Phase 2 Proof-of-Concept Study",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/addition-vx-661-kalydecor-ivacaftor-improves-lung-function",
                "content": "  -Data provide proof-of-concept for use of VX-661 to further enhance CFTR function in people taking KALYDECO who have the F508del mutation and another mutation known to respond to KALYDECO alone- -Statistically significant improvements in lung function, as well as decreases in sweat chloride,  ",
                "1d_change": -1.7628418269,
                "index_price": -0.1727675758,
                "norm_price": -1.5900742512
            },
            {
                "index": 376,
                "date": "2014-05-01",
                "press_title": "Vertex Reports First Quarter 2014 Financial Results and Provides Updates on Key Business Priorities",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-first-quarter-2014-financial-results-and-provides",
                "content": "  -Net product revenues of $100 million for KALYDECO in cystic fibrosis- -Cash, cash equivalents and marketable securities of $1.32 billion on March 31, 2014 - -Six-month dosing period complete for Phase 3 TRAFFIC and TRANSPORT studies of lumacaftor in combination with ivacaftor for people with CF  ",
                "1d_change": -1.7628418269,
                "index_price": -0.1727675758,
                "norm_price": -1.5900742512
            },
            {
                "index": 377,
                "date": "2014-02-21",
                "press_title": "U.S. Food and Drug Administration Approves KALYDECO™ (ivacaftor) for Use in Eight Additional Mutations that Cause Cystic Fibrosis",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/us-food-and-drug-administration-approves-kalydecotm-ivacaftor",
                "content": "  -KALYDECO is the first medicine to treat the underlying cause of CF for people with specific mutations in the CFTR gene- -KALYDECO facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein- -The eight additional mutations are present in  ",
                "1d_change": -0.583687327,
                "index_price": 0.3539729226,
                "norm_price": -0.9376602495
            },
            {
                "index": 378,
                "date": "2014-01-29",
                "press_title": "Vertex Reports Full-Year and Fourth Quarter 2013 Financial Results and Provides Financial Guidance for 2014",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2013-financial",
                "content": "  -Full-year 2013 total revenues of $1.21 billion , including net product revenues of $371.3 million for KALYDECO in cystic fibrosis and $466.3 million for INCIVEK in hepatitis C- -Cash, cash equivalents and marketable securities of approximately $1.47 billion on December 31, 2013- -Company expects  ",
                "1d_change": 4.370059526,
                "index_price": 0.2251666281,
                "norm_price": 4.1448928979
            },
            {
                "index": 379,
                "date": "2014-01-12",
                "press_title": "Vertex Reviews Corporate Strategy and Outlines Key 2014 Business Priorities at the 32nd Annual J.P. Morgan Healthcare Conference",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-reviews-corporate-strategy-and-outlines-key-2014-business",
                "content": "  -KALYDECO: 2014 revenue growth anticipated from geographic expansion and approval for use in patients with additional CFTR mutations- -Lumacaftor in combination with ivacaftor: results from two Phase 3 studies, TRAFFIC and TRANSPORT, expected mid-year in people with two copies of the F508del  ",
                "1d_change": 1.9400364938,
                "index_price": -0.1294268727,
                "norm_price": 2.0694633665
            },
            {
                "index": 380,
                "date": "2014-01-09",
                "press_title": "Vertex Announces Sustained Viral Response Rate (SVR4) Data from All-Oral Study of VX-135 in Combination with Daclatasvir in Hepatitis C",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-sustained-viral-response-rate-svr4-data-all",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first data from the initial cohorts of an open-label Phase 2a study of VX-135, Vertex's nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor, in combination with daclatasvir, Bristol-Myers  ",
                "1d_change": 3.541742329,
                "index_price": 0.1829163049,
                "norm_price": 3.3588260241
            },
            {
                "index": 381,
                "date": "2014-01-08",
                "press_title": "Vertex Announces Appointment of Jeffrey A. Chodakewitz, M.D., as Chief Medical Officer and Senior Vice President of Global Medicines Development",
                "release_url": "https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-appointment-jeffrey-chodakewitz-md-chief",
                "content": "  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Jeffrey A. Chodakewitz , M.D., as Chief Medical Officer and Senior Vice President. Dr. Chodakewitz has more than 20 years of experience leading global development organizations in the  ",
                "1d_change": 2.3191780007,
                "index_price": 0.0125116541,
                "norm_price": 2.3066663466
            }
        ]
    }
]